Compounds that inhibit MCL-1 protein

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, 
                         
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.15/376,456, filed Dec. 12, 2016, which is a continuation of U.S. patentapplication Ser. No. 14/839,149, filed Aug. 28, 2015, now U.S. Pat. No.9,562,061, which claims the benefit of U.S. Provisional PatentApplication No. 62/043,929, filed Aug. 29, 2014, each of which is herebyincorporated by reference in its entirety and for all purposes as iffully set forth herein.

FIELD OF THE INVENTION

The present invention relates to compounds that inhibit myeloid cellleukemia 1 protein (Mcl-1, also abbreviated as MCL-1 or MCL1); methodsof treating diseases or conditions, such as cancer, using the compounds;and pharmaceutical compositions containing the compounds.

BACKGROUND OF THE INVENTION

One common characteristic of human cancer is overexpression of Mcl-1.Mcl-1 overexpression prevents cancer cells from undergoing programmedcell death (apoptosis), allowing the cells to survive despite widespreadgenetic damage.

Mcl-1 is a member of the Bcl-2 family of proteins. The Bcl-2 familyincludes pro-apoptotic members (such as BAX and BAK) which, uponactivation, form a homo-oligomer in the outer mitochondrial membranethat leads to pore formation and the escape of mitochondrial contents, astep in triggering apoptosis. Antiapoptotic members of the Bcl-2 family(such as Bcl-2, Bcl-XL, and Mcl-1) block the activity of BAX and BAK.Other proteins (such as BID, BIM, BIK, and BAD) exhibit additionalregulatory functions.

Research has shown that Mcl-1 inhibitors can be useful for the treatmentof cancers. MCl-1 is overexpressed in numerous cancers. See Beroukhim etal. 53(2010) Nature 463, 899-905. Cancer cells containing amplificationssurrounding the Mcl-1 and Bcl-2-1-1 anti-apoptotic genes depend on theexpression of these genes for survival. Beroukhim et al. Mcl-1 is arelevant target for the re-iniation of apoptosis in numerous cancercells. See G. Lessene, P. Czabotar and P. Colman, Nat. Rev. Drug.Discov., 2008, 7, 989-1000; C. Akgul Cell. Mol. Life Sci. Vol. 66, 2009;and Arthur M. Mandelin II, Richard M. Pope, Expert Opin. Ther. Targets(2007) 11(3):363-373.

New compositions and methods for preparing and formulating Mcl-1inhibitors would be useful.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates the Mcl-1 inhibitor in-vivo efficacy of the compoundof Example 4.

FIG. 2 illustrates the Mcl-1 inhibitor in-vivo efficacy of the compoundof Example 17.

FIG. 3 illustrates the Mcl-1 inhibitor in-vivo efficacy of the compoundof Example 20.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides compounds of FormulaI,

wherein, b, represented by the symbol

is a single or double chemical bond which may be cis or trans; R is ahalo; R¹ is H, C₁₋₆alkyl, and (CH₂CH₂O)_(n)CH₃, wherein n is an integerfrom 1 to 4; R² is H or C₁₋₆alkyl; R^(2A) is H or C₁₋₆alkyl; R³ is H orC₁₋₆ alkyl, and R^(3A) is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or(CH₂)_(m)—C₃₋₆ cycloalkyl, wherein m is an integer from 1 to 4. In oneembodiment, R is Cl. In one embodiment, R¹ is C₁₋₆ alkyl. In anotherembodiment, R¹ is CH₃. In one embodiment, R² is H and R^(2A) is C₁₋₆alkyl. In one embodiment, R³ is H and R^(3A) is C₁₋₆ alkyl. In anotherembodiment, b indicates a double bond.

In some embodiments of the invention the compound of Formula I is acompound of Formula II,

wherein R¹, R², R^(2A), R³ and R^(3A) are defined above.

In some embodiments of the invention, the present invention providescompounds having the following structures:

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments.

-   -   1. One embodiment of the present invention is directed to a        compound, wherein the compound has a structure selected from:

-   -   7. or a pharmaceutically acceptable salt thereof, and a        pharmaceutically acceptable excipient, in conjunction with any        of the above or below embodiments.

One embodiment of the present invention is directed to a compound havingthe structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

Another embodiment of the present invention is directed to a compoundhaving the structure

or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in in conjunction with any of the above or belowembodiments.

One embodiment of the present invention is directed to a pharmaceuticalcomposition comprising the compound of Formula I, or pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable excipient.

Another embodiment of the present invention is directed to a method ofinhibiting myeloid cell leukemia 1 protein (Mcl-1) of a cell comprisingcontacting the cell with the compound of Formula I in an effectiveamount to inhibit the Mcl-1, in conjunction with any of the above orbelow embodiments. In one embodiment, the contacting is in vitro. Inanother embodiment, the contacting is in vivo. In one embodiment, thecontacting comprises administering the compound to a subject. In oneembodiment, the administering is oral, parenteral, via injection, viainhalation, transdermal, or transmucosal. In one embodiment, the subjectsuffers from cancer.

One embodiment of the present invention is directed to a method of thetreatment of cancer, comprising administering to a patient in needthereof a therapeutically effective amount of the compound of Formula Ior a pharmaceutical composition comprising the compound of Formula I, orpharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient, in conjunction with any of the above or belowembodiments. In one embodiment, the cancer is a hematologic malignancy.In one embodiment, the cancer is selected from the group consisting ofbreast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer,kidney cancer, lung cancer, non-small cell lung cancer, lymphoma,non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acutemyelogenous leukemia. In one embodiment, the cancer is multiple myeloma.In another embodiment, the method further comprises the step ofadministering to the patient in need thereof a therapeutically effectiveamount of at least one additional pharmaceutically active compound. Inone embodiment, the additional pharmaceutically active compound iscarfilzomib, in conjunction with any of the above embodiments.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure belongs. Methods and materials aredescribed herein for use in the present disclosure; other, suitablemethods and materials known in the art can also be used. The materials,methods, and examples are illustrative only and not intended to belimiting. All publications, patent applications, patents, sequences,database entries, and other references mentioned herein are incorporatedby reference in their entirety. In case of conflict, the presentspecification, including definitions, will control.

Other features and advantages of the disclosure will be apparent fromthe following detailed description and figures, and from the claims.

DETAILED DESCRIPTION

The symbol “—” represents a covalent bond and can also be used in aradical group to indicate the point of attachment to another group. Inchemical structures, the symbol — is commonly used to represent a methylgroup in a molecule.

As used herein, chemical structures which contain one or morestereocenters depicted with dashed and bold bonds (i.e.,

and

) are meant to indicate absolute stereochemistry of the stereocenter(s)present in the chemical structure. As used herein, bonds symbolized by asimple line do not indicate a stereo-preference. Unless otherwiseindicated to the contrary, chemical structures that include one or morestereocenters which are illustrated herein without indicating absoluteor relative stereochemistry encompass all possible stereoisomeric formsof the compound (e.g., diastereomers, enantiomers) and mixtures thereof.Structures with a single bold or dashed line, and at least oneadditional simple line, encompass a single enantiomeric series of allpossible diastereomers.

As used herein, the term “about” is meant to account for variations dueto experimental error. All measurements reported herein are understoodto be modified by the term “about,” whether or not the term isexplicitly used, unless explicitly stated otherwise. As used herein, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise.

The term “alkyl” means a straight or branched chain hydrocarbon.Representative examples of alkyl groups include methyl, ethyl, propyl,isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl and hexyl.Typical alkyl groups are alkyl groups having from 1 to 8 carbon atoms,which groups are commonly represented as C₁₋₈ alkyl.

The term “compound”, as used herein is meant to include allstereoisomers, geometric isomers, tautomers, and isotopes of thestructures depicted. Compounds herein identified by name or structure asone particular tautomeric form are intended to include other tautomericforms unless otherwise specified.

All compounds, and pharmaceutically acceptable salts thereof, can befound together with other substances such as water and solvents (e.g.,hydrates and solvates).

The term “cycloalkyl” means a cyclic, nonaromatic hydrocarbon.Representative examples of cycloalkyl groups include cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A cycloalkyl groupcan contain one or more double bonds. Representative examples ofcycloalkyl groups that contain double bonds include cyclopentenyl,cyclohexenyl, cyclohexadienyl and cyclobutadienyl. Common cycloalkylgroups are C₃₋₈ cycloalkyl groups.

The term “excipient”, as used herein, means any pharmaceuticallyacceptable additive, carrier, diluent, adjuvant or other ingredient,other than the active pharmaceutical ingredient (API), which istypically included for formulation and/or administration to a patient.Handbook of Pharmaceutical Excipients, 5^(th) Edition, R. C. Rowe, P. J.Sheskey, and S. C. Owen, editors, Pharmaceutical Press, 2005, Hardback,928, 0853696187.

For the terms “for example” and “such as” and grammatical equivalencesthereof, the phrase “and without limitation” is understood to followunless explicitly stated otherwise.

The term “halogen” or “halo” means F, Cl, Br or I.

The term “patient” means subjects including animals, such as dogs, cats,cows, horses, sheep and humans. Particular patients are mammals. Theterm patient includes males and females.

The term “patient in need” means a patient having, or at risk of having,one or more diseases or conditions where the Mcl-1 protein is involved,such as cancers. Identifying a patient in need can be in the judgment ofa subject or a health care professional and can be subjective (e.g.,opinion) or objective (e.g., measurable by a test or diagnostic method).

The phrases “parenteral administration” and “administered parenterally”as used herein means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,subarachnoid, intraspinal and intrastemal injection, and infusion.

Compositions suitable for parenteral injection may comprisephysiologically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions, or emulsions, and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents,solvents, or vehicles include water, ethanol, polyols (propylene glycol,polyethylene glycol, glycerol, and the like), suitable mixtures thereof,vegetable oils (such as olive oil) and injectable organic esters such asethyl oleate. Proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersions, and by the use of surfactants.

The term “pharmaceutically acceptable” is employed herein to refer tothose ligands, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for administrationto a patient, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable carrier” as used herein means apharmaceutically acceptable material, composition, or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulatingmaterial. As used herein the language “pharmaceutically acceptablecarrier” includes buffer, sterile water for injection, solvents,dispersion media, coatings, antibacterial and antifungal agents,isotonic and absorption delaying agents, and the like, compatible withpharmaceutical administration. Each carrier must be “acceptable” in thesense of being compatible with the other ingredients of the formulationand not injurious to the patient. Some examples of materials which canserve as pharmaceutically acceptable carriers include: (1) sugars, suchas lactose, glucose, and sucrose; (2) starches, such as corn starch,potato starch, and substituted or unsubstituted (3-cyclodextrin; (3)cellulose, and its derivatives, such as sodium carboxymethyl cellulose,ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5)malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter andsuppository waxes; (9) oils, such as peanut oil, cottonseed oil,safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10)glycols, such as propylene glycol; (11) polyols, such as glycerin,sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyloleate and ethyl laurate; (13) agar; (14) buffering agents, such asmagnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19)ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxiccompatible substances employed in pharmaceutical formulations. Incertain embodiments, pharmaceutical compositions provided herein arenon-pyrogenic, i.e., do not induce significant temperature elevationswhen administered to a patient.

The term “pharmaceutically acceptable salt” refers to the relativelynon-toxic, inorganic and organic acid addition salts of a compoundprovided herein. These salts can be prepared in situ during the finalisolation and purification of a compound provided herein, or byseparately reacting the compound in its free base form with a suitableorganic or inorganic acid, and isolating the salt thus formed.Representative salts include the hydrobromide, hydrochloride, sulfate,bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate,stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate,maleate, fumarate, succinate, tartrate, naphthylate, mesylate,glucoheptonate, lactobionate, laurylsulphonate salts, and amino acidsalts, and the like. (See, for example, Berge et al. (1977)“Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19.)

The phrases “systemic administration”, “administered systemically”,“peripheral administration”, and “administered peripherally” as usedherein mean the administration of a ligand, drug, or other material viaroute other than directly into the central nervous system, such that itenters the patient's system and thus, is subject to metabolism and otherlike processes, for example, subcutaneous administration.

The term “therapeutically effective amount” means an amount of acompound that ameliorates, attenuates or eliminates one or more symptomof a particular disease or condition, or prevents or delays the onset ofone of more symptom of a particular disease or condition.

The terms “treating”, “treat” or “treatment” and the like includepreventative (e.g., prophylactic) and palliative treatment.

The methods provided herein include the manufacture and use ofpharmaceutical compositions, which include one or more of the compoundsprovided herein. Also included are the pharmaceutical compositionsthemselves.

In some embodiments, a compound provided herein may contain one or moreacidic functional groups and, thus, is capable of formingpharmaceutically acceptable salts with pharmaceutically acceptablebases. The term “pharmaceutically acceptable salts” in these instancesrefers to the relatively non-toxic inorganic and organic base additionsalts of a compound provided herein. These salts can likewise beprepared in situ during the final isolation and purification of thecompound, or by separately reacting the purified compound in its freeacid form with a suitable base, such as the hydroxide, carbonate, orbicarbonate of a pharmaceutically acceptable metal cation, with ammonia,or with a pharmaceutically acceptable organic primary, secondary, ortertiary amine. Representative alkali or alkaline earth salts includethe lithium, sodium, potassium, calcium, magnesium, and aluminum salts,and the like. Representative organic amines useful for the formation ofbase addition salts include ethylamine, diethylamine, ethylenediamine,ethanolamine, diethanolamine, piperazine, and the like (see, forexample, Berge et al., supra).

Wetting agents, emulsifiers, and lubricants, such as sodium laurylsulfate and magnesium stearate, as well as coloring agents, releaseagents, coating agents, sweetening, flavoring, and perfuming agents,preservatives and antioxida

Examples of pharmaceutically acceptable antioxidants include: (1) watersoluble antioxidants, such as ascorbic acid, cysteine hydrochloride,sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like;(2) oil-soluble antioxidants, such as ascorbyl palmitate, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propylgallate, alpha-tocopherol, and the like; and (3) metal chelating agents,such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol,tartaric acid, phosphoric acid, and the like.

A pharmaceutical composition may also contain adjuvants such aspreservatives, wetting agents, emulsifying agents, and dispersingagents. Prevention of the action of microorganisms may be ensured by theinclusion of various antibacterial and antifungal agents, for example,paraben, chlorobutanol, phenol sorbic acid, and the like. It may also bedesirable to include tonicity-adjusting agents, such as sugars and thelike into the compositions. In addition, prolonged absorption of theinjectable pharmaceutical form may be brought about by the inclusion ofagents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of one or more compoundsprovided herein, it is desirable to slow the absorption of the compoundfrom subcutaneous or intramuscular injection. For example, delayedabsorption of a parenterally administered compound can be accomplishedby dissolving or suspending the compound in an oil vehicle.

The compounds of the present invention are administered to a patient ina therapeutically effective amount. The compounds can be administeredalone or as part of a pharmaceutically acceptable composition orformulation. In addition, the compounds or compositions can beadministered all at once, as for example, by a bolus injection, multipletimes, such as by a series of tablets, or delivered substantiallyuniformly over a period of time, as for example, using transdermaldelivery. The dose of the compound or composition can be varied overtime. All combinations, delivery methods and administration sequencesare contemplated.

The compounds of the present invention and in some embodiments, otheradditional pharmaceutically active compounds, can be administered to apatient either orally, rectally, parenterally, (for example,intravenously, intramuscularly, or subcutaneously) intracisternally,intravaginally, intraperitoneally, intravesically, locally (for example,powders, ointments or drops), or as a buccal or nasal spray. All methodsthat are used by those skilled in the art to administer apharmaceutically active agent are contemplated.

Compositions prepared as described herein can be administered in variousforms, depending on the disorder to be treated and the age, condition,and body weight of the patient, as is well known in the art. Forexample, where the compositions are to be administered orally, they maybe formulated as tablets, capsules, granules, powders, or syrups; or forparenteral administration, they may be formulated as injections(intravenous, intramuscular, or subcutaneous), drop infusionpreparations, or suppositories. For application by the ophthalmic mucousmembrane route, they may be formulated as eye drops or eye ointments.These formulations can be prepared by conventional means in conjunctionwith the methods described herein, and, if desired, the activeingredient may be mixed with any conventional additive or excipient,such as a binder, a disintegrating agent, a lubricant, a corrigent, asolubilizing agent, a suspension aid, an emulsifying agent, or a coatingagent.

Formulations suitable for oral administration may be in the form ofcapsules (e.g., gelatin capsules), cachets, pills, tablets, lozenges(using a flavored basis, usually sucrose and acacia or tragacanth),powders, troches, granules, or as a solution or a suspension in anaqueous or non-aqueous liquid, or as an oil-in-water or water-in-oilliquid emulsion, or as an elixir or syrup, or as pastilles (using aninert matrix, such as gelatin and glycerin, or sucrose and acacia)and/or as mouthwashes, and the like, each containing a predeterminedamount of a compound provided herein as an active ingredient. Acomposition may also be administered as a bolus, electuary, or paste.Oral compositions generally include an inert diluent or an ediblecarrier.

Pharmaceutically compatible binding agents, and/or adjuvant materialscan be included as part of an oral composition. In solid dosage formsfor oral administration (capsules, tablets, pills, dragees, powders,granules, and the like), the active ingredient can be mixed with one ormore pharmaceutically acceptable carriers, such as sodium citrate ordicalcium phosphate, and/or any of the following: (1) fillers orextenders, such as starches, cyclodextrins, lactose, sucrose, saccharin,glucose, mannitol, and/or silicic acid; (2) binders, such as, forexample, carboxymethylcellulose, microcrystalline cellulose, gumtragacanth, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/oracacia; (3) humectants, such as glycerol; (4) disintegrating agents,such as agar-agar, calcium carbonate, potato, corn, or tapioca starch,alginic acid, Primogel, certain silicates, and sodium carbonate; (5)solution retarding agents, such as paraffin; (6) absorptionaccelerators, such as quaternary ammonium compounds; (7) wetting agents,such as, for example, acetyl alcohol and glycerol monostearate; (8)absorbents, such as kaolin and bentonite clay; (9) lubricants, such atalc, calcium stearate, magnesium stearate, Sterotes, solid polyethyleneglycols, sodium lauryl sulfate, and mixtures thereof; (10) a glidant,such as colloidal silicon dioxide; (11) coloring agents; and (12) aflavoring agent such as peppermint, methyl salicylate, or orangeflavoring. In the case of capsules, tablets, and pills, thepharmaceutical compositions may also comprise buffering agents. Solidcompositions of a similar type may also be employed as fillers in softand hard-filled gelatin capsules using such excipients as lactose ormilk sugars, as well as high molecular weight polyethylene glycols, andthe like.

A tablet may be made by compression or molding, optionally with one ormore accessory ingredients. Compressed tablets may be prepared usingbinder (for example, gelatin or hydroxypropylmethyl cellulose),lubricant, inert diluent, preservative, disintegrant (for example,sodium starch glycolate or cross-linked sodium carboxymethyl cellulose),surface-active or dispersing agent. Molded tablets may be made bymolding in a suitable machine a mixture of a powdered compound moistenedwith an inert liquid diluent.

Tablets, and other solid dosage forms, such as dragees, capsules, pills,and granules, may optionally be scored or prepared with coatings andshells, such as enteric coatings and other coatings well known in thepharmaceutical-formulating art. They may also be formulated so as toprovide slow or controlled release of the active ingredient thereinusing, for example, hydroxypropylmethyl cellulose in varying proportionsto provide the desired release profile, other polymer matrices,liposomes, microspheres, and/or nanoparticles. They may be sterilizedby, for example, filtration through a bacteria-retaining filter, or byincorporating sterilizing agents in the form of sterile solidcompositions which can be dissolved in sterile water, or some othersterile injectable medium immediately before use. These compositions mayalso optionally contain opacifying agents and may be of a compositionthat they release the active ingredient(s) only, or preferentially, in acertain portion of the gastrointestinal tract, optionally, in a delayedmanner. Examples of embedding compositions which can be used includepolymeric substances and waxes. The active ingredient can also be inmicro-encapsulated form, if appropriate, with one or more of theabove-described excipients.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups,and elixirs. In addition to the active ingredient, the liquid dosageforms may contain inert diluents commonly used in the art, such as, forexample, water or other solvents, solubilizing agents, and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils (in particular, cottonseed, groundnut, corn, germ, olive,castor, and sesame oils), glycerol, tetrahydrofuryl alcohol,polyethylene glycols, and fatty acid esters of sorbitan, and mixturesthereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring, coloring, perfuming, and preservative agents.

Suspensions, in addition to the active compound(s) may containsuspending agents as, for example, ethoxylated isostearyl alcohols,polyoxyethylene sorbitol and sorbitan esters, microcrystallinecellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth,and mixtures thereof.

Pharmaceutical compositions suitable for parenteral administration caninclude one or more compounds provided herein in combination with one ormore pharmaceutically acceptable sterile aqueous or nonaqueoussolutions, dispersions, suspensions or emulsions, or sterile powderswhich may be reconstituted into sterile injectable solutions ordispersions just prior to use, which may contain antioxidants, buffers,bacteriostats, solutes which render the formulation isotonic with theblood of the intended recipient or suspending or thickening agents.

In one embodiment, the IV formulation consists of a compositioncontaining hydroxypropyl beta cyclodextrin within a pH range between8-10 as a buffered or unbuffered solution. The IV formulation can beformulated as a sterile solution ready for injection, a sterile solutionready for dilution into an IV admixture or a sterile solid forreconstituion. The API in the IV formulation may exist as a freeacid/base or an in situ salt.

Examples of suitable aqueous and nonaqueous carriers which may beemployed in the pharmaceutical compositions provided herein includewater for injection (e.g., sterile water for injection), bacteriostaticwater, ethanol, polyols (such as glycerol, propylene glycol,polyethylene glycol such as liquid polyethylene glycol, and the like),sterile buffer (such as citrate buffer), and suitable mixtures thereof,vegetable oils, such as olive oil, injectable organic esters, such asethyl oleate, and Cremophor EL™ (BASF, Parsippany, N.J.). In all cases,the composition must be sterile and should be fluid to the extent thateasy syringability exists. Proper fluidity can be maintained, forexample, by the use of coating materials, such as lecithin, by themaintenance of the required particle size in the case of dispersions,and by the use of surfactants.

The composition should be stable under the conditions of manufacture andstorage and must be preserved against the contaminating action ofmicroorganisms such as bacteria and fungi. Prevention of the action ofmicroorganisms can be achieved by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, ascorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, polyalcohols such asmannitol, sorbitol, and sodium chloride in the composition. Prolongedabsorption of the injectable compositions can be brought about byincluding in the composition an agent that delays absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle, which containsa basic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the methods of preparation arefreeze-drying (lyophilization), which yields a powder of the activeingredient plus any additional desired ingredient from a previouslysterile-filtered solution thereof.

Injectable depot forms can be made by forming microencapsule ornanoencapsule matrices of a compound provided herein in biodegradablepolymers such as polylactide-polyglycolide. Depending on the ratio ofdrug to polymer, and the nature of the particular polymer employed, therate of drug release can be controlled. Examples of other biodegradablepolymers include poly(orthoesters) and poly(anhydrides). Depotinjectable formulations are also prepared by entrapping the drug inliposomes, microemulsions or nanoemulsions, which are compatible withbody tissue.

For administration by inhalation, the compounds can be delivered in theform of an aerosol spray from a pressured container or dispenser thatcontains a suitable propellant (e.g., a gas such as carbon dioxide) or anebulizer. Such methods include those described in U.S. Pat. No.6,468,798. Additionally, intranasal delivery can be accomplished, asdescribed in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol.,88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Pat. No.6,472,375, which is incorporated herein by reference in its entirety),microencapsulation and nanoencapsulation can also be used. Biodegradabletargetable microparticle delivery systems or biodegradable targetablenanoparticle delivery systems can also be used (e.g., as described inU.S. Pat. No. 6,471,996, which is incorporated herein by reference inits entirety).

Systemic administration of a therapeutic compound as described hereincan also be by transmucosal or transdermal means. Dosage forms for thetopical or transdermal administration of a compound provided hereininclude powders, sprays, ointments, pastes, creams, lotions, gels,solutions, patches, and inhalants. The active component may be mixedunder sterile conditions with a pharmaceutically acceptable carrier, andwith any preservatives, buffers, or propellants which may be required.For transmucosal or transdermal administration, penetrants appropriateto the barrier to be permeated are used in the formulation. Suchpenetrants are generally known in the art, and include, for example, fortransmucosal administration, detergents, bile salts, and fusidic acidderivatives. Transmucosal administration can be accomplished through theuse of nasal sprays or suppositories. For transdermal administration,the active compounds are formulated into ointments, salves, gels, orcreams as generally known in the art.

The ointments, pastes, creams, and gels may contain, in addition to oneor more compounds provided herein, excipients, such as animal andvegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycols, silicones, bentonites, silicic acid,talc, and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a compound providedherein, excipients such as lactose, talc, silicic acid, aluminumhydroxide, calcium silicates, and polyamide powder, or mixtures of thesesubstances. Sprays can additionally contain customary propellants, suchas chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons,such as butane and propane.

A compound provided herein can be administered by aerosol. This isaccomplished by preparing an aqueous aerosol, liposomal preparation, orsolid particles containing a compound or composition provided herein. Anonaqueous (e.g., fluorocarbon propellant) suspension could be used. Insome embodiments, sonic nebulizers are used because they minimizeexposing the agent to shear, which can result in degradation of thecompound.

Ordinarily, an aqueous aerosol can be made by formulating an aqueoussolution or suspension of the agent together with conventionalpharmaceutically acceptable carriers and stabilizers. The carriers andstabilizers vary with the requirements of the particular composition,but typically include nonionic surfactants (TWEEN® (polysorbates),PLURONIC® (poloxamers), sorbitan esters, lecithin, CREMOPHOR®(polyethoxylates)), pharmaceutically acceptable co-solvents such aspolyethylene glycol, innocuous proteins like serum albumin, sorbitanesters, oleic acid, lecithin, amino acids such as glycine, buffers,salts, sugars, or sugar alcohols. Aerosols generally are prepared fromisotonic solutions.

Transdermal patches have the added advantage of providing controlleddelivery of a compound provided herein to the body. Such dosage formscan be made by dissolving or dispersing the agent in the proper medium.Absorption enhancers can also be used to increase the flux of thecompound across the skin. The rate of such flux can be controlled byeither providing a rate controlling membrane or dispersing the compoundin a polymer matrix or gel.

The pharmaceutical compositions can also be prepared in the form ofsuppositories or retention enemas for rectal and/or vaginal delivery.Formulations presented as a suppository can be prepared by mixing one ormore compounds provided herein with one or more suitable nonirritatingexcipients or carriers comprising, for example, cocoa butter,glycerides, polyethylene glycol, a suppository wax or a salicylate,which is solid at room temperature, but liquid at body temperature and,therefore, will melt in the rectum or vaginal cavity and release theactive agent. Formulations which are suitable for vaginal administrationalso include pessaries, tampons, creams, gels, pastes, foams, or sprayformulations containing such carriers as are known in the art to beappropriate.

In one embodiment, the therapeutic compounds are prepared with carriersthat will protect the therapeutic compounds against rapid eliminationfrom the body, such as a controlled release formulation, includingimplants and microencapsulated delivery systems. Biodegradable,biocompatible polymers can be used, such as ethylene vinyl acetate,polyanhydrides, polyglycolic acid, collagen, polyorthoesters, andpolylactic acid. Such formulations can be prepared using standardtechniques, or obtained commercially (e.g., from Alza Corporation andNova Pharmaceuticals, Inc). Liposomal suspensions (including liposomestargeted to selected cells with monoclonal antibodies to cellularantigens) can also be used as pharmaceutically acceptable carriers.These can be prepared according to methods known to those skilled in theart, for example, as described in U.S. Pat. No. 4,522,811, which isincorporated herein by reference in its entirety for all purposes.

The compounds of the present invention are used in the treatment ofdiseases, disorders or symptoms mediated by Mcl-1 inhibition. Examplesof diseases, disorders or symptoms mediated by Mcl-1 inhibition include,but are not limited to, cancers. Non-limiting examples of cancersinclude breast cancer, colorectal cancer, skin cancer, melanoma, ovariancancer, kidney cancer, lung cancer, non-small cell lung cancer,lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia,and acute myelogenous leukemia.

The cancers can include carcinomas (originating in the outer layer ofcells of the skin and internal membranes, e.g., breasts, kidneys, lungs,skin); sarcomas (arising from connective tissue such as bone, muscle,cartilage, and blood vessels), and hematologic malignancies (e.g.,lymphomas and leukemias, which arise in the blood or blood-formingorgans such as the spleen, lymph nodes, and bone marrow). Cancer cellscan include, for example, tumor cells, neoplastic cells, malignantcells, metastatic cells, and hyperplastic cells.

In an embodiment, the disease, disorder or symptom is ahyperproliferative disorder, e.g., a lymphoma, leukemia, carcinoma(e.g., renal, breast, lung, skin), multiple myeloma, or a sarcoma. Inone embodiment, the leukemia is acute myeloid leukemia. In oneembodiment, the hyperproliferative disorder is a relapsed or refractorycancer.

Actual dosage levels of the active ingredients in the pharmaceuticalcompositions provided herein may be varied so as to obtain an amount ofthe active ingredient which is effective to achieve the desiredtherapeutic response for a particular patient, composition, and mode ofadministration, without being toxic to the patient.

The specific dosage and dosage range depends on a number of factors,including the requirements of the patient, the severity of the conditionor disease being treated, the pharmacokinetic characteristics of thecompound(s) employed, and the route of administration. In someembodiments, the compositions provided herein can be provided in anaqueous solution containing about 0.1-10% w/v of a compound disclosedherein, among other substances, for parenteral administration. Typicaldose ranges can include from about 0.01 to about 50 mg/kg of body weightper day, given in 1-4 divided doses. Each divided dose may contain thesame or different compounds. The dosage will be a therapeuticallyeffective amount depending on several factors including the overallhealth of a patient, and the formulation and route of administration ofthe selected compound(s).

Dosage forms or compositions containing a compound as described hereinin the range of 0.005% to 100% with the balance made up from non-toxiccarrier may be prepared. Methods for preparation of these compositionsare known to those skilled in the art. The contemplated compositions maycontain about 0.001%-100% active ingredient, in one embodiment fromabout 0.1 to about 95%, in another embodiment from about 75 to about85%. Although the dosage will vary depending on the symptoms, age andbody weight of the patient, the nature and severity of the disorder tobe treated or prevented, the route of administration and the form of thedrug, in general, a daily dosage of from about 0.01 to about 3,000 mg ofthe compound is recommended for an adult human patient, and this may beadministered in a single dose or in divided doses. The amount of activeingredient which can be combined with a carrier material to produce asingle dosage form will generally be that amount of the compound whichproduces a therapeutic effect.

The pharmaceutical composition may be administered at once, or may bedivided into a number of smaller doses to be administered at intervalsof time. It is understood that the precise dosage and duration oftreatment is a function of the disease being treated and may bedetermined empirically using known testing protocols or by extrapolationfrom in vivo or in vitro test data. It is to be noted thatconcentrations and dosage values may also vary with the severity of thecondition to be alleviated. It is to be further understood that for anyparticular patient, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of thecompositions, and that the concentration ranges set forth herein areexemplary only and are not intended to limit the scope or practice ofthe claimed compositions.

The precise time of administration and/or amount of the composition thatwill yield the most effective results in terms of efficacy of treatmentin a given patient will depend upon the activity, pharmacokinetics, andbioavailability of a particular compound, physiological condition of thepatient (including age, sex, disease type and stage, general physicalcondition, responsiveness to a given dosage, and type of medication),route of administration, etc. However, the above guidelines can be usedas the basis for fine-tuning the treatment, e.g., determining theoptimum time and/or amount of administration, which will require no morethan routine experimentation consisting of monitoring the patient andadjusting the dosage and/or timing

The compounds of the present invention can be administered alone, incombination with other compounds of the present invention, or with otherpharmaceutically active compounds or agents. The other pharmaceuticallyactive compounds/agents can be intended to treat the same disease orcondition as the compounds of the present invention or a differentdisease or condition. If the patient is to receive or is receivingmultiple pharmaceutically active compounds or agents, the compounds canbe administered simultaneously, or sequentially.

The compounds of the present invention, or pharmaceutically acceptablesalts thereof, may be used in combination with one or more additionalpharmaceutically active compounds/agents.

One or more additional pharmaceutically active compounds or agents maybe administered separately, as part of a multiple dose regimen, from thecompound of Formula I (e.g., sequentially, e.g., on differentoverlapping schedules with the administration of one or more compoundsof Formula I (including any subgenera or specific compounds thereof). Inother embodiments, the one or more additional compounds/agents may bepart of a single dosage form, mixed together with the compound ofFormula I in a single composition. In still another embodiment, the oneor more additional compounds/agents can be given as a separate dose thatis administered at about the same time that one or more compounds ofFormula I are administered (e.g., simultaneously with the administrationof one or more compounds of Formula I (including any subgenera orspecific compounds thereof). Both the compound of Formula I and the oneor more additional compounds/agents can be present at dosage levels ofbetween about 1 to 100%, and more preferably between about 5 to 95% ofthe dosage normally administered in a monotherapy regimen.

In a particular embodiment, the additional pharmaceutically activecompound/agent is a compound or agent that can be used to treat acancer. For example, the additional pharmaceutically activecompound/agent can be selected from antineoplastic agents,anti-angiogenic agents, chemotherapeutic agents, and peptidal cancertherapy agents. In another embodiment, the antineoplastic agents areselected from antibiotic-type agents, alkylating agents, antimetaboliteagents, hormonal agents, immunological agents, interferon-type agents,kinase inhibitors, proteasome inhibitors, and combinations thereof. Itis noted that the additional pharmaceutically active compound/agent maybe a traditional small organic chemical molecule or can be amacromolecule such as a protein, antibody, peptibody, DNA, RNA or afragment of such macromolecules.

Examples of additional pharmaceutically active compounds/agents that canbe used in the treatment of cancers and that can be used in combinationwith one or more compounds of the present invention include: acemannan;aclarubicin; aldesleukin; alitretinoin; amifostine; amrubicin;amsacrine; anagrelide; arglabin; arsenic trioxide; BAM 002 (Novelos);bicalutamide; broxuridine; celmoleukin; cetrorelix; cladribine;clotrimazole; DA 3030 (Dong-A); daclizumab; denileukin diftitox;deslorelin; dilazep; docosanol; doxercalciferol; doxifluridine;bromocriptine; cytarabine; HIT diclofenac; interferon alfa; tretinoin;edelfosine; edrecolomab; eflornithine; emitefur; epirubicin; epoetinbeta; etoposide phosphate; exisulind; fadrozole; finasteride;fludarabine phosphate; formestane; fotemustine; gallium nitrate;gemtuzumab zogamicin; gimeracil/oteracil/tegafur combination; glycopine;goserelin; heptaplatin; human chorionic gonadotropin; human fetal alphafetoprotein; ibandronic acid; interferon alfa; interferon alfa natural;interferon alfa-2; interferon alfa-2a; interferon alfa-2b; interferonalfa-N1; interferon alfa-n3; interferon alfacon-1; interferon alphanatural; interferon beta; interferon beta-1a; interferon beta-1b;interferon gamma natural; interferon gamma-1a; interferon gamma-1b;interleukin-1 beta; iobenguane; irsogladine; lanreotide; LC 9018(Yakult); leflunomide; lenograstim; lentinan sulfate; letrozole;leukocyte alpha interferon; leuprorelin; levamisole+fluorouracil;liarozole; lobaplatin; lonidamine; lovastatin; masoprocol; melarsoprol;metoclopramide; mifepristone; miltefosine; mirimostim; mismatched doublestranded RNA; mitoguazone; mitolactol; mitoxantrone; molgramostim;nafarelin; naloxone+pentazocine; nartograstim; nedaplatin; nilutamide;noscapine; novel erythropoiesis stimulating protein; NSC 631570octreotide; oprelvekin; osaterone; paclitaxel; pamidronic acid;peginterferon alfa-2b; pentosan polysulfate sodium; pentostatin;picibanil; pirarubicin; rabbit antithymocyte polyclonal antibody;polyethylene glycol interferon alfa-2a; porfimer sodium; raltitrexed;rasburicase; rhenium Re 186 etidronate; RII retinamide; romurtide;samarium (153 Sm) lexidronam; sargramostim; sizofuran; sobuzoxane;sonermin; strontium-89 chloride; suramin; tasonermin; tazarotene;tegafur; temoporfin; teniposide; tetrachlorodecaoxide; thymalfasin;thyrotropin alfa; toremifene; tositumomab-iodine 131; treosulfan;tretinoin; trilostane; trimetrexate; triptorelin; tumor necrosis factoralpha natural; ubenimex; bladder cancer vaccine; Maruyama vaccine;melanoma lysate vaccine; valrubicin; verteporfin; virulizin; zinostatinstimalamer; abarelix; AE 941 (Aeterna); ambamustine; antisenseoligonucleotide; bcl-2 (Genta); APC 8015 (Dendreon);dexaminoglutethimide; diaziquone; EL 532 (Elan); EM 800 (Endorecherche);eniluracil; etanidazole; fenretinide; galocitabine; gastrin 17immunogen; HLA-B7 gene therapy (Vical); granulocyte macrophage colonystimulating factor; histamine dihydrochloride; ibritumomab tiuxetan;ilomastat; IM 862 (Cytran); interleukin-2; iproxifene; LDI 200(Milkhaus); leridistim; lintuzumab; CA 125 monoclonal antibody (MAb)(Biomira); cancer MAb (Japan Pharmaceutical Development); HER-2 and FcMAb (Medarex); idiotypic 105AD7 MAb (CRC Technology); idiotypic CEA MAb(Trilex); LYM-1-iodine 131 MAb (Techniclone); polymorphic epithelialmucin-yttrium 90 MAb (Antisoma); marimastat; menogaril; mitumomab;motexafin gadolinium; MX 6 (Galderma); nolatrexed; P 30 protein;pegvisomant; porfiromycin; prinomastat; RL 0903 (Shire); rubitecan;satraplatin; sodium phenylacetate; sparfosic acid; SRL 172 (SR Pharma);SU 5416 (SUGEN); TA 077 (Tanabe); tetrathiomolybdate; thaliblastine;thrombopoietin; tin ethyl etiopurpurin; tirapazamine; cancer vaccine(Biomira); melanoma vaccine; melanoma oncolysate vaccine; viral melanomacell lysates vaccine; valspodarl; fluorouracil; 5-fluorouracil;pacitaxel; imatinib; altretamine; cladibrine; cyclophosphamine;decarazine; irinotecan; mitosmycin; mitoxane; topotecan; vinorelbine;adriamycin; mithram; imiquimod; alemtuzmab; exemestane; bevacizumab;cetuximab; azacitidine; clofarabine; decitabine; desatinib; dexrazoxane;docetaxel; epirubicin; oxaliplatin; erlotinib; raloxifene; fulvestrant;letrozole; gefitinib; gemtuzumab; trastuzumab; gefitinib; ixabepilone;lapatinib; lenalidomide; aminolevulinic acid; temozolomide; nelarabine;sorafenib; nilotinib; pegaspargase; pemetrexed; rituximab; dasatinib;thalidomide; bexarotene; temsirolimus; bortezomib; carfilozmib;oprozomib; vorinostat; capecitabine; zoledronic acid; anastrozole;sunitinib; aprepitant and nelarabine, or a pharmaceutically acceptablesalt thereof.

Additional pharmaceutically active compounds/agents that can be used inthe treatment of cancers and that can be used in combination with one ormore compound of the present invention include: epoetin alfa;darbepoetin alfa; panitumumab; pegfilgrastim; palifermin; filgrastim;denosumab; ancestim; AMG 102; AMG 386; AMG 479; AMG 655; AMG 745; AMG951; and AMG 706, or a pharmaceutically acceptable salt thereof.

In certain embodiments, a composition provided herein is conjointlyadministered with a chemotherapeutic agent. Suitable chemotherapeuticagents may include, natural products such as vinca alkaloids (e.g.,vinblastine, vincristine, and vinorelbine), paclitaxel,epidipodophyllotoxins (e.g., etoposide and teniposide), antibiotics(e.g., dactinomycin (actinomycin D), daunorubicin, doxorubicin, andidarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin(mithramycin), mitomycin, enzymes (e.g., L-asparaginase whichsystemically metabolizes L-asparagine and deprives cells which do nothave the capacity to synthesize their own asparagine), antiplateletagents, antiproliferative/antimitotic alkylating agents such as nitrogenmustards (e.g., mechlorethamine, cyclophosphamide and analogs,melphalan, and chlorambucil), ethylenimines and methylmelamines (e.g.,hexaamethylmelaamine and thiotepa), CDK inhibitors (e.g., seliciclib,UCN-01, P1446A-05, PD-0332991, dinaciclib, P27-00, AT-7519, RGB286638,and SCH727965), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g.,carmustine (BCNU) and analogs, and streptozocin), trazenes-dacarbazinine(DTIC), antiproliferative/antimitotic antimetabolites such as folic acidanalogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil,floxuridine, and cytarabine), purine analogs and related inhibitors(e.g., mercaptopurine, thioguanine, pentostatin and2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole,exemestane, and letrozole), and platinum coordination complexes (e.g.,cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane,aminoglutethimide, histone deacetylase (HDAC) inhibitors (e.g.,trichostatin, sodium butyrate, apicidan, suberoyl anilide hydroamicacid, vorinostat, LBH 589, romidepsin, ACY-1215, and panobinostat), mTorinhibitors (e.g., temsirolimus, everolimus, ridaforolimus, andsirolimus), KSP(Eg5) inhibitors (e.g., Array 520), DNA binding agents(e.g., Zalypsis), PI3K delta inhibitor (e.g., GS-1101 and TGR-1202),PI3K delta and gamma inhibitor (e.g., CAL-130), multi-kinase inhibitor(e.g., TG02 and sorafenib), hormones (e.g., estrogen) and hormoneagonists such as leutinizing hormone releasing hormone (LHRH) agonists(e.g., goserelin, leuprolide and triptorelin), BAFF-neutralizingantibody (e.g., LY2127399), IKK inhibitors, p38MAPK inhibitors,anti-IL-6 (e.g., CNTO328), telomerase inhibitors (e.g., GRN 163L),aurora kinase inhibitors (e.g., MLN8237), cell surface monoclonalantibodies (e.g., anti-CD38 (HUMAX-CD38), anti-CS1 (e.g., elotuzumab),HSP90 inhibitors (e.g., 17 AAG and KOS 953), P13K/Akt inhibitors (e.g.,perifosine), Akt inhibitor (e.g., GSK-2141795), PKC inhibitors (e.g.,enzastaurin), FTIs (e.g., Zarnestra™), anti-CD138 (e.g., BT062), Torc1/2specific kinase inhibitor (e.g., INK128), kinase inhibitor (e.g.,GS-1101), ER/UPR targeting agent (e.g., MKC-3946), cFMS inhibitor (e.g.,ARRY-382), JAK1/2 inhibitor (e.g., CYT387), PARP inhibitor (e.g.,olaparib and veliparib (ABT-888)), BCL-2 antagonist. Otherchemotherapeutic agents may include mechlorethamine, camptothecin,ifosfamide, tamoxifen, raloxifene, gemcitabine, navelbine, sorafenib, orany analog or derivative variant of the foregoing.

The compounds of the present invention may also be used in combinationwith radiation therapy, hormone therapy, surgery and immunotherapy,which therapies are well known to those skilled in the art.

In certain embodiments, a pharmaceutical composition provided herein isconjointly administered with a steroid. Suitable steroids may include,but are not limited to, 21-acetoxypregnenolone, alclometasone,algestone, amcinonide, beclomethasone, betamethasone, budesonide,chloroprednisone, clobetasol, clocortolone, cloprednol, corticosterone,cortisone, cortivazol, deflazacort, desonide, desoximetasone,dexamethasone, diflorasone, diflucortolone, difuprednate, enoxolone,fluazacort, flucloronide, flumethasone, flunisolide, fluocinoloneacetonide, fluocinonide, fluocortin butyl, fluocortolone,fluorometholone, fluperolone acetate, fluprednidene acetate,fluprednisolone, flurandrenolide, fluticasone propionate, formocortal,halcinonide, halobetasol propionate, halometasone, hydrocortisone,loteprednol etabonate, mazipredone, medrysone, meprednisone,methylprednisolone, mometasone furoate, paramethasone, prednicarbate,prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodiumphosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol,triamcinolone, triamcinolone acetonide, triamcinolone benetonide,triamcinolone hexacetonide, and salts and/or derivatives thereof. In aparticular embodiment, the compounds of the present invention can alsobe used in combination with additional pharmaceutically active agentsthat treat nausea. Examples of agents that can be used to treat nauseainclude: dronabinol; granisetron; metoclopramide; ondansetron; andprochlorperazine; or a pharmaceutically acceptable salt thereof.

As one aspect of the present invention contemplates the treatment of thedisease/conditions with a combination of pharmaceutically activecompounds that may be administered separately, the invention furtherrelates to combining separate pharmaceutical compositions in kit form.The kit comprises two separate pharmaceutical compositions: a compoundof the present invention, and a second pharmaceutical compound. The kitcomprises a container for containing the separate compositions such as adivided bottle or a divided foil packet. Additional examples ofcontainers include syringes, boxes, and bags. In some embodiments, thekit comprises directions for the use of the separate components. The kitform is particularly advantageous when the separate components arepreferably administered in different dosage forms (e.g., oral andparenteral), are administered at different dosage intervals, or whentitration of the individual components of the combination is desired bythe prescribing health care professional.

The compounds of the present invention can be administered aspharmaceutically acceptable salts, esters, amides or prodrugs. The term“salts” refers to inorganic and organic salts of compounds of thepresent invention. The salts can be prepared in situ during the finalisolation and purification of a compound, or by separately reacting apurified compound in its free base or acid form with a suitable organicor inorganic base or acid and isolating the salt thus formed.Representative salts include the hydrobromide, hydrochloride, sulfate,bisulfate, nitrate, acetate, oxalate, palmitiate, stearate, laurate,borate, benzoate, lactate, phosphate, tosylate, citrate, maleate,fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate,lactobionate, and laurylsulphonate salts, and the like. The salts mayinclude cations based on the alkali and alkaline earth metals, such assodium, lithium, potassium, calcium, magnesium, and the like, as well asnon-toxic ammonium, quaternary ammonium, and amine cations including,but not limited to, ammonium, tetramethylammonium, tetraethylammonium,methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine,and the like. See, for example, S. M. Berge, et al., “PharmaceuticalSalts,” J Pharm Sci, 66: 1-19 (1977).

The term “prodrug” means compounds that are transformed in vivo to yielda compound of the present invention. The transformation may occur byvarious mechanisms, such as through hydrolysis in blood. A discussion ofthe use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugsas Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, andin Bioreversible Carriers in Drug Design, ed. Edward B. Roche, AmericanPharmaceutical Association and Pergamon Press, 1987.

To illustrate, if the compound of the invention contains a carboxylicacid functional group, a prodrug can comprise an ester formed by thereplacement of the hydrogen atom of the acid group with a group such as(C₁-C₈ alkyl, (C₂-C₁₂)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl havingfrom 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)ethyl having from 5 to10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbonatoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms,N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms,1-(N-(alkoxycarbonyl)aminomethyl having from 4 to 10 carbon atoms,3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,di-N,N—(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as (3-dimethylaminoethyl),carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl andpiperidino-, pyrrolidino- or morpholino(C₂₋₃)alkyl.

Similarly, if a compound of the present invention comprises an alcoholfunctional group, a prodrug can be formed by the replacement of thehydrogen atom of the alcohol group with a group such as(C₁-C₆)alkanoyloxymethyl, 1-((C₁-C₆)alkanoyloxy)ethyl,1-methyl-1-((C₁-C₆)alkanoyloxy)ethyl, (C₁-C₆)alkoxycarbonyloxymethyl,N—(C₁-C₆)alkoxycarbonylaminomethyl, succinoyl, (C₁-C₆)alkanoyl,α-amino(C₁-C₄)alkanoyl, arylacyl and α-aminoacyl, orα-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independentlyselected from the naturally occurring L-amino acids, —P(O)(OH)₂,—P(O)(O(C₁-C₆)alkyl)₂ or glycosyl (the radical resulting from theremoval of a hydroxyl group of the hemiacetal form of a carbohydrate).

The compounds of the present invention may contain asymmetric or chiralcenters, and therefore, exist in different stereoisomeric forms. It iscontemplated that all stereoisomeric forms of the compounds as well asmixtures thereof, including racemic mixtures, form part of the presentinvention. In addition, the present invention contemplates all geometricand positional isomers. For example, if the compound contains a doublebond, both the cis and trans forms (designated as Z and E,respectively), as well as mixtures, are contemplated.

Mixture of stereoisomers, such as diastereomeric mixtures, can beseparated into their individual stereochemical components on the basisof their physical chemical differences by known methods such aschromatography and/or fractional crystallization. Enantiomers can alsobe separated by converting the enantiomeric mixture into a diasteromericmixture by reaction with an appropriate optically active compound (e.g.,an alcohol), separating the diastereomers and converting (e.g.,hydrolyzing) the individual diastereomers to the corresponding pureenantiomers.

The compounds of the present invention may exist in unsolvated as wellas solvated forms with pharmaceutically acceptable solvents such aswater (hydrate), ethanol, and the like. The present inventioncontemplates and encompasses both the solvated and unsolvated forms.

It is also possible that compounds of the present invention may exist indifferent tautomeric forms. All tautomers of compounds of the presentinvention are contemplated. Those skilled in the art will recognize thatthe compound names and structures contained herein may be based on aparticular tautomer of a compound. While the name or structure for onlya particular tautomer may be used, it is intended that all tautomers areencompassed by the present invention, unless stated otherwise.

It is also intended that the present invention encompass compounds thatare synthesized in vitro using laboratory techniques, such as those wellknown to synthetic chemists; or synthesized using in vivo techniques,such as through metabolism, fermentation, digestion, and the like. It isalso contemplated that the compounds of the present invention may besynthesized using a combination of in vitro and in vivo techniques.

The compounds of the present invention may exist in various solid statesincluding crystalline states and as an amorphous state. The differentcrystalline states, also called polymorphs, and the amorphous states ofthe present compounds are contemplated as part of this invention.

EXAMPLES

The examples presented below illustrate specific embodiments of thepresent invention. These examples are meant to be representative and arenot intended to limit the scope of the claims in any manner.

The following abbreviations may be used herein:

-   -   ˜ about    -   Ac₂O acetic anhydride    -   AcOH acetic acid    -   Al₂O₃ aluminum oxide    -   Calcd Calculated    -   CO₂ carbon dioxide    -   CSA 10-camphorsulfonic acid    -   DBU 1,8-diazabicyclo[5.4.0]undec-7-ene    -   DCE Dichloroethane    -   DCM Dichloromethane    -   DEA Diethylamine    -   Dess-Martin        1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3-periodinane;        (1H)-one    -   DIEA or DIPEA Diisopropylethylamine    -   DMAP 4-dimethylaminopyridine    -   DMF N,N-dimethylformamide    -   DMSO dimethyl sulfoxide    -   EDC N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide    -   ee or e.e. enantiomeric excess    -   eq Equivalent    -   ESI or ES electrospray ionization    -   Et Ethyl    -   Et₂O diethyl ether    -   EtOAc ethyl acetate    -   Et₃N triethylamine    -   EtOH ethyl alcohol    -   g gram(s)    -   GC gas chromatography    -   h hour(s)    -   ¹H NMR proton nuclear magnetic resonance spectroscopy    -   H₂ hydrogen gas    -   H₂O Water    -   H₂SO₄ sulfuric acid    -   HATU        1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium        3-oxide hexafluorophosphate    -   HCl hydrochloric acid    -   Hex hexane(s)    -   HPLC high performance liquid chromatography    -   IP intraperitoneal    -   IPA isopropyl alcohol    -   IPAc isopropyl acetate    -   K₂CO₃ potassium carbonate    -   K₃PO₄ potassium phosphate    -   KF Karl Fischer titration    -   KHMDS potassium hexamethyldisilazide    -   KOAc potassium acetate    -   KOH potassium hydroxide    -   L liter(s)    -   LAH lithium aluminium hydride    -   LCMS, LC-MS or LC/MS liquid chromatography mass spectrometry    -   LiHMDS lithium hexamethyldisilazide    -   LiOH lithium hydroxide    -   M molar (mol L⁻¹)    -   Me methyl    -   MeCN acetonitrile    -   MeI iodomethane    -   MeOH methyl alcohol    -   MeTHF methyltetrahydrofuran    -   mg milligram(s)    -   MgSO₄ magnesium sulphate    -   min minute(s)    -   mL milliliter(s)    -   MS mass spectrometry    -   MSA methanesulfonic acid    -   MSCl methanesulfonyl chloride    -   MTBE methyl tert-butyl ether    -   m/z mass-to-charge ratio    -   N Normality (Eq/L)    -   N₂ nitrogen gas    -   NaCl sodium chloride    -   Na₂CO₃ sodium carbonate    -   NaHCO₃ sodium bicarbonate    -   NaH₂PO₄ sodium dihydrogen phosphate    -   NaNO₂ sodium nitrite    -   NaOH sodium hydroxide    -   NaOtBu sodium tert-butoxide    -   Na₂SO₄ sodium sulfate    -   Na₂S₂O₃ sodium thiosulfate    -   NH₃ ammonia, azane    -   NH₄Cl ammonium chloride    -   NH₄OH ammonium hydroxide    -   NMP 1-methyl-2-pyrrolidinone    -   NMR nuclear magnetic resonance spectroscopy    -   PO per oral    -   POCl₃ phosphoryl chloride    -   PhMe toluene    -   ppm parts per million    -   QD once daily    -   QNMR quantitative NMR    -   RBF round-bottomed flask    -   RT or rt or r.t. room temperature    -   sat. or sat'd or satd Saturated    -   SFC supercritical fluid chromatography    -   SiO₂ silicon dioxide, silica    -   SOCl₂ thionyl chloride    -   TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl    -   TFA triflouroacetic acid    -   THF Tetrahydrofuran    -   TLC thin layer chromatography    -   TsOH toluene sulfonic acid    -   v/v volume per volume

It is noted that when a percent (%) is used with regard to a liquid, itis a percent by volume with respect to the solution. When used with asolid, it is the percent with regard to the solid composition.

Biological Assays

Cell free Mcl-1: Bim Affinity Assay (Mcl-1 HTRF)

The inhibition of the Mcl-1/Bim interaction was measured using atime-resolved fluorescence resonance energy transfer (TR-FRET) assay.The recombinant human Mcl-1 (C-terminally 6× His tagged Mcl-1 containingresidues 171-327) was generated at Amgen Inc (Thousand Oaks, Calif.). Abiotinylated peptide derived from human Bim (residues 51-76) waspurchased from CPC Scientific (San Jose, Calif.). The TR-FRET assay wasconducted in a 384-well white OptiPlate™ (PerkinElmer, Waltham, Mass.)in a total volume of 40 μL. The reaction mixture contained 0.1 nMMcl-1(171-327), 0.05 nM biotin-Bim(51-76), 0.05 nM LANCE® Eu-W1024Anti-6× His (PerkinElmer), 0.072 nM Streptavidin-XLent (Cisbio, Bedford,Mass.), and serially diluted test compounds in the binding buffer of 20mM Hepes, pH 7.5, 150 mM NaCl, 0.016 mM Brij® 35, and 1 mMdithiothreitol. Test compounds were pre-incubated with Mcl-1(171-327)and biotin-Bim (51-76) for 60 min before addition of the detectionmixture (LANCE® Eu-W1024 Anti-6× His and Streptavidin-XLent). Thereaction plates were further incubated overnight and then were read onan Envision® multimode reader (PerkinElmer). Fluorescence signals weremeasured at 620 nm (40-nm bandwidth) and 665 nm (7.5-nm bandwidth) witha 60 μs delay after excitation at 320 nm (75-nm bandwidth). The signalratio at 665/620 nm corresponded to the Mcl-1/Bim interaction and wasused in all data analyses. The IC₅₀ values of test compounds weredetermined from duplicate data by analyzing competition curves using afour-parameter sigmoidal model in GraphPad Prism (GraphPad Software, SanDiego, Calif.) or in Genedata Screener® (Genedata, Basel, Switzerland).

Cell-Based Assay (Split Luciferase)

A split luciferase complementation assay was developed to determine theinhibition of Mcl-1/Bak protein-protein interactions in cells. ApcDNA-Luc(1-298)-BAK expression vector encoding amino acids (1-298) ofFirefly luciferase fused to human Bak was generated along with apcDNA-Luc(395-550)-Mcl-1 expression vector encoding amino acids(395-550) of Firefly luciferase fused to the human Mcl-1 gene. Humanembryonic kidney (HEK) 293 M cells were transiently transfected withpcDNA-Luc(1-298)-BAK and pcDNA-Luc(395-550)-Mcl-1 at a 3:1 DNA mixratio. Transient transfection was performed using Lipofectamine®LTX/Plus™ reagent (Life Technologies, Grand Island, N.Y.). 24 h aftertransfection, cells were collected using non-enzyme based celldissociation buffer StemPro® Accutase® (Life Technologies), andresuspended in serum-free Opti-MEM® (Life Technologies). Cells were thenseeded into assay plates with serially diluted test compounds in 0.3%DMSO at density of a 5000 cells/well. Cells were then incubated for 4 hat 37° C. in a cell culture incubator supplement with 5% CO₂. Testplates were equilibrated to room temperate for 30 min before addition of30 μL Steady-Glo® Luciferase assay reagent (Promega, Madison, Wis.) intoeach test well. Luminescence was determined using an EnVision®Multilabel plate reader 25 min after the addition of detection reagent.IC₅₀ values were then calculated with Xlfit using a logistical4-parameter fit model in GraphPad Prism (GraphPad Software, San Diego,Calif.) or in Genedata Screener® (Genedata, Basel, Switzerland).

Cell Viability Assay (OPM-2 10 FBS)

The human multiple myeloma cell line, OPM-2, was cultured in completegrowth medium containing RPMI 1640 and 10% fetal bovine serum (FBS).Cells were seeded into 384-well plates at 3000 cells/well density incomplete growth medium containing 10% FBS, and incubated for 16 h withserially diluted test compounds in a 37° C. incubator with 5% CO₂. Cellviability was tested using CellTiter-Glo® assay (Promega, Madison, Wis.)according to the manufacturer recommendations. Luminescence wasdetermined using an EnVision® Multilabel plate reader 25 min after theaddition of detection reagent. IC₅₀ values were then calculated withXlfit using a logistical 4-parameter fit model in GraphPad Prism(GraphPad Software, San Diego, Calif.) or in Genedata Screener®(Genedata, Basel, Switzerland).

Results for compounds tested in these biological assays are set forthbelow.

Split Mcl-1 HTRF Luciferase OPM-2 10% Example # (nM) (μM) FBS (μM) 10.85225 0.16327 1.88 2 0.21889 0.016948 0.10469 3 0.18143 0.0322750.4845 4 0.36286 0.030808 0.23574 5 0.5115 0.0645 1.135 6 0.4465 0.057450.3945 7 1.175 0.147 1.06 8 0.977 0.211 1.68 9 1.2445 0.12655 1.1975 101.1846 0.2322 9.41 11 0.27715 0.042346 0.3225 12 9.48 1.0163 22.2 130.44069 0.034118 0.353 14 0.7012 0.090865 2.0977 15 64.42 0.951 12.6 162.08 0.107 4.335 17 0.24701 0.031189 0.25999 18 0.37167 0.042467 0.6943319 2.875 0.529 3.99 20 0.64711 0.050429 0.3905 21 2.78 0.1925 4.17 220.70423 0.11712 1.254 23 3.68 0.3715 — 24 0.153 0.020067 0.1246 250.5425 0.0779 0.4045 26 2.6433 0.40167 3.46 27 19.85 1.14 — 28 0.89550.14387 1.54 29 9.435 0.458 5.575 30 0.38025 0.02645 0.16075 31 5.80.543 3.56 32 0.8105 0.0495 0.24167 33 7.02 0.872 14.9 34 0.437 0.0376750.253 35 0.9545 0.08435 0.723 36 44.45 1.5 — 37 0.6.08 0.667 5.74 380.3.3 1.04 — 39 10.678 — 40 7.68 0.297 7.295 41 4.415 0.1285 4.75 427.55 0.8495 — 43 1.75 0.1295 0.9015 44 0.297 0.0215 0.2075 45 5.5050.455 20 46 0.728 0.0783 0.334 47 0.2485 0.06005 0.2835 48 3.89 0.4775.58 49 0.3165 0.0462 0.1845 50 1.014 0.2325 1.3245 51 24.3 0.792 14.452 0.882 0.14 1.114 53 1.39 0.05145 0.3285 54 0.15275 0.02915 0.13115 5515.25 0.863 8.69 56 0.2895 0.03195 0.2075 57 2.155 0.3745 2.395 580.9175 0.0482 0.496 59 0.492 0.06155 0.247 60 0.51367 0.023433 0.1579861 2.675 0.06865 1.32 62 10.265 0.166 6.7 63 0.42325 0.030684 0.18329 6413.65 0.318 8.63 65 5.305 0.376 3.28 66 2.115 0.224 2.33 67 1.08450.08485 0.6 68 0.501 0.0164 0.17885 69 8.66 0.425 2.71 70 0.63850.034675 0.23825 71 5.415 0.354 2.22 72 2.705 0.16905 1.555 73 0.3670.0344 0.174 74 2.225 0.273 1.74 75 2.835 0.159 2.56 76 1.1245 0.077350.6685 77 6.125 0.26 3.16 78 2.665 0.42 2.74

OPM2 Multiple Myeloma Xenograft Model

Female Athymic nude (Harlan, Inc., Indianapolis, Ind.) mice wereinoculated subcutaneously with 5 million OPM-2 cells. FIGS. 1, 2 and 3illustrate the results of the treatment with test compounds in variousconcentrations, compared to the vehicle, defined as the excipient(s)without an active compound, and in FIG. 2 additionally compared toBortezomib™, a compound commercially available from MillenniumPharmaceuticals, Inc. (Cambridge, Mass.). The treatment was initiated 14days later when the tumors had reached an average volume of 100-200 mm³and continued for an additional 10 days. Tumor volumes and body weightswere recorded using electronic calipers and an analytical scale,respectively, twice per week. Statistical analysis was performed usingRepeated Measures ANOVA (RMANOVA) followed by Dunnett's post-hocanalysis.

The following synthetic schemes show generally how to make intermediatesand compounds of the present invention.

General Synthetic Schemes

General Procedure 1

Intermediates III can be prepared using standard chemistry techniques.For example, cyclobutane carbaldehyde II was combined with oxazepine Iin an appropriate solvent at a temperature below RT, preferably about 0°C. Sodium cyanoborohydride was added, and the mixture was added to NaOHsolution, to provide compound III.

General Procedure 2

Intermediates IV can be prepared using standard peptide like chemistry.For example, DMAP was added to carboxylic acid Intermediate AA andIntermediate EE in an appropriate solvent at a temperature below RT,preferably about 0° C., followed by the addition of EDC hydrochloride.The mixture was warmed to ambient temperature, to provide carboxamideIV.

General Procedure 3

Example A intermediates can be prepared using standard chemistrytechniques. For example, carboxamide IV was combined with DCM followedby the addition of Hoveyda-Grubbs II. The mixture was cooled to ambienttemperature to provide Example A.

General Procedure 4

Intermediates V can be prepared using standard chemistry techniques. Forexample, Intermediate AA was combined with Intermediate EE in anappropriate solvent followed by the addition of Hoveyda-Grubbs II toprovide compound V.

General Procedure 5

Example A intermediates can be prepared using standard chemistrytechniques. For example, N,N-dimethylpyridin-4-amine was combined withcompound VI in an appropriate solvent at a temperature below RT,preferably about 0° C., followed by the addition ofN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride. Theresulting mixture warmed to ambient temperature to provide Example A.

General Procedure 6

Example B intermediates can be prepared using standard chemistrytechniques. For example, sodium hydride was added to a solution ofExample A at a temperature below RT, preferably about 0° C., followed bythe addition of MeI. The resulting mixture warmed to ambient temperatureto provide Example B.

General Procedure 7

Intermediates such as Example C can be prepared using standard chemistrytechniques. For example, Example A and/or B and/or VII and platinum (IV)oxide were combined in an appropriate solvent at ambient temperature toprovide Example C.

Compounds of the present invention generally can be prepared combiningand further elaborating synthetic intermediates generated fromcommercially available starting materials. The syntheses of theseintermediates are outlined below and further exemplification is found inthe specific examples provided.

Intermediate AA11A(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

STEP 1: (R)-6-CHLORO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,2′-OXIRANE] AND(R)-6-CHLORO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,2′-OXIRANE]

A 2L 4-necked-RBF was charged with6-chloro-3,4-dihydro-1(2H)-naphthalenone (123 g, 681 mmol),trimethylsulfonium iodide (143 g, 701 mmol), and DMSO (1100 mL). KOH (76g, 1362 mmol) (pellets) was added. The suspension was stirred at ambienttemperature for 2 days, after which time crude ¹H NMR showed noremaining starting material. The solution was poured into 800 g ofcrushed ice, rinsed with MTBE (200 mL), and an additional portion ofMTBE (700 mL) was added. The resulting mixture was stirred for 5 min andafter partition, the bottom aqueous layer was extracted with MTBE twice(500 mL, 300 mL), and combined with the main MTBE extract. The combinedorganic stream was washed with brine (2×600 mL) and 330 g of Al₂O₃(neutral) was added. The resulting suspension was stirred for 5 min at22° C., filtered, and washed with MTBE (400 mL). The filtrate wasconcentrated to give the product as a red viscous oil (125 g, 94%).

STEP 2: (S)-6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-CARBALDEHYDE AND(R)-6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-CARBALDEHYDE

A 3 L 3-necked-RBF was charged with racemic6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,2′-oxirane] (160 g, 822mmol) and THF (1760 mL). After the batch was cooled to −8° C. with a dryice/IPA bath, boron trifluoride diethyl etherate (5.07 mL, 41.1 mmol)was added over 3 min. An exotherm raised the batch temp to 10° C.instantly. The batch was stirred at −5 to 0° C. for 5 min, and LC/MSanalysis of a sample (quenched into cold NaHCO₃ solution) showedcomplete conversion. The reaction was quenched by the addition of sat.NaHCO₃ (300 mL) at −5° C. followed by MTBE (400 mL) and the mixture wastransferred to a separatory funnel and rinsed with MTBE (240 mL). Afterpartition, the aqueous layer was discarded along with some white solid(likely boric acid or borax). The organic layer was washed with brine(350 mL) and concentrated under reduced pressure to give a red oil. Thecrude material was used directly in Step 4.

STEP 3: (6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1,1-DIYL)DIMETHANOL

Racemic 6-chloro-1,2,3,4-tetrahydro-1-naphthalenecarbaldehyde wascharged onto a 3 L 3-necked-RBF and rinsed with diethylene glycol (1000mL). Formaldehyde (37% solution in H₂O; 652 mL, 8757 mmol) was added andthe resulting biphasic emulsion was cooled to 5° C. with a dry ice/IPAbath. KOH (45% aqueous solution, 652 mL, 11.9 mol) was added over ˜30min, maintaining the temperature below 20° C. After complete addition,the batch (20° C.) was slowly heated to 45° C. (Caution: exothermicreaction) and aged for 1 h. HPLC showed complete conversion. Someviscous insoluble tar was formed, which was removed prior to aqueousworkup. To the batch was added brine (500 mL) and the mixture wasextracted with DCM until the product content in the aqueous phase wasless than 5%. The combined DCM extract was concentrated to 750 mL as ared oil, washed with H₂O (500 mL), and the product began to crystallizeout. Upon separation, the clear top aqueous layer was discarded and thebottom layer was stirred in ice/H₂O bath for 30 min, filtered, andwashed with DCM (˜100 mL) and H₂O (100 mL). The product was dried underdry air/vacuum to give a first crop (113 g, 498 mmol, 57% yield). TheDCM layer from the resulting mother liquor was separated andconcentrated to 200-300 g (KF=0.5%), seeded, and stirred in ice/H₂O bathfor 30 min. The product was filtered, washed with DCM (50 mL), and driedin dry air/vacuum to give a second crop (14.3 g, 63.1 mmol, 7% yield)for a combined total yield of6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol of 127 g(64%).

STEP 4:(S)-(6-CHLORO-1-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL4-BROMOBENZOATE

To a solution of2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine(R,R-Kang Catalyst) (1.57 g, 2.64 mmol) in dry DCM (450 mL), copper(II)chloride (0.355 g, 2.64 mmol) was added and the resulting green coloredsolution was stirred at rt for 1 h. This solution was added via cannulato a solution of(6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (30 g,132.73 mmol) in dry DCM (800 mL). The resulting mixture was cooled to−78° C. and a light green colored precipitation was observed. A solutionof 4-bromobenzoyl chloride (34.77 g, 158.79 mmol) in DCM (500 mL) wasthen slowly added, followed by the dropwise addition ofN-ethyl-N-isopropylpropan-2-amine (20 g, 154 mmol). The resultingreaction mixture was stirred at −78° C. for 3 h, then it was quenchedwith pH 3 phosphate buffer (1 L) and warmed to ambient temperature withvigorous stirring. The mixture was then diluted with DCM (2 L) and thelayers were separated. The organic phase was washed with pH 3 buffer (1L), sat. NaHCO₃ (1 L), and brine (2 L) then it was dried over Na₂SO₄,filtered, and concentrated. The crude material was purified by columnchromatography over SiO₂ gel (100-200 mesh, 80% DCM in Hex) to affordpure(S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (45 g, 84%; e.r=91.4:8.6). ChiralCel® OD-H (250 mm×4.6mm); Mobile Phase: n-Hexane:IPA: 90:10; Run Time: 20 min; flow rate: 1mL/min; sample preparation: IPA. Retention time (major peak)-9.32 min;Retention time (minor peak)-11.46 min).

STEP 5: (R)-(6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL4-BROMOBENZOATE

To a stirred solution of(S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (100 g, 244.5 mmol) in DCM (2.5 L), Dess-Martinperiodinane (121.4 g, 293.3 mmol) was added at 10° C. The cooling bathwas removed after addition and the reaction mixture was stirred for 30min at ambient temperature. H₂O (9 mL) was then added and the resultingbiphasic mixture was stirred at ambient temperature for 30 min. Thereaction mixture was cooled to 0° C. and quenched with 2 L of a 1:1mixture of 10% Na₂S₂O₃/sat. NaHCO₃ solution. The reaction mixture wasstirred further at ambient temperature for 10 min, then the layers wereseparated and the aqueous layer was extracted with EtOAc (2×1.5 L). Thecombined organic layer was washed with 1 L of 10% Na₂S₂O₃/sat. NaHCO₃solution and 1 L of brine, then it was dried over Na₂SO₄, filtered, andconcentrated. Purification of the residue by column chromatography overSiO₂ gel (100-200 mesh, 5% EtOAc/Hex) provided(R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (80 g, 81%).

The enantiomeric purity of the title compound could be improved by thefollowing procedure:(R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (190 g) was added in toluene (950 mL) and heated to 50°C. to complete dissolution. The homogeneous solution was cooled toambient temperature and seeded with racemic compound. The solution wascooled to −25° C. and aged overnight. The mother liquor was thendecanted and concentrated to afford 160 g of enantiomerically enriched(R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (94% ee as determined by chiral HPLC). Chiral HPLCconditions: Column: ChiralCel® OD-H (250 mm×4.6 mm); Mobile Phase:n-Hexane:IPA: 90:10. Run Time: 20 min. Flow rate: 1 mL/min. Samplepreparation: ethanol. Retention time (major peak): 8.488 min (96.97%);Retention time (minor peak): 9.592 min (3.03%).

STEP 6:(R)-(6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHANOL

To a solution of(R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl4-bromobenzoate (75 g, 183.8 mmol) in anhydrous MeOH (1 L), p-TsOH (1 g,9.2 mmol) and trimethyl orthoformate (58.4 mL, 551 mmol) were added andthe reaction mixture was refluxed until the starting material wascompletely consumed (˜4 h). The reaction mass was concentrated to 50%volume and diluted with THF (1 L) and 1N NaOH (1 L, 1 mol). Theresulting reaction mixture was stirred at 40° C. overnight and thenconcentrated under reduced pressure. The residue was diluted with EtOAc(1.5 L). The aqueous layer was separated and extracted with EtOAc (2×500mL) and the combined organic layers were washed with 1N NaOH (1 L) andbrine (1 L), dried over Na₂SO₄ and concentrated under reduced pressure.The crude material was purified by column chromatography over 100-200mesh size SiO₂ gel (10% EtOAc/Hex) to give pure(R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanolas a light brown thick oil (44 g, 89%).

STEP 7: TERT-BUTYL-4-FLUORO-3-NITROBENZOATE

To a solution of 4-fluoro-3-nitrobenzoic acid (100 g, 540.2 mmol) int-butanol (2.5 L), DMAP (13.18 g, 108.04 mmol) and di tert-butyldicarbonate (248 mL, 1080.4 mmol) were added and the reaction mixturewas heated at 40° C. overnight. Upon completion, the reaction mixturewas diluted with H₂O and the aqueous phase was extracted with EtOAc(3×1.5 L). The combined organic layer was washed further with H₂O (1×1L), brine (1×1 L), and dried over Na₂SO₄. The solvent was removed underreduced pressure and the crude to material thus obtained was purified bycolumn chromatography (100-200 mesh size SiO₂ gel, eluting with agradient of 100% Hex to 5% EtOAc in Hex) affording puretert-butyl-4-fluoro-3-nitrobenzoate (70 g, 54%) as light yellow solid.

STEP 8: (R)-TERT-BUTYL4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

A solution of(R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol(70 g, 259.2 mmol) in dry THF (3.5 L) was cooled to 0° C. and LiHMDS (1M in THF; 363 mL, 363 mmol) was added dropwise. After 5 min, a solutionof tert-butyl 4-fluoro-3-nitrobenzoate (74.9 g, 311 mmol) in THF (500mL) was added dropwise via dropping funnel and the resulting mixture waswarmed to ambient temperature. Upon completion (˜1 h), the mixture wascooled to 0° C., quenched with sat. NH₄Cl solution (1 L) and extractedwith EtOAc (3×1 L). The combined organic layers were washed with NH₄Cl(1 L) and brine (1 L), dried over Na₂SO₄ and concentrated under reducedpressure. The crude material thus obtained was purified by columnchromatography using 100-200 mesh size SiO₂ gel (5% EtOAc/hexane) toafford (R)-tert-butyl4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoateas yellow thick oil (110 g, 87% yield).

STEP 9A:(R-4-((6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOICACID

To a solution of (R)-tert-butyl4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate(35 g, 71.25 mmol) in MeCN (1 L), erbium triflate (4.3 g, 7.1 mmol) andH₂O (13 mL) were added. The resulting mixture was heated to 80° C.overnight. The solvent was then removed under reduced pressure and theresidue was dissolved in Et₂O (1.5 L) and washed with 1N HCl (500 mL)and brine (500 mL). The organic layer was dried over Na₂SO₄, filtered,and concentrated to afford(R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoicacid (30 g), which was used without further purification.

Alternatively,(R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoicacid may be prepared from(6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (Step 4) asfollows:

A 250 mL 3-necked-RBF was charged with copper (II) chloride (0.095 g,0.02 eq),2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (0.42g, 0.02 eq) and THF (28.5 g, 4V). After inertion with N₂, the batch wasstirred at 20° C. for 0.5 h. To the homogenous green solution was added(6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (8.0 g, 1.00eq) followed by THF (14.2 g, 2V) and 4-methylmorpholine (3.75 g, 1.05eq). The reaction mixture was cooled to −20° C., and a solution of1-napthoyl chloride (7.06 g, 1.05 eq) in THF (21.3 g, 3V) was added tothe batch over 0.5 h maintaining the temperature below −15° C. Afteraging at −20° C. for 20 h, an aliquot of the reaction slurry was sampledand assayed by HPLC. The slurry was directly filtered through aglass-fritted funnel while maintaining the temperature at −20° C. Thefilter cake was washed with two portions of cold (<−10° C.) THF (2×14.2g, 2V) rinsed through the reaction vessel. The filter cake(4-methylmorpholine.HCl) was transferred to a labeled container. Themother liquor and washes were concentrated to a minimum volume anddistillative solvent swap by charging toluene until the batch volume is6V and toluene/THF ratio is >98:2 (v/v) as measured by QNMR. To thebatch at 20° C. was added heptane (11 g, 2V) and the slurry was heatedto 85° C. (dissolution observed). The solution was cooled to 75° C. andcharged with seed (0.27 g, 0.02 eq). The slurry was cooled to 20° C.over 3 h and aged for >1 h. The batch was filtered through aglass-fritted filter and the cake was washed with toluene/heptane (3:1v/v) (11 g, 2V) then toluene/heptane (1:1 v/v) (11 g, 2V). The cake wasdried under N₂ for 12 h at ambient temperature and the cake was assayeddry by QNMR (<1 wt % toluene and heptane). The product was obtained asan off-white solid (8.75 g, 63% after wt adjustment).

A 60 L jacketed reactor vented with a bleach scrubber was charged with(S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl1-naphthoate (2.693 Kg, 88.6 wt %, 6.3 mol) followed by DCM (17.9 Kg, 5vol) and EtNiPr₂ (2.84 Kg, 3.5 eq). After N₂ inertion, the batch wasagitated and cooled to 0° C. To the alcohol slurry mixture in thereactor was added a solution of freshly prepared sulfur trioxidepyridine (2.10 Kg, 2.5 eq of sulfur trioxide pyridine in 7.43 Kg, 3 vol.DMSO) over 30 min while maintaining the batch temperature below 15° C.After addition, HPLC assay showed >99% conversion. The batch wasquenched by the addition of H₂O (14 L, 5 vol) over 20 min. maintainingthe batch temperature below 15° C. and then toluene (16.8 L, 6 vol) wasadded. After partition, the organic layer was treated with H₂O (14 L, 5vol) and toluene (16.8 L, 6 vol). The top organic layer was washed with2 N HCl twice (14 L each, 5 vol) and brine (14 L, 5 vol). The organiclayer was drained to a clean container, assayed by HPLC and thentransferred back to the clean 60 L reactor through an inline filter. Thebatch was concentrated to a minimal volume and solvent switched to MeOHuntil the batch volume was 28 L (10 vol) and MeOH/toluene ratio was 3:1(v/v) as measured by QNMR. The batch was then transferred to a 30 Ljacketed reactor through an inline filter. After adjustment of the batchtemperature to 30° C., the batch was seeded with the aldehyde (51 g,0.02 eq) as a slurry in MeOH (400 mL). After the slurry was aged for 30min at 30° C., the batch was solvent switched by distillation with MeOHuntil the batch volume is 11 L (4 vol) and MeOH/toluene ratio is ≥99:1(v/v). The batch was then cooled to 5° C. and MeOH/H₂O mixture (3.70 KgMeOH+1.34 Kg H₂O) was added over 1.5 h to bring the total solvent volumeto approximately 5.5 vol and final MeOH/H₂O to 90/10 (v/v). The batchwas heated to 65° C. over 30 min, and cooled to 20° C. over 2 h and agedfor 2 h. The batch was filtered through an Aurora® filter fitted with≤25 μm filter cloth. The cake was washed with MeOH/H₂O (10:1) (1×2 vol),then MeOH/H₂O (2:1) (1×2 vol). The cake was dried under N₂ at ambienttemperature for ≥4 h until dry to give the product as an off-white solid(1.99 Kg, 72% after wt % adjustment).

A 3-necked 250 mL RBF was charged with(R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl1-naphthoate (10 g, 94.4 wt %, 95.3% LCAP, >99% ee), methanol (100 mL),trimethyl orthoformate (7 mL), and TsOH.H₂O (0.24 g). The RBF wasinerted with Nz, and agitation was initiated. The batch was heated to60° C. and aged for 2 h. HPLC assay showed ≥98% conversion.

The batch was concentrated under vacuum (˜150-190 torr, external temp˜40° C.) to minimal volume using a rotoevaporator. The batch was turnedover to THF by charging THF three times (50 mL each time) and distillingunder vacuum (˜165 torr, external temp ˜40° C.). After each of the firsttwo THF charges, the batch was concentrated down to a minimal volume,and after the last THF charge and distillation QNMR analysis of a sampleshowed the target ratio of >20/1 THF/MeOH (v/v). LiOH.H₂O (10.46 g, 10eq) and H₂O (50 mL) were charged to the 3-necked 250 mL RBF. Thereaction mixture was heated to 65° C. and aged for 18 h. HPLC assayshowed >99% conversion. The batch was cooled to 20° C. and transferredto a 500-mL separatory funnel. MTBE (106 mL) was charged to theseparatory funnel and the funnel was shaken well. After settling for 5min, the bottom aqueous layer was drained. The top organic layer waswashed with 20% K₂CO₃ twice (32 mL and 11 mL). The batch was transferredto a 250 mL RBF. Assay by HPLC showed <2% naphthanoic acid by-product.The batch was concentrated to a minimal volume at reduced pressure onthe rotoevaporator (300 mbar, external temp ˜40° C.). The batch wasturned over to THF using a rotoevaporator (˜250 mbar, external temp ˜40°C.) by adding and distilling THF (˜50 mL, ˜50 mL). After each THFcharge, the batch was distilled down to a minimal volume. THF (50 mL)was charged to the 250 mL RBF. KF of a sample showed 0% H₂O (≤0.1%acceptable). The batch was polish filtered (60 mL medium-frit funnel)into a clean and dry 250 mL 3-necked-RBF using THF (50 mL) for rinsingand volume adjusting. To the batch was added 4-fluoro-3-nitrobenzoicacid (4.61 g, 1.0 eq), the mixture was cooled to −20° C., and 20%potassium tert-butoxide THF solution (40 mL) was added over 1.5 h,maintaining the batch temperature at −20±10° C. (exothermic). Aftercomplete addition, the batch was aged at −20° C. and an aliquot assayedby HPLC after 1.5 h showed 98% conversion. To the batch in the flask wasadded sat. NH₄Cl solution (10 mL), maintaining the temperature at−20±10° C., followed by addition of H₂O (20 mL) and MeTHF (34 mL) at−20±20° C. The mixture was warmed to 20° C. and agitated for 13 h. Thebatch was transferred to a separatory funnel, allowed to settle for ˜5min, and the bottom aqueous layer was removed keeping the rag with theorganic stream. The top organic stream was washed with sat. NH₄Clsolution (10 mL) and H₂O (20 mL) at 20° C. After ˜5 min of settling, theaqueous layer was separated. To the total crude organic stream (KF=14%)was added MSA (4 mL) in a 250 mL 3-necked-RBF. The batch was heated toreflux (65° C.) for 25 h and LC assay showed full conversion (≥97%).

The batch was cooled to <20° C. and K₃PO₄.H₂O (4.5 g) and H₂O (7 mL)were added. The batch was transferred to a separatory funnel and thebottom aqueous layer was drained to give the aldehyde product crudesolution. The combined organic crude stream was concentrated to minimumvolume using a rotary evaporator. To the batch in a 500 mL RBF wascharged AcOH (˜50 mL, ˜50 mL) and distilled using a rotary evaporator atreduced pressure (30 mbar, external temp ˜40° C.). The THF level wasmeasured by QNMR and none was observed. The mixture was transferred to a250 mL 3-necked RBF and AcOH was added to adjust the total volume to ˜40mL, when crystallization occurred. To the batch was added H₂O (12 mL)over ˜1 h. After aging for >1 h, LC assay of supernatant concentrationwas 9 mg/mL. If concentration is >10 mg/mL then a small portion of H₂O(0.2 vol) can be added; after checking by LC, repeat if necessary. Thebatch was filtered, washed with 20% H₂O/AcOH (23 mL) and dried underN₂/vacuum for 3.25 h to give the title compound (8.22 g) as an off-whitesolid (82% yield corrected for purity).

STEP 9B: (R)-TERT BUTYL4-((6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

To a solution of (R)-tert-butyl4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate(1 g, 2.033 mmol) in anhydrous acetone (41 mL) was added Amberlyst®-15(1 g, 2.033 mmol; prewashed with 2×10 mL dry acetone). The mixture washeated to 50° C. for 3.5 h, then filtered and rinsed with DCM. Thefiltrate was concentrated and dried under high vacuum overnight (itturned a dark red color). LC/MS and NMR analysis suggested ˜10% ofcorresponding carboxylic acid was present as well as 0.5 eq mesityloxide. The mixture was advanced to Step 11 without further purification.

STEP 10:(S)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

A solution of crude(R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoicacid (30 g, 77.10 mmol) in AcOH (1 L) was heated to 70° C. and ironpowder (28 g, 500 mmol) was added. The resulting mixture was heated for˜4 h at 70° C. AcOH was then removed under reduced pressure and theresidue was dissolved in DCE (1 L). Sodium triacetoxy borohydride (46.5g, 740 mmol) was added portion-wise and the reaction mixture was stirredat ambient temperature for 1 h. The reaction was then quenched with H₂Ofollowed by 10% aqueous citric acid (500 mL). The aqueous phase wasextracted with DCM (2×1 L) and the combined organic layer was washedwith brine (500 mL), dried over Na₂SO₄ and concentrated under reducedpressure. The residue was purified by column chromatography using100-200 mesh size SiO₂ gel (40% EtOAc/Hex) to afford pure(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid as white solid (24 g, 99% after two steps). Alternatively,(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid with((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonicacid (1:1) may be prepared as follows:

A pressure reactor was charged with(R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoicacid (20 g, 94 wt %), 5% Pt/S/C wet (2.2 g), THF (400 mL) and titaniumisopropoxide (0.5 mL). The reactor was sealed, purged with inert gas (3cycles, at least once with stirring), and then purged with H₂ (1 cycle).The reactor was pressurized with H₂ to 70 psig, stirring (950 rpm) wasinitiated, and the temperature was increased to 90° C. maintaining theH₂ pressure in the reactor (70 psig at 22-30° C., 80 psig at 50-60° C.and 90 psig at 88-91° C.). After 16 h, the reactor was cooled to ambienttemperature and purged with inert gas (3 cycles). HPLC analysis of thereaction confirmed >98% conversion.

The reaction mixture was filtered through a Celite® pad (2 inch) usingadditional THF for rinses, and the filtrate was concentrated underreduced pressure at 40° C. To the residue was added IPA (60 mL) and 2-4%aqueous MeOH (10 mL). The mixture was stirred for 10 min and then it wasfiltered through a Celite® pad (2 inch). MeOH was evaporated underreduced pressure at 40° C. and to the concentrated IPA solution cooledto ambient temperature was added a solution of +CSA (56.0 g) in IPA (200mL) dropwise over 2 h. After to 10% of the CSA solution has been added,the mixture was seeded with crystals of the title compound (10-15 mg)followed by the addition of the remaining CSA solution. After stirringat ambient temperature overnight, the mixture was filtered, and thefilter cake was washed with 100 mL of IPA and dried under vacuum/N₂ atambient temperature. The product is isolated as a white solid:(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid with((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonicacid (1:1) (85-88% yield, >99.5% ee).

STEP 11A: (S)-METHYL6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (130 g, 379 mmol) in methanol (6 L) was added Amberlyst®-15 (130 g,pre-washed with anhydrous methanol) and heated to reflux for 10 h.Amberlyst® was then removed by filtration and rinsed with methanol(3×300 mL). The combined filtrate was concentrated and the residue waspurified by column chromatography to give pure (S)-methyl6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylateas a white solid (105 g, 77%). Chiral HPLC conditions: Column:ChiralCel® OD-H (250 mm×4.6 mm, 5 μm); Mobile Phase: n-Hexane:EtOH:95:05. Run Time: 25 min. Flow rate: 1 mL/min. Retention time (minorpeak): 10.162 min (1.98%); Retention time (major peak): 12.292 min(98.02%).

STEP 11B: (S)-TERTBUTYL6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (R)-tert-butyl4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate(0.9 g, 2.018 mmol) in AcOH (20.22 mL, 353 mmol) at 70° C. was addediron (0.676 g, 12.11 mmol). The mixture was stirred vigorously for 4 h,then concentrated, and the residue was diluted with 20 mL 1,2-DCE.Sodium triacetoxyhydroborate (1.711 g, 8.07 mmol) was added and themixture was stirred at ambient temperature for 20 min. Upon quenching byaddition of 20 mL H₂O, a thick slurry was formed. 20 mL 10% citric acidsolution was added and the mixture became lighter in color. The layerswere separated and the aqueous layer was extracted with 2×20 mL DCM. Thecombined organics were washed with 10 mL 10% citric acid and 10 mLbrine, dried over MgSO₄, filtered, and concentrated. The residue wasdeposited on 3 g SiO₂ gel and purified using 5-10% EtOAc in Hex to give(S)-tert-butyl6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(557 mg, 1.393 mmol, 69.0% yield). Further elution with 30% EtOAc in Hexprovided(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (132 mg, 0.384 mmol, 19.02% yield).

STEP 12: (1R,2S)-1,2-CYCLOBUTANEDIYLDIMETHANOL

To a rapidly stirred solution of LAH (1.0 M solution in THF, 1000 mL,1000 mmol) at ambient temperature in a 3000 mL 3-necked RBF under astream of argon, solid (1R,5S)-3-oxabicyclo[3.2.0]heptane-2,4-dione (40g, 317 mmol) was gradually added over 2 h, maintaining the internaltemperature of the reaction mixture below 50° C. The reaction wasstirred overnight at ambient temperature under argon. After 16 h, thereaction mixture was cooled by an ice bath to 10° C., and, under a faststream of argon, a solution of 36 mL H₂O was added drop wise by additionfunnel at a rate that maintained the temperature to between 12-15° C.,approximately 1 mL/min, with vigorous stirring (500 rpm). The mixturewas then vigorously stirred (500 rpm) in the ice-bath for 1 h, thenremoved from the bath and stirred to rt for 1 h before cooling againwith an ice bath to 5-10° C. To the mixture was added 36 mL of a 15%NaOH aqueous solution over a period of 45 min, maintaining thetemperature between 10-20° C. To the mixture was added 108 mL H₂O dropwise by addition funnel, maintaining the temperature between 10-20° C.,over 1 h. Upon completed addition of the H₂O, the flask was removed fromthe ice bath, equilibrated to rt and left to stir vigorously under argonovernight. After stirring for 16 h, the mixture was filtered and thefiltrate concentrated under reduced pressure to afford a colorless,slightly opaque oil. The oil was taken up in Et₂O and stirred overanhydrous MgSO₄ and filtered through a pad of Celite®. The filtrateconcentrated under reduced pressure to afford 32.8 g of a colorless oil,which was used in the next step without further purification (89%yield).

STEP 13: CIS-CYCLOBUTANE-1,2-DIYLBIS(METHYLENE) DIACETATE

Ac₂O (2.59 mL; 3.0 eq) was added to theCIS-1,2-cyclobutanediyldimethanol (1.06 g, 9.15 mmol) and the resultingsolution was heated to 50° C. After stirring overnight, the mixture wasassayed by GC and showed complete conversion. The mixture was thendiluted with 15 mL of heptane and concentrated under vacuum to give aclear oil. The oil was dissolved in 15 mL heptane and concentrated backdown to an oil (azeotropic removal of Ac₂O) to give the title compoundas an oil (1.827 g, 88% yield, 88.3% purity by QNMR using benzylbenzoate as an internal standard).

STEP 14: ((1R,2S)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL ACETATE

A 12 L 3-neck-RBF equipped with mechanical stirrer was charged with a 1Msodium citrate solution (prepared by mixing sodium citrate tribasicdihydrate; 682 g, 2320 mmol) and H₂O to reach total volume 2.3 L) and3.48 L H₂O (˜25° C.). The mixture was cooled using an ice/H₂O bath to˜20.2° C. pH˜8.46 (measured with pH probe). Amano Lipase fromPseudomonas fluorescens (41.8 g, 1547 mmol) was then added in one charge(pH ˜8.12) and the mixture was vigorously stirred at ambient temperaturefor ˜5 min. (1R,2S)-cyclobutane-1,2-diylbis(methylene) diacetate (348 g,1547 mmol) was added in one charge and the resulting mixture was stirredvigorously at ambient temperature monitoring internal temperature andpH. After stirring the mixture overnight (˜20.9° C. and pH˜5.45) analiquot was collected, extracted with IPAc, diluted with MeCN andanalyzed by GC and the reaction was deemed complete (1.21% SM leftover,0.17% of enantiomer, 1.8% of diol). Celite® (70 g) added to the reactionmixture and the slurry was filtered through a Celite® pad on a mediumporosity glass filter (fast filtration, 15-20 min), rinsing with 2.5 LIPA. The biphasic mixture was transferred into a 12 L-extractor andstirred for 1 min. The aqueous layer was separated and extracted withIPAc (1×4 L), and the combined organic extract was concentrated in vacuoobtaining 337.28 g (99.6% ee; 50-60 mol % of residual IPA by ¹HNMR;QNMR: 37.63 mg+benzyl benzoate (Aldrich catalog # B6630, lot #MKBG9990V, 61.27 mg; Result: 65 wt %; corrected yield 89%). The crudeproduct was used as such for the next step.

STEP 15: ((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL ACETATE

A 2-L Atlas reactor was charged with((1R,2S)-2-(hydroxymethyl)cyclobutyl)methyl acetate (126.39 g, 79.6 wt %by QNMR; 636 mmol) and 1 L of DCM and the jacket temperature was set to20° C. Iodobenzene diacetate (225 g, 700 mmol) was added as a solid(endothermic addition: the temperature decreased to 15° C.). TEMPO (3.97g, 25.4 mmol) was added as a solid in one portion resulting in a cloudyorange solution, which became clear over the course of 20 min. Afterstirring at 20° C. overnight, an aliquot was collected, diluted withMeOH, and analyzed by GC. An Additional kicker charge of iodobenzenediacetate and TEMPO can be used to push the reaction to completion ifnecessary. The reaction mixture was then cooled to 1.8° C. (internaltemperature, ice/dry ice/H₂O bath) and DIPEA (194 mL, 1113 mol) wasadded drop-wise via addition funnel over 65 min keeping internaltemperature <5° C. The cooling bath was removed and the mixture wasallowed to warm to ambient temperature with stirring. After 48 h analiquot was collected, diluted with methanol, and analyzed by GC showinga 12:1 ratio of trans:cis isomers. The reaction mixture was then cooledto <5° C. (ice/H₂O bath) and H₂O (230 mL) was added over ˜10 min(internal temperature reached 14° C.). The organic layer was separated,washed with H₂O (125 mL) and 1M aqueous NaH₂PO₄ (90 mL) and concentratedin vacuo to afford 273.4 g of ((1R,2R)-2-formylcyclobutyl)methyl acetate(QNMR: 68.85 mg+benzyl benzoate (Aldrich catalog # B6630, Lot #MKBG9990V, 72.36 mg). The crude product was used as such for next step.

STEP 16:((1R,2R)-2-((R)-(1H-BENZO[D][1,2,3]TRIAZOL-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYLACETATE

To a solution of crude ((1R,2R)-2-formylcyclobutyl)methyl acetate (5 g,10.27 mmol) in 8 mL MTBE was added benzotriazole (1.296 g, 10.00 mmol)as a solid (slightly exothermic). The clear solution became increasinglycloudy and a precipitate formed. The mixture was allowed to equilibrateovernight at ambient temperature then heptane was added (6 mL). Afteraging for 6 h the mixture was filtered at ambient temperature and washedwith 10 mL of 1:1 MTBE/heptane. The white solid was air dried on thefrit under vacuum obtaining 2.48 g of((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methylacetate.

STEP 17: (S)-METHYL5-(((1S,2R)-2-ACETOXYCYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

((1R,2R)-2-Formylcyclobutyl)methyl acetate (from Step 16; 4.36 g, 27.9mmol) was added to a solution of (S)-methyl6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(5.0 g, 13.97 mmol) (Step 12) in DCM (78 mL) and AcOH (38.8 mL). Thesolution was stirred at ambient temperature for 10 min, then cooled to0° C., and sodium cyanoborohydride (1.463 mL, 27.9 mmol) was addedslowly over 1 h. The mixture was stirred at 0° C. for 10 min, thenpoured slowly into cold NaOH solution, and extracted with EtOAc (120mL). The organic phase was washed with brine, dried over anhydrousNa₂SO₄, and concentrated. The residue was loaded to a 220 g ISCO goldcolumn and eluted with 0% to 10% EtOAc/Hex to provide the title compound6.0 g of the title compound as a white solid. m/z (ESI +ve ion) 498.1(M+H)⁺.

STEP 18A: (S)-METHYL6′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

KOH (0.278 mL, 10.14 mmol) was added to a solution of (S)-methyl5-(((1R,2S)-2-(acetoxymethyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Step 18; 1.530 g, 3.07 mmol) in MeOH (99 mL). The mixture wasstirred at ambient temperature for 4 h, then neutralized with 1N HCl topH=7, and concentrated under reduced pressure. The aqueous residue wasextracted with EtOAc (400 mL) and the organic extract was washed withbrine, dried over anhydrous Na₂SO₄, and filtered through a short plug ofSiO₂ gel to afford the title compound as a white solid. (1.354 g wasobtained. m/z (ESI, +ve ion) 456.2 (M+H)⁺)

Alternatively, (S)-methyl6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylatemay be prepared as follows:

To a slurry of(S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid with((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonicacid (1:1) (Step 11) (32.22 g, 52.5 mmol) and((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methylacetate (Step 17) (15.89 g, 57.7 mmol) in DCM (226 mL, 7 mL/g) was addedsodium triacetoxylborohydride (13.90 g, 65.6 mmol) in 4 portions over 30min. Additional((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methylacetate (2.89 g, 10.50 mmol) and sodium triacetoxyborohydride (2.78 g,13.12 mmol) were added to drive the reaction to completion (determinedby HPLC assay). 80 mL of H₂O was then added and the resulting mixturewas agitated for 5 min. The layers were separated, the organic phase waswashed with 60 mL H₂O and 20 mL of brine, and then concentrated to anoil under reduced pressure. The residue was dissolved in 50 mL of MeOHand 40 mL of 5N NaOH were then added at ambient temperature(exothermic). Upon reaction completion (determined by HPLC assay), thereaction mixture was partitioned between 133 mL of MTBE and 35 mL of 1.5M citric acid. The organic phase was transferred to a RBF and thesolvent was exchanged to MeCN via atmospheric distillation. Thissolution was seeded at 62° C. (a slurry developed), was allowed to reachambient temperature, and then aged overnight. The slurry was filtered at20.5° C. through a coarse frit glass sinter funnel and the filter cakewas washed using 60 mL of MeCN, then dried in a vacuum oven at 40° C. toconstant weight. Final mass: 21.87 g (96.4 w t % by HPLC).

A 100 mL 3-necked-RBF was charged with(S)-6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (4.53 g, 1.0 eq), MeOH (45 mL, 10 vol), and then a preparedsolution of SOCl₂ (11.28 mL, 1.0M in MeCN, 1.1 eq). Under an atmosphereof N₂, the batch was heated to 55° C. and stirred for 18 h (oruntil >99% conversion as determined by HPLC). The reaction mixture wasthen allowed to cool to 20° C. over 2 h. To the resulting white slurrywas added Hunig's base (3.94 mL, 2.2 eq) and after aging for 0.5 h, H₂O(9.0 mL, 2V) was added as antisolvent over 1 h. The white slurry wasaged for >2 h and the batch was filtered through a glass-fritted filterand the cake was washed with MeOH/H₂O (5:1 v/v) (9.0 mL, 2V) thenMeOH/H₂O (2:1 v/v) (9.0 mL, 2V). The cake was dried under N2 with vacuumfor 12 h at ambient temperature. The product was obtained as a whitesolid (4.36 g, 92% yield).

STEP 18B: (S)-TERTBUTYL6′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tertbutyl6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA11A, Step 12B) following the procedures described forIntermediate AA11A, Steps 18-19A).

STEP 19A: (S)-METHYL6′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a cooled (−70° C.) solution of DMSO (7.12 mL, 2.5 eq) and DCM (183mL, 10 vol) in a 1 L 3-necked-RBF inerted with Nz was added oxalylchloride (26.1 mL, 1.0M in DCM, 1.3 eq) at a rate to maintaintemperature below −70° C. The batch was aged below −70° C. for 30 minand then a prepared solution of (S)-methyl6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Step 19A; 18.3 g, 1.0 eq) in DCM (183 mL, 10 vol) was added at arate to maintain reaction temperature <−70° C. The batch was aged for1.5 h and then Et₃N (22.4 mL, 4.0 eq) was added at a rate to maintainbatch temperature <−70° C. After aging for 1 h, the batch was allowed towarm to −20° C. and H₂O (366 mL, 20 vol) was added. The batch wasagitated at 20° C. and the phases separated. The organic layer waswashed with 2×1N HCl (183 mL, 10 vol) and brine (183 mL, 10 vol). Theorganic layer was polish filtered and concentrated in vacuo to afford(S)-methyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(19.91 g, 94% yield corrected for wt %) as a tan foam.

STEP 19B: (S)-TERTBUTYL6′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tertbutyl6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA 11A, Step 19B) following the procedure described forIntermediate AA11A, step 20A.

STEP 20: (S)-METHYL6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

An oven dried 3-necked-RBF equipped with a pressure-equalizing additionfunnel, thermocouple, and magnetic stirbar was cooled to ambienttemperature under a purge of argon gas. The flask was charged with(1R,2S)-2-morpholino-1-phenylpropan-1-ol (40.2 g, 182 mmol; preparedaccording to the literature procedure by Brubaker, J. D.; Myers, A. G.Org. Lett. 2007, 9, 3523-3525) against a positive pressure of argon. Theaddition funnel was charged with toluene (450 mL), which was droppedinto the reactor. The solution was cooled in an ethyleneglycol-CO₂ bath(˜−12° C.) and treated with butyllithium solution (2.5 M in Hex, 72.6mL, 182 mmol), causing a white solid to precipitate that gradually wentinto solution as it was stirred over 30 min. Divinylzinc solution (605mL, 182 mmol; prepared according to Brubaker, J. D.; Myers, A. G. Org.Lett. 2007, 9, 3523-3525. The concentration of divinylzinc solution wasdetermined by titrating against iodine (Krasovskiy, A.; Knochel, P.Synthesis 2006, 890-891; concentration was generally ˜0.25M) was added,and the solution was aged with stirring in the cold bath for 1 h; theinternal temperature was −15° C. (S)-methyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Step 20A; 48.5 g, 107 mmol) (azeotroped thrice with toluene) wasadded as a solution in toluene (200 mL, 150 mL+2×25 mL cannula/vialrinse) via cannula (16 G), over ˜20 min. The internal temperature roseto −10° C. The mixture was stirred for 90 min while maintaining theinternal reaction temperature below −5° C. The addition funnel wascharged with 30% w/w aqueous citric acid (450 mL), then the reaction wasquenched by adding the solution to the reaction mixture. The reactor wasremoved from the bath and permitted to stir at ambient temperature. Thesolution was transferred to a separatory funnel and the flask was rinsedwith toluene and 30% aqueous citric acid (50 mL each). The layers weremixed and then separated. The organic layer was washed with H₂O (250mL), then brine (250 mL), and finally dried with MgSO₄. The solution wasfiltered and concentrated to yield a yellow oil, ˜90 g after vacuumovernight, 20:1 dr. This was split into 3 batches and purified by columnchromatography 10 to 20% EtOAc/Hex 1.5 kg SiO₂, to provide(S)-methyl-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(43.3 g, 84%). The aqueous layer and washings were placed in an ice/H₂Obath and basified to pH>13 by addition of 8N aqueous NaOH. This solutionwas then extracted with toluene (3×250 mL). The combined organicextracts were washed with H₂O (250 mL) and brine (250 mL), then driedwith MgSO₄. The solution was filtered and concentrated to recover theligand in >95% yield.

STEP 21:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

To a solution of (S)-methyl6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Step 21; 4.59 g, 9.52 mmol) in a mixture of THF (18 mL), MeOH(6.00 mL) and H₂O (6.00 mL) was added LiOH.H₂O (0.799 g, 19.05 mmol) andthe reaction was stirred at 50° C. for 4 h. The reaction mixture wasconcentrated to 15 mL, cooled to 0° C. and acidified with 2N HCl topH=3. The resulting viscous oil was diluted with 20 mL of H₂O and 50 mLof EtOAc and a clear two-layer mixture was obtained. More EtOAc (ca. 200mL) was added and the organic layer was separated, washed with brine,dried with MgSO₄, filtered and concentrated under reduced pressure. Thecrude material was loaded onto a column (220 g), and purified with EtOAcin Hex using the following gradient: 0-2.5 min 0% of EtOAc, 2.5 m-6 m0-20% EtOAc, 6 m-35 m 20-60% EtOAc, 35 m-40 m 70% EtOAc to give(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (4.22 g, 9.02 mmol, 95% yield) as a white solid.

Intermediate AA12A(S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

STEP 1A: (S)-METHYL6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

Under argon atmosphere, a dry 3-necked-RBF charged with dry Hex (27 mL)was cooled to 0° C. To this solution was added borane-methyl sulfidecomplex (3.29 mL, 34.6 mmol) and cyclohexene (7.01 mL, 69.3 mmol) andthe mixture was stirred at 0° C. for 2 h. To the resulting whitesuspension was added 1-pentyne (3.41 mL, 34.6 mmol) and the mixture wasstirred at ambient temperature for 0.5 h. The mixture was then cooled to−78° C. and diethylzinc, 1.0 M solution in Hex (32.3 mL, 32.3 mmol) wasadded. After addition the mixture was warmed to 0° C., stirred for 3 minthen recooled to −78° C. This solution was to named solution A. Aseparate flask was charged with a mixture of ((S)-methyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA11A, Step 20A, 5.24 g, 11.54 mmol) and(2s)-3-exo-(morpholino) isoborneol (0.486 g, 2.032 mmol) in Hex (50.9mL) and toluene (16.97 mL). The mixture was stirred at ambienttemperature until all solid was dissolved, then cooled to 0° C. Underargon atmosphere 54 mL of solution A was added slowly via syringe during1.6 h. After stirring for 5 min at 0° C., the mixture was quenched withsat. NH₄Cl solution (70 mL), diluted with H₂O (30 mL) and extracted withEtOAc (3×270 mL), washed with brine, dried over anhydrous Na₂SO₄ andconcentrated. The residue was loaded to a 330 g ISCO gold column andeluted with 0% to 5% EtOAc/Hex, to provide the title compound 3.8 g as awhite solid. m/z (ESI, +ve ion) 524.1 (M+H)⁺.

STEP 1B: (S)-TERTBUTYL6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATEAND (S)-TERTBUTYL6′-CHLORO-5-(((1R,2R)-2-((R,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (5)-tert-butyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(3.19 g, Intermediate AA11A, Step 20B) following the procedure describedfor Intermediate AA12A, Step 1A. The crude material was absorbed onto aplug of SiO₂ and purified on a 330 g ISCO gold column eluting with 0 to15% EtOAc in heptanes over 45 min to provide (S)-tertbutyl6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(2.36 g). Further elution provided (5)-tert-butyl6′-chloro-5-(((1R,2R)-2-((R,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(0.45 g).

STEP 2:(S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

A mixture of (S)-methyl6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Intermediate AA12A, Step A; 4.6 g, 8.78 mmol) and LiOH.H₂O (3.68g, 88 mmol) in MeOH (98 mL) and THF (98 mL) (with a few drops of H₂O)was stirred at 50° C. overnight. The solvent was removed and the residuewas acidified with 1N HCl to pH 2-3. The mixture was extracted withEtOAc (80 mL×3) and the combined organic layer was washed with brine (10mL), dried over anhydrous MgSO₄ and concentrated under reduced pressureto give(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (4.25 g, 8.34 mmol, 95% yield). Alternatively, the title compoundmay be synthesized as follows:

To a solid mixture of (S)-tert-butyl6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA12A, Step 1B, first eluting isomer, 4.50 g 7.95 mmol)and LiOH.H₂O (1.66 g, 39.7 mmol) was added solvent dioxane/MeOH (1:1)(159 mL). The mixture was heated to 65° C. and stirred overnight. Themixture was then diluted with H₂O and acidified with 1.0 N HCl to pH˜4.The organic solvents were evaporated under reduced pressure and to theresidue was added H₂O. The aqueous mixture was then extracted with EtOActhree times, and the combined organic extract was concentrated. Theresidue was purified on a 120 g SiO₂ gel column eluting with a gradientof 0-70% EtOAc in Hex to provide(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (3.80 g, 7.45 mmol, 94% yield).

Intermediate AA13A(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

STEP 1A: (S)-METHYL6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

An oven-dried 200-mL flask charged with a suspension of(1R,2R)—N-methyl-1-phenyl-1-(((1S,5S,10R)-10-(trimethylsilyl)-9-borabicyclo[3.3.2]decan-9-yl)oxy)propan-2-amine(5.40 g, 14.54 mmol) in Et₂O (73 mL) under argon was cooled to −78° C.and treated with allylmagnesium bromide (13.22 mL, 13.22 mmol) solution,dropwise. The mixture was allowed to warm to ambient temperature andstirred for 1 h. The solution (0.17 M; solution A) was then recooled to−78° C.

A separate 200 mL flask charged with ((S)-methyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA11A, Step 20A, 2.0 g, 4.41 mmol) in Et₂O (22.03 mL)under argon was cooled to −78° C. To this solution was added 40 mL ofthe above-referenced solution A and the resulting mixture was stirred at−78° C. for 40 min. 4-methylmorpholine 4-oxide (3.10 g, 26.4 mmol) wasthen added and the mixture was allowed to warm to ambient temperaturefor 10 min. Methanol (10 mL) was added and the volatile organics wereevaporated under reduced pressure at ambient temperature. Additionalmethanol (100 mL) was added and after stirring at ambient temperaturefor 1 h the mixture was concentrated. The residue was diluted with EtOAc(450 mL), washed with 1N HCl (15 mL), Na₂CO₃ solution (10 mL), and brine(6 mL), dried over anhydrous Na₂SO₄ and concentrated. The residue wasloaded to a 220 g ISCO gold column and eluted with 0% to 5% EtOAc/Hex,to provide 1.88 g of the title compound as a white solid. m/z (ESI, +veion) 496.0 (M+H)⁺.

STEP 1B: (S)-TERTBUTYL6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tert-butyl6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA11A, Step 20B; 3.0 g) following the procedure describedfor Intermediate AA13A, Step 1A. The crude material was purified on a220 g SiO₂ gel column eluting with 5% EtOAc in Hex over 60 min toprovide (5)-tert-butyl6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(2.19 g).

STEP 2:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

A mixture of (S)-methyl6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(from Intermediate AA13A, Step 1A; 1.88 g, 3.79 mmol) and LiOH solution(1M) (34.1 mL, 34.1 mmol) in MeOH (34 mL) and THF (50 mL) was stirred at65° C. for 50 min. After cooling to ambient temperature, the mixture wasacidified with 1N HCl to pH 2 to 3, extracted with EtOAc (350 mL), driedover anhydrous Na₂SO₄ and concentrated to provide 1.82 g of the titlecompound as a white solid. m/z (ESI, +ve ion) 482.0 (M+H)⁺.

Alternatively, the title compound may be synthesized as follows:

To a solution of (S)-tert-butyl6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA13A, Step 1B; 250 mg, 0.465 mmol) in DCM (3.717 mL) atambient temperature, TFA (0.929 mL) was added and the reaction mixturewas stirred for 4 h. The crude reaction mixture was then concentrated,the residue was taken up in EtOAc, washed once with sat. NaHCO₃, driedover MgSO₄, filtered and concentrated to give a white foam. The crudematerial was used as such, without further purification.

Intermediate EE11 N,N-BIS(4-METHOXYBENZYL)AMINE

A solution of 4-methoxybenzaldehyde (Spectrochem; 100 g, 734.5 mmol) and4-methoxybenzyl amine (G.L.R.; 100 g, 734.5 mmol) in toluene (0.8 L) wasrefluxed at 130° C. using a Dean-Stark apparatus for 6 h. The reactionwas monitored by TLC and upon completion, excess solvent was removedunder reduced pressure and the residue was dissolved in methanol (0.8L). The resulting solution was cooled to 0° C. and sodium borohydride(36.12 g, 954.8 mmol) was added in portions. After complete addition,the reaction mixture was stirred for 3 h at ambient temperature.Methanol was removed, and the residue was diluted with H₂O (1.0 L) andEtOAc (2.0 L). The layers were separated and the aqueous layer wasextracted with EtOAc (2×1.0 L). The combined organic layer was washedwith H₂O, brine, and dried over Na₂SO₄. Solvent was removed underreduced pressure and the crude material obtained was purified by columnchromatography over SiO₂ gel (100-200 mesh size) eluting with a gradientof 100% Hex to 25% EtOAc in Hex affording the title compound (160 g,84.6%) as a colorless but opaque liquid.

Intermediate EE12 N,N-BIS(4-METHOXYBENZYL)METHANESULFONAMIDE

A mixture of methanesulfonamide (Sigma-Aldrich, 5 g, 52.6 mmol),p-methoxybenzyl chloride (14.98 mL, 110 mmol), K₂CO₃ anhydrous (36.3 g,263 mmol) and potassium iodide (0.873 g, 5.26 mmol) in anhydrous2-butanone (175 mL) was refluxed (75° C.) overnight. The reaction wasmonitored by TLC and LC/MS and upon completion, the mixture was cooledto ambient temperature, filtered, washed with Et₂O and concentrated. Thecrude material (17.54 g, 52.3 mmol, 99% yield) was used with no furtherpurification. MS (ESI, positive ion) m/z: 358.1 (M+Na).

Intermediate EE13 N,N-BIS(4-METHOXYBENZYL)ETHANESULFONAMIDE

To a solution of N,N-bis(4-methoxybenzyl)amine (Intermediate EE11; 200g, 775.19 mmol) in DCM (2.5 L) was added Et₃N (336.17 mL, 2325.5 mmol),and the reaction mixture was cooled to 0° C. Ethanesulfonyl chloride (95mL, 1007.75 mmol) was added in drop-wise manner followed by DMAP (19.0g, 155.03 mmol). The resulting reaction mixture was stirred at ambienttemperature for 30 min. The reaction was monitored by TLC and uponcompletion, the mixture was diluted with H₂O and the layers wereseparated and the aqueous phase was extracted with DCM (3×1.5 L). Thecombined organic layer was washed with H₂O, brine, and dried overNa₂SO₄. The solvent was removed under reduced pressure to afford thecrude material which was purified by column chromatography over SiO₂ gel(100-200 mesh), eluting with a gradient of 0-12% EtOAc in Hex affordingthe title compound (145 g, 53.4%) as a white fluffy solid.

Intermediate EE14 N,N-BIS(4-METHOXYBENZYL)PROPANESULFONAMIDE

To a solution of N,N-bis(4-methoxybenzyl)amine (Intermediate EE11; 405g, 1569.7 mmol) in DCM (4.0 L) was added Et₃N (681.0 mL, 4709.3 mmol),and the reaction mixture was cooled to 0° C. Propanesufonyl chloride(231 mL, 2040.6 mmol) was added in a drop-wise manner followed by DMAP(38.3 g, 313.9 mmol). The resulting mixture was stirred at ambienttemperature for 30 min. The reaction was monitored by TLC and uponcompletion, the mixture was diluted with 2.0 L of H₂O, the layers wereseparated and the aqueous phase was extracted with DCM (3×2.0 L). Thecombined organic layer was washed with H₂O, brine, and dried overNa₂SO₄. The solvent was removed under reduced pressure to afford thecrude material which was purified by column chromatography over SiO₂ gel(100-200 mesh), eluting with a gradient of 0-12% EtOAc in Hex affordingthe title compound (300 g, 52.44%) as white fluffy solid.

Intermediate EE15 BUT-3-ENE-1-SULFONAMIDE

STEP 1: SODIUM BUT-3-ENE-1-SULFONATE

A mixture of 4-bromo-1-butene (LLBChem, 3.01 mL, 29.6 mmol) and sodiumsulfite (4.11 g, 32.6 mmol) in H₂O (20 mL) was stirred at 110° C.overnight. The reaction was monitored by TLC and upon completion, H₂Owas removed under reduced pressure and the residue was triturated withacetone. The solid obtained was filtered to afford the title compound asa white solid (4.53 g) which was used as such in next step.

STEP 2: BUT-3-ENE-1-SULFONAMIDE

A mixture of sodium but-3-ene-1-sulfonate (4.50 g, 28.5 mmol) andphosphorus oxychloride (70 mL) was stirred at 135° C. for 7 h.Phosphorus oxychloride was then removed under reduced pressure to obtaina dark residue containing a white solid. This residue was diluted withMeCN (20 mL), and then filtered to remove the precipitate. The filtratewas cooled to 0° C. and treated with ammonia solution (30% aqueous) (30mL) dropwise. After complete addition, the reaction was stirred at 0° C.for 30 min. The mixture was diluted with EtOAc (300 mL), washed withbrine, and dried over anhydrous Na₂SO₄. The solvent was removed underreduced pressure and the residue was purified by column chromatographyover SiO₂ gel (100-200 mesh; eluting with 1:1 EtOAc/Hex), affording thetitle compound as a white solid (1.55 g, yield: 40%). MS (ESI, positiveion) m/z: 117.1 (M+1).

Intermediate EE16 N,N-BIS(4-METHOXYBENZYL)BUT-3-ENE-1-SULFONAMIDE

A mixture of but-3-ene-1-sulfonamide (Intermediate EE15; 1.5 g, 11.10mmol), p-methoxybenzyl chloride (3.76 mL, 27.7 mmol), K₂CO₃ anhydrous(7.67 g, 55.5 mmol) and sodium iodide (0.166 g, 1.110 mmol) in anhydrous2-butanone (55.5 mL) was refluxed (75° C.) overnight. The reaction wasmonitored by TLC and LC/MS and upon completion, the mixture was cooledto ambient temperature, filtered, and concentrated. The crude materialwas absorbed onto a plug of SiO₂ gel and purified by chromatographythrough SiO₂ gel (100-200 mesh), eluting with 0 to 30% EtOAc in Hex, toprovide the title compound (4.10 g, 10.92 mmol, 98% yield) as acolorless oil. MS (ESI, positive ion) m/z: 376.2 (M+1).

Intermediate EE17 (R)-PENT-4-ENE-2-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-2-SULFONAMIDE AND(R)—N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-2-SULFONAMIDE

N,N-bis(4-methoxybenzyl)but-3-ene-1-sulfonamide (Intermediate EE16; 50.0g, 133.2 mmol) was azeotroped with toluene and dried under vacuum for 1h. THF (890 mL) was added and the mixture was cooled to −78° C. Butyllithium (2.5 M in Hex, 63.9 mL, 159.9 mmol) was then added and thereaction mixture was stirred at −78° C. for 1 h. This anion solution wasadded slowly to a solution of MeI (16.8 mL, 266.5 mmol) in THF (300 mL)cooled to −78° C. The resulting reaction mixture was stirred for another15 min at −78° C. On completion of the reaction (monitored by TLC) themixture was quenched with sat. NH₄Cl solution and extracted with EtOAc.The organic layer was dried over Na₂SO₄ and concentrated under reducedpressure to obtain crude material which was purified by columnchromatography over SiO₂ gel eluting with 5-10% EtOAc in Hex to providethe title compound as a racemic mixture (22.0 g) of semisolid nature.Separation of the enantiomers by SFC (Column: Chiralpak® AD-H, 50×250mm, 5 μm; Mobile Phase A: CO₂; Mobile Phase B: Ethanol; Isocratic: 40% Bwith CO₂ recycler on; Flow Rate: 200 g/min; Loading: 2.0 mL of sampleprepared as above (˜100 mg); Detection: UV @ 230 nm; Cycle Time: 5 min;Total Elution Time: 10 min; Instrument: Thar 350 (Lakers)) provided(S)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide as the firsteluting isomer (retention time: 2.22 min) and(R)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide as the secondeluting isomer (retention time: 2.57 min).

STEP 2: (R)-PENT-4-ENE-2-SULFONAMIDE

To a solution of (R)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide(Intermediate EE17, Step 1, second eluting isomer; 221 mg, 0.567 mmol)in DCM (2.8 mL), was added trifluoroacetic acid (1.7 mL, 22.70 mmol)dropwise (the clear solution very rapidly turned dark). After stirringfor 7 h (TLC 30% EtOAc/Hex showed complete loss of starting material)the mixture was diluted with EtOAc, washed with sat. NaHCO₃, backextracted with EtOAc, dried over MgSO₄, and concentrated. The crudematerial was purified via chromatography (12 g ISCO gold column; 0-40%EtOAc Hex) to provide (R)-pent-4-ene-2-sulfonamide (70 mg, 0.469 mmol,83% yield)

Intermediate EE172 (S)-PENT-4-ENE-2-SULFONAMIDE

This intermediate was synthesized from(S)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide (Intermediate EE17,Step 1, first eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE18 (R)-HEX-5-ENE-3-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-3-SULFONAMIDE AND(R)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-3-SULFONAMIDE

N,N-bis(4-methoxybenzyl)but-3-ene-1-sulfonamide (Intermediate EE16; 40.0g, 106.6 mmol) was azeotroped in toluene under vacuum for 2 h. THF (700mL) was added under argon atmosphere and the reaction mixture was cooledto −78° C. Butyl lithium (2.5 M in Hex; 71.6 mL, 127.9 mmol) was addedand the reaction mixture was stirred at −78° C. for 1 h. This anionsolution was added slowly to a solution of ethyl iodide (36.44 mL, 340.1mmol) in THF (40 mL) cooled to −78° C. The resulting reaction mixturewas then quenched with sat. NH₄Cl solution, allowed to reach ambienttemperature and extracted with EtOAc. The organic layer was dried overNa₂SO₄ and concentrated under reduced pressure to obtain crude materialwhich was purified by column chromatography over SiO₂ gel eluting with5-10% EtOAc in Hex to provide the title compound as a racemic mixture(24 g) of semisolid nature. MS (ESI, positive ion) m/z; 404.03 (M+1).Separation of the enantiomers by SFC (Sample preparation: 14.4 g/200 mL(72 mg/mL) sample solution in MeOH:DCM (3:1); Column: Chiralpak® AD-H,30×250 mm, 5 μm; Mobile Phase A: CO₂; Mobile Phase B: MeOH (20 mM NH₃);Isocratic: 50% B, Flow Rate: 100 mL/min; Outlet Pressure: 100 bar;Loading: 1.0 mL of sample solution prepared as above (72 mg); Detection:UV @ 227 nm; Cycle Time: 8 min; Total Elution Time: 17 min; Instrument:Thar 350 SFC) provided(S)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide as the first elutingisomer and (R)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide as thesecond eluting isomer.

STEP 2: (R)-HEX-5-ENE-3-SULFONAMIDE

This intermediate was synthesized from(R)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide (Intermediate EE18,Step 1, second eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE182 (S)-HEX-5-ENE-3-SULFONAMIDE

This intermediate was synthesized from(S)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide (Intermediate EE18,Step 1, first eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE19 N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE

STEP 1: SODIUM PENT-4-ENE-1-SULFONATE

To a 3 L 3-necked-RBF equipped with a mechanical stirrer, a N₂ gasinlet, a condenser, and a temperature probe was charged5-bromo-1-pentene (Sigma Aldrich, 200 g, 1342 mmol), sodium sulfite(Strem Chemicals; 186 g, 1476 mmol), and H₂O (400 mL). The mixture washeated to reflux (set at 100° C. and refluxed at 93-94° C.) 4 h; aliquotNMR showed >95% conversion. The mixture was concentrated and azeotropedwith acetone to remove H₂O. The crude solid was washed with acetone andfiltered to afford sodium pent-4-ene-1-sulfonate (350 g, 2033 mmol).

STEP 2: PENT-4-ENE-1-SULFONAMIDE

To a 3 L 3-necked-RBF equipped with a mechanical stirrer, a N₂ gasinlet, a condenser, and a temperature probe was charged sodiumpent-4-ene-1-sulfonate (100 g, 581 mmol) (˜150 g of crude material fromStep 1) and phosphorus oxychloride (Sigma Aldrich; 532 mL, 5808 mmol).The mixture was heated to 90° C. for 18 h after which the reaction wasfiltered and the solid was washed with MeCN. The organic solution wasconcentrated and azeotroped with MeCN to remove POCl₃ to afford 85 gpent-4-ene-1-sulfonyl chloride intermediate. This material (solution in300 mL MeCN) was charged onto a 1 L 3-necked-RBF equipped with amechanical stirrer, a N₂ gas inlet, a condenser, and a temperatureprobe. The reaction was cooled to 0-5° C. and NH₄OH (Sigma Aldrich; 28%NH₃; 404 mL, 2904 mmol) was added slowly over 30 min. The reaction wasstirred at 0-5° C. for 1 h, after which EtOAc (300 mL) was added and themixture was extracted with EtOAc and concentrated to affordpent-4-ene-1-sulfonamide (50 g, 335 mmol, 57.7% yield) as a brown oil.

STEP 3: N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE

The title compound was synthesized from pent-4-ene-1-sulfonamide (4.5 g,30.2 mmol) following the procedure described for Intermediate EE16.Purification of the crude material providedN,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide (11.4 g, 29.3 mmol, 97%yield) as a colorless oil.

Intermediate EE20 (R)-HEX-5-ENE-2-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-2-SULFONAMIDE AND(R)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-2-SULFONAMIDE

A solution of N,N-bis(4-methoxybenzyl)ethanesulfonamide (Intermediate toEE13; 140.0 g, 400.64 mmol) in THF (1.4 L, THF was purged with argon for15 min before using) was cooled to −78° C. and butyl lithium solution(2.6 M in Hex, 200.0 mL, 520.83 mmol) was added drop-wise. The resultingsolution was stirred at −78° C. for 10 min, and 4-bromo-1-butene (73.2mL, 721.15 mmol) was added over 2 min. After 5 min, the reaction wasallowed to reach ambient temperature and stir for 1 h. The reaction wasmonitored by TLC and upon completion, the mixture was quenched with sat.NH₄Cl solution (400 mL) and the resulting aqueous layer was extractedwith EtOAc (2×1.0 L). The combined organic layer was washed with brineand dried over Na₂SO₄. The solvent was removed under reduced pressure toafford the crude material which was purified by column chromatography(SiO₂ gel 100-200 mesh) eluting with a gradient of 0-4% acetone in Hexaffording the title compound (racemic mixture, 80.0 g, 49.5%) as acolorless thick oil. MS (ESI, positive ion) m/z: 404.25 (M+1).Separation of the enantiomers by SFC (Sample preparation: 75 g/1.5 L (50mg/mL) sample solution in MeOH; Column: Chiralpak® IF, 21×250 mm, 5 μm;Mobile Phase A: CO₂; Mobile Phase B: MeOH (0.2% DEA); Isocratic: 40% B;Flow Rate: 80 mL/min; Outlet Pressure: 100 bar; Loading: 3.0 mL ofsample solution prepared as above (150 mg); Detection: UV @ 225 nm;Cycle Time: 3.9 min; Total Elution Time: 6 min; Instrument: Thar 80 SFC)provided (S)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide as thefirst eluting isomer and(R)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide as the secondeluting isomer.

STEP 2: (R)-HEX-5-ENE-2-SULFONAMIDE

The title compound was synthesized from(R)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide (Intermediate EE20,Step 1, second eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE202 (S)-HEX-5-ENE-2-SULFONAMIDE

The title compound was synthesized from(S)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide (Intermediate EE20,Step 1, first eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE21 (R)-HEPT-6-ENE-3-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEPT-6-ENE-3-SULFONAMIDE AND(R)—N,N-BIS(4-METHOXYBENZYL)HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized fromN,N-bis(4-methoxybenzyl)propanesulfonamide (Intermediate EE14) using theprocedure described for Intermediate AA20, Step 1. Separation of theenantiomers by SFC (Sample preparation: 40.55 g/170 mL (238.5 mg/mL)sample solution in MeOH; Column: Chiralpak® AD-H, 50×150 mm, 5 μm;Mobile Phase A: CO₂; Mobile Phase B: MeOH (20 mM NH₃); Isocratic: 50% B;Flow Rate: 190 mL/min; Outlet Pressure: 100 bar; Loading: 1.5 mL ofsample solution prepared as above (357.8 mg); Detection: UV @ 227 nm;Cycle Time: 17.5 min; Total Elution Time: 21 min; Instrument: Thar 350SFC) provided (S)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide asthe first eluting isomer and(R)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide as the secondeluting isomer.

STEP 2: (R)-HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized from(R)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide (Intermediate EE21,Step 1, second eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE212 (S)-HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized from(S)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide (Intermediate EE21,Step 1, first eluting isomer) using the procedure described forIntermediate EE17, Step 2.

Intermediate EE22 (2R,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

STEP 1: (4S,5S)-4,5-DIMETHYL-1,3,2-DIOXATHIOLANE 2,2-DIOXIDE

To a 500-mL, 3-necked-RBF (equipped with a H₂O-cooled reflux condenserand an HCl trap) was added (2s,3s)-(+)-2,3-butanediol (Aldrich; 15.00mL, 166 mmol) and CCl₄ (120 mL). SOCl₂, reagentplus (14.57 mL, 200 mmol)was then added drop wise via a syringe over a period of 20 min and theresulting mixture was heated to 98° C. for 45 min, then allowed to coolto rt. The reaction mixture was then cooled in an ice/H₂O bath, MeCN(120 mL) and H₂O (150 mL) were added followed by ruthenium(III) chloride(0.035 g, 0.166 mmol). Sodium periodate (53.4 g, 250 mmol) was thenadded slowly portion wise over 30 min. The resulting biphasic brownmixture was stirred vigorously while allowed to reach rt for a period of1.5 h (internal temperature never increased above rt). TLC (50% EtOAc inheptanes) showed complete conversion. The crude mixture was then pouredinto ice H₂O and extracted twice with 300 mL of Et₂O. The combinedorganic layers were washed once with 200 mL of sat. sodium bicarbonate,washed once with 200 mL of brine, dried over Na₂SO₄, and concentrated byrotary evaporation to give (4S,5S)-4,5-dimethyl-1,3,2-dioxathiolane2,2-dioxide (21.2 g, 139 mmol) as a red oil.

STEP 2: (2S,3S)-3-METHYLHEX-5-EN-2-OL

To a 500 mL flask was added (4S,5S)-4,5-dimethyl-1,3,2-dioxathiolane2,2-dioxide (from Intermediate EE22, Step 1; 21.2 g, 139 mmol) and THF(220 mL) at which time the solution was cooled to −78° C. and wassubjected to 3 cycles of evacuation/back-filling with argon. To thesolution was added dilithium tetrachlorocuprate(ii), 0.1M solution inTHF (69.7 mL, 6.97 mmol). The resulting mixture was stirred at −78° C.for 30 min and then allylmagnesium bromide, 1.0 M solution in Et₂O (397mL, 397 mmol) was added slowly via cannula over 80 min. The resultingmixture was stirred at 0° C. for 4 h. The mixture was quenched with 200mL H₂O and allowed to reach rt at which time the volatiles were removedby rotary evaporation. To the aqueous residue was then added 50% H₂SO₄(150 mL), the mixture was stirred for 5 min, Et₂O was then added (400mL) and the mixture was stirred vigorously at rt overnight. The layerswere separated; the aqueous layer was extracted with 300 mL Et₂O and thecombined organic layers were washed with 300 mL of sat. NaHCO₃, driedover Na₂SO₄, filtered and concentrated by rotary evaporation to give(2S,3S)-3-methylhex-5-en-2-ol (6.7 g, 58.7 mmol) as a clear oil.

STEP 3: 2-(((2R,3S)-3-METHYLHEX-5-EN-2-YL)THIO)PYRIMIDINE

To a 2000 mL dry RBF containing a stirring solution of tributylphosphine(57.7 mL, 231 mmol) in 1000 mL degassed THF (sparged with argon for 30min plus 5 cycles of pump/add argon) at 0° C. was added diethylazodicarboxylate (40 wt. % solution in toluene; 103 mL, 262 mmol) dropwise under an atmosphere of argon. A solution of(2S,3S)-3-methylhex-5-en-2-ol (from Intermediate EE22, Step 2; 17.6 g,154 mmol; dried over Na₂SO₄) was added drop wise as a solution in 50 mLof THF to the solution of phosphine/diethyl azodicarboxylate complex,via syringe-filter (0.45 um). The resulting ROH/diethylazodicarboxylate/tri-n-butylphosphine mixture was aged at zero degreesfor 15 min (solution turned light orange), at which timepyrimidine-2-thiol (49.3 g, 439 mmol) was added gradually to the top ofthe reaction vessel (as a solid) under positive argon pressure. Thereaction was stirred at 0° C. for 1 h then at rt 15 h (reaction notcomplete at 12 h by LC/MS). The crude reaction was then filtered toremove excess pyrimidine-2-thiol, diluted with 1000 mL of EtOAc,extracted twice with 500 mL of 1 N K₂CO₃, and once with 500 mL of brine.The aqueous layer was back extracted with 300 mL of EtOAc and thecombined organic layers were dried over Na₂SO₄. The organic solution wasthen filtered, the solvent removed by rotary evaporation and the crudefiltered to remove the (E)-diethyl diazene-1,2-dicarboxylate generatedin the reaction. The filtrate (125 g) was passed through a SiO₂ plug(500 g eluting with 2 L of DCM) to give 75 g of crude product aftersolvent removal. The crude product was purified again on a Combiflash®(125 g gold SiO₂ column), eluting with 10% EtOAc in heptanes to give2-(((2R,3S)-3-methylhex-5-en-2-yl)thio)pyrimidine (20.37 g, 98 mmol) asa light yellow oil.

STEP 4: 2-(((2R,3S)-3-METHYLHEX-5-EN-2-YL)SULFONYL)PYRIMIDINE

To a 500 mL 3-necked-RBF with a reflux condenser was addedphenylphosphonic acid (3.95 g, 24.96 mmol), sodium tungstate oxidedihydrate (8.23 g, 24.96 mmol), tetrabutylammonium sulfate (50 wt. %solution in H₂O, 28.7 mL, 24.96 mmol), a catalytic amount of hydrogenperoxide (30% in H₂O, 12.75 mL, 125 mmol), toluene (200 mL) and2-(((2R,3S)-3-methylhex-5-en-2-yl)thio)pyrimidine (from IntermediateEE22, Step 3; 52 g, 250 mmol). The reaction was stirred at 45° C. for 5min at which time hydrogen peroxide 30% in H₂O (58.6 mL, 574 mmol) wasadded portion wise (10 mL at a time). Five min after the first portionof hydrogen peroxide was added, an exotherm was observed (65° C.), thereaction was taken out of oil bath, the addition was stopped and theflask placed in a H₂O bath until temperature stabilizes. The flask wastaken out of the H₂O bath and the portion wise addition of hydrogenperoxide was continued at a rate in which the internal temperaturestayed between 45° C. and 55° C. (40 min). An ice bath was utilized ifthe temperature went above 60° C. and an oil bath was used if thetemperature fell below 45° C. The reaction was then stirred at 45° C.for 1 h. The reaction was diluted with 1400 mL of EtOAc and extractedtwo times with 500 mL of H₂O and once with 500 mL of brine. The organiclayer was dried over Na₂SO₄, filtered, concentrated, and the crudepurified on a Combiflash® (330 g gold SiO₂ column per 30 grams ofcrude), eluting with 0%-50% EtOAc in heptanes to give2-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)pyrimidine (55.7 g, 232 mmol)as a light yellow oil.

STEP 5: SODIUM (2R,3S)-3-METHYLHEX-5-ENE-2-SULFINATE

To a solution of 2-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)pyrimidine(from Intermediate EE22, Step 4; 52 g, 216 mmol) in MeOH (400 mL) at rtwas added sodium methoxide solution (51.0 mL, 223 mmol) over 70 min. Thesodium methoxide was added portion wise, the internal temperature wasmonitored, and the addition was slowed or the reaction was cooled in aH₂O bath, never letting the internal temperature exceeded 30° C. Themixture was concentrated by rotary evaporation and the waxy solid wastriturated with MTBE (add 200 mL MTBE, stir for 1 h using a spatula tobreak up clumps), filtered (use a stream of N₂ over filter cake), andwashed with 100 mL of cold MTBE to obtain sodium(2R,3S)-3-methylhex-5-ene-2-sulfinate (46 g, 250 mmol) as a an off whitesolid.

STEP 6: (2R,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

To a 1000 mL 3-necked-RBF was added sodium(2R,3S)-3-methylhex-5-ene-2-sulfinate (from Intermediate EE22, Step 5;46 g, 225 mmol), 500 mL of H₂O and KOAc (44.1 g, 449 mmol) at rt. Theflask was place in a 45° C. oil bath and hydroxylamine-O-sulfonic acid(21.09 g, 187 mmol) was added portion wise over 90 min. The internaltemperature of the reaction was monitored and the reaction was removedfrom the oil bath (if needed) to control exotherm (Tmax=55° C.). Thereaction was monitored by LC/MS every 10 min and was complete after theaddition of 0.83 eq. of hydroxylamine-O-sulfonic acid. The mixture wasthen cooled to rt and was extracted with 1000 mL of EtOAc. The organicphase was extracted three times with 500 mL of 1 N HCl, two times with300 mL of sat. sodium bicarbonate, once with 200 mL of brine, dried overNa₂SO₄, filtered, and concentrated by rotary evaporation to provide(2R,3S)-3-methylhex-5-ene-2-sulfonamide (32 g, 181 mmol) as a whitesolid.

Example 1(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-11′,11′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6.)0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: 2,2-DIMETHYLPENT-4-EN-1-OL

To a 100 mL flask was added methyl 2,2-dimethylpent-4-enoate(Sigma-Aldrich; 8.40 g, 59.1 mmol), lithium tetrahydroborate (4.06 mL,124 mmol) and then slowly (1 mL every 5 min) MeOH (5.26 mL, 130 mmol).The reaction was stirred at 22° C. for 2 h. The reaction was thenquenched with 300 mL of H₂O and extracted 2 times with 300 mL of Et₂O.The organic layer was dried over Na₂SO₄, filtered, and the solvent wasremoved by rotary evaporation (slowly over 4 h with the H₂O bath at 0°C. and slowly reducing the pressure, no trace product in the trap) togive 2,2-dimethylpent-4-en-1-ol (6.75 g, 59.1 mmol, 100% yield) as aclear oil.

STEP 2: 2,2-DIMETHYLPENT-4-EN-1-YL METHANESULFONATE

To a solution of 2,2-dimethylpent-4-en-1-ol (from Step 1, 6.5 g, 56.9 tommol) in DCM (40 mL) cooled to −78° C. was added MsCl (6.75 mL, 85mmol). After addition the mixture was placed in an ice bath and stirredfor 16 h (bath was at rt after 16 h). The reaction was filtered anddiluted with 400 mL of DCM. The organic layer was extracted once with200 mL of H₂O and again with 200 mL of 1N HCl. The organic layer wasdried over Na₂SO₄, filtered, and concentrated to give an orange oil. Thecrude product was purified on a Combiflash® (80 g gold SiO₂ column),eluting with 10% to 50% EtOAc in heptanes, to give2,2-dimethylpent-4-en-1-yl methanesulfonate (6.66 g, 34.6 mmol, 60.8%yield) as a clear oil.

STEP 3: 2-((2,2-DIMETHYLPENT-4-EN-1-YL)THIO)PYRIMIDINE

A solution of pyrimidine-2-thiol (962 mg, 8.58 mmol) and sodiummethoxide (30 wt % solution in methanol, 1.825 mL, 9.83 mmol) in MeOH (8mL) was treated with a solution of 2,2-dimethylpent-4-en-1-ylmethanesulfonate (1500 mg, 7.80 mmol) in 2 mL of MeOH. To the solutionwas added 20 mL of DMF and then the solution was degassed by bubblingargon through the reaction mixture for 10 min. The reaction was heatedto 130° C. while venting off MeOH through two 18 gauge needles for 11 h.The reaction was diluted with 300 mL of EtOAc and extracted twice with200 mL of brine. The organic layer was dried over Na₂SO₄, filtered,concentrated, and the crude was purified on a Combiflash® (24 g goldSiO₂ column), eluting with 10% to 50% EtOAc in heptanes, to give2-((2,2-dimethylpent-4-en-1-yl)thio)pyrimidine (1250 mg, 6.00 mmol, 77%yield) as a clear oil.

STEP 4: 2-((2,2-DIMETHYLPENT-4-EN-1-YL)SULFONYL)PYRIMIDINE

To a 25 mL flask were added phenylphosphonic acid (0.056 mL, 0.504mmol), sodium tungstate oxide dihydrate (0.051 mL, 0.504 mmol),tetrabutylammonium sulfate (50 wt. % solution in H₂O, 0.580 mL, 0.504mmol) and hydrogen peroxide (30% in H₂O, 1.287 mL, 12.60 mmol). Thereaction was stirred at 22° C. for 5 min at which time2-((2,2-dimethylpent-4-en-1-yl)thio)pyrimidine (from Step 3, 1050 mg,5.04 mmol) was added as a solution in 5 mL of toluene. The reaction wasstirred 22° C. for 30 min than at 50° C. for 1 h. The reaction wasdiluted with 300 mL of EtOAc and extracted once with 100 mL of H₂O andthen once with 100 mL of brine. The organic layer was dried over Na₂SO₄,filtered, concentrated and the crude was purified on a Combiflash® (12 ggold SiO₂ column), eluting with 10% to 50% EtOAc in heptanes, to give2-((2,2-dimethylpent-4-en-1-yl)sulfonyl)pyrimidine (910 mg, 3.79 mmol,75% yield) as a clear oil.

STEP 5: SODIUM 2,2-DIMETHYLPENT-4-ENE-1-SULFINATE

To a 100 mL flask was added2-((2,2-dimethylpent-4-en-1-yl)sulfonyl)pyrimidine (from Step 4, 910 mg,3.79 mmol) and MeOH (20 mL) at which time sodium methoxide solution (30wt % solution in methanol, 0.710 mL, 3.79 mmol) was added at 22° C. andthe mixture was stirred for 45 min. The reaction mixture was thenconcentrated by rotary evaporation and the residue was triturated withEt₂O. The solid was collected and dried to give sodium2,2-dimethylpent-4-ene-1-sulfinate (465 mg, 2.52 mmol, 66.7% yield) as abright orange solid.

STEP 6: 2,2-DIMETHYLPENT-4-ENE-1-SULFONAMIDE

To a solution of sodium 2,2-dimethylpent-4-ene-1-sulfinate (from Step 5,465 mg, 2.52 mmol) and sodium acetate (414 mg, 5.05 mmol) in H₂O (20 mL)at rt was added hydroxylamine-o-sulfonic acid (571 mg, 5.05 mmol). Themixture was heated to 50° C. and stirred for 1 h then stirred at rt for4 h. The mixture was extracted with EtOAc, the organic phase was driedover Na₂SO₄, filtered and concentrated. The crude was purified on aCombiflash® (12 g gold SiO₂ column), eluting with 10% to 50% EtOAc inheptanes, to provide 2,2-dimethylpent-4-ene-1-sulfonamide (246 mg, 1.388mmol, 55.0% yield) as a white solid.

STEP 7:(S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-5,5-DIMETHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

To a 100 mL flask was added(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 100 mg, 0.196 mmol),2,2-dimethylpent-4-ene-1-sulfonamide (from Step 6, 104 mg, 0.588 mmol)and DCE (2 mL). The solution was sparged with argon for 15 min at whichtime(1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI)chloride (12.29 mg, 0.020 mmol) was added as a 0.2 mL solution in DCE atrt. The mixture was stirred at rt for 16 h. The reaction mixture wasthen bubbled with air for 5 min and filtered. The solvent was removedfrom the filtrate and the crude product was directly purified on aCombiflash® (12 g gold SiO₂ column), eluting with 50%-90% EtOAc inheptanes+0.2% AcOH, to give(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-5,5-dimethyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (98 mg, 0.159 mmol, 81% yield) as a white solid.

STEP 8:(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-11′,11′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0˜3,6˜.0˜19,24˜]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a 250 mL flask containing(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-5,5-dimethyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (from Step 7, 98 mg, 0.159 mmol) which was previously dried byazeotroping twice with 5 mL of toluene, was addedN,N-dimethylpyridin-4-amine (33.0 mg, 0.270 mmol) and 100 mL of DCM. Thereaction mixture was cooled to 0° C. at whichN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (60.9 mg,0.318 mmol) was added. The reaction was stirred at rt for 12 h. Themixture was then quenched with 100 mL of 1N HCl and extracted with 300mL of DCM. The organic layer were dried over anhydrous Na₂SO₄, filtered,and concentrated by rotary evaporation. The crude was first purified ona Combiflash® (12 g gold SiO₂ column), eluting with 30%-70% EtOAc inheptanes+0.2% AcOH, followed by preparative reverse-phase HPLC (Gemini™Prep C₁₈ 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of10% to 90% MeCN in H₂O, where both solvents contain 0.1% TFA, 45 minmethod), to give(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-11′,11′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (2.5 mg, 4.17 μmol, 2.63% yield) as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (br. s., 1H), 7.70 (d, J=8.4 Hz,1H), 7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.93 (s, 2H),6.85-6.79 (m, 1H), 5.98-5.82 (m, 1H), 5.69 (dd, J=8.1, 15.4 Hz, 1H),4.27-4.17 (m, 1H), 4.14-4.01 (m, 2H), 4.15-3.94 (m, 1H), 3.79-3.60 (m,2H), 3.25 (d, J=13.3 Hz, 2H), 3.14-2.95 (m, 1H), 2.86-2.62 (m, 2H),2.49-2.21 (m, 3H), 2.14-1.89 (m, 4H), 1.86-1.80 (m, 3H), 1.69-1.61 (m,1H), 1.48-1.36 (m, 1H), 1.26 (s, 6H). m/z (ESI, +ve ion) 599.0 (M+H)⁺.

Example 2(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N-(((2R,3S)-3-METHYLHEX-5-EN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

DMAP (3.42 g, 28.0 mmol) was added to a solution of(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA11A; 7.7 g, 16.45 mmol) and(2R,3S)-3-methylhex-5-ene-2-sulfonamide (Intermediate EE22; 5.83 g, 32.9mmol) in DCM (411 mL) cooled to 0° C. EDC hydrochloride (6.31 g, 32.9mmol) was then added slowly portionwise. The mixture was stirred whileallowing to reach ambient temperature overnight. The mixture was washedwith 1N HCl and brine and the aqueous layer was back-extracted withEtOAc. The combined organics were dried over MgSO₄, filtered andconcentrated. The yellow oily residue was loaded onto a 220 ISCO goldcolumn and purified eluting with 0% to 20% EtOAc (containing 0.3%AcOH)/heptanes, to provide(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(7.89 g, 12.58 mmol, 76% yield).

STEP 2:(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a 20 L reactor blanketed in argon was charged 14 L of 1,2-DCE.(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(18.75 g, 29.9 mmol) was added as a solution in 400 mL 1,2-DCE followedby a 400 mL rinse. The reactor was sealed and purged with argon.Hoveyda-Grubbs II (1.873 g, 2.99 mmol) was added as a solution in 150 mLof 1,2-DCE followed by a 50 mL rinse. The reactor was heated to 60° C.over 1 h with an argon sweep of the headspace and held at temperaturefor 9 h. The reaction was quenched by the addition of2-(2-(vinyloxy)ethoxy)ethanol (1.501 g, 11.36 mmol), cooled to ambienttemperature, and concentrated to ˜200 mL volume by rotary evaporation.The reaction was transferred to a 1 L RBF and diluted to 500 mL volumewith 1,2-DCE. The reaction was treated with 52 g of Silicycle Si-Thiol(SiliCycle Inc., Quebec City, Quebec CANADA Cat # R51030B) with stirringfor 9 h at 40° C., filtered and rinsed with 2×65 mL DCM. The solutionwas passed through a Whatman GF/F filter cup (GE Healthcare Bio-SciencesPittsburgh, Pa., USA) to afford a transparent yellow solution. Thereaction was concentrated to afford a crude product mass of 27.4 g. Theresidue was slurried in 250 mL IPAc and evaporated to dryness threetimes. The reaction was suspended in 270 mL IPAc, heated to dissolution,allowed to cool to ambient temperature, and stirred for 18. The solidswere filtered and washed with 65 mL IPAc. The solid was air-dried for 30min then placed under high vacuum for 3 h to afford 12.56 g of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide which is 91.7% by weight. ¹H NMR (500 MHz, CD₂Cl₂) δ8.06 (s, 1H), 7.71 (d, J=8.56 Hz, 1H), 7.17 (dd, J=8.44, 2.32 Hz, 1H),7.09 (d, J=2.20 Hz, 1H), 6.91 (s, 3H), 5.81 (ddd, J=14.92, 7.82, 4.16Hz, 1H), 5.71 (dd, J=15.41, 8.31 Hz, 1H), 4.16-4.26 (m, 2H), 3.83 (d,J=14.43 Hz, 1H), 3.69 (d, J=14.43 Hz, 1H), 3.25 (d, J=14.43 Hz, 1H),3.04 (dd, J=15.28, 9.66 Hz, 1H), 2.68-2.84 (m, 2H), 2.41 (app qd,J=9.80, 3.70 Hz, 1H), 2.25-2.34 (m, 1H), 1.93-2.00 (m, 5H), 1.74-2.11(m, 9H), 1.62-1.73 (m, 1H), 1.43 (d, J=7.09 Hz, 3H) 1.35-1.42 (m, 1H)1.03 (d, J=6.60 Hz, 3H). MS (ESI, +ve ion) m/z 599.2 (M+H)⁺.

Example 3(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,21)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A 1000 mL RBF was charged with(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(Example 2, Step 1, 710 mg, 1.132 mmol) and DCM (569.00 mL). Thesolution was sparged with argon for 15 min, then Hoveyda-Grubbs II (70.9mg, 0.113 mmol) was added. The mixture was stirred at 45° C. for 15 h.The reaction mixture was sparged with air for 20 min while cooling toambient temperature, then concentrated under reduced pressure. The crudeoil was absorbed onto a plug of SiO₂ gel and purified through a 220 gISCO gold column, eluting with 10-20 (15 min)-50% EtOAc (containing 0.3%AcOH) in heptanes over 36 min to provide(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 3) as the first eluting minor isomer followedby(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2) as the second eluting major isomer. Thesemi-pure material thus obtained was loaded onto a SiO₂ gel column andpurified eluting with 5% acetone in DCM to provide the title compound.¹H NMR (500 MHz, CD₂Cl₂) δ 8.83 (br. s., 1H), 7.71 (d, J=8.3 Hz, 1H),7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.11 (dd, J=1.6, 8.2 Hz, 1H), 7.09 (d,J=2.2 Hz, 1H), 7.02 (s, 1H), 6.93 (d, J=8.1 Hz, 1H), 5.82-5.75 (m, 1H),5.67 (dd, J=6.5, 11.4 Hz, 1H), 4.43 (s, 1H), 4.12-4.05 (m, 2H),3.85-3.76 (m, 2H), 3.67 (d, J=14.4 Hz, 1H), 3.25 (d, J=14.4 Hz, 1H),3.28-3.19 (m, 1H), 2.83-2.65 (m, 3H), 2.38-2.23 (m, 2H), 2.19-2.11 (m,2H), 2.10-1.99 (m, 3H), 1.97-1.87 (m, 2H), 1.87-1.80 (m, 1H), 1.79-1.70(m, 2H), 1.47 (d, J=7.3 Hz, 3H), 1.47-1.40 (m, 1H), 1.06 (d, J=6.6 Hz,3H). MS (ESI, +ve ion) m/z 599.1 (M+H)⁺.

Example 4(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-METHOXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE-13′,13′-DIOXIDE

To a slurry of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2; 32.6 g, 49.1 mmol) (containing 9.8% toluene,starting material was not completely soluble in Me-THF) and MeI (15.2mL, 245 mmol) in Me-THF (820 mL) was added KHMDS (1.0 M in THF, 167 mL,167 mmol) dropwise for 30 min while maintaining reaction temperaturebetween −44° C. and −38° C. under N₂. After the mixture was stirred at−44° C. for 30 min, the reaction was allowed to warm to rt and stirredfor 1.5 h (LC/MS confirmed the reaction was complete). The reactionmixture was cooled to 5° C., quenched (170 mL of sat. aqueous NH₄Cl and170 mL of H₂O) while maintaining temperature between 5° C. and 14° C.,and acidified (340 mL of 10% aqueous citric acid). The organic layer wasseparated and the aqueous layer was back-extracted with EtOAc (500 mL).The combined organic layers were washed with brine (3×500 mL), dried(MgSO₄), and concentrated under reduced pressure to provide a crudetarget compound (30.1 g, 49.1 mmol, quantitatively) (purity >98% with noover 1% major impurity from HPLC) as a bright yellow solid. After thesame scale reaction was repeated four times, all the crude to products(4×49.1 mmol=196 mmol) were dissolved in EtOAc, combined, andconcentrated under reduced pressure. Then the combined crude product wasrecrystallized as follows: ethanol (800 mL) was added to the crudeproduct and the resulting slurry solution was shaken while heating thesolution for 20 min. H₂O (250 mL) was added dropwise for 30 min at rtand the slurry was cooled down to 0° C. After the slurry was kept in anice bath for 4 h, the solid product was filtered through filter paper.The filter cake was rinsed with ice-cold 30% H₂O in EtOH (300 mL) andair-dried for 2 days. The product was further dried under high vacuum at40° C. for 4 days to provide the pure target compound (115 g, 188 mmol,96% yield) as a white solid. ¹H NMR (600 MHz, DMSO-d₆) δ 11.91 (s, 1H),7.65 (d, J=8.6 Hz, 1H), 7.27 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.4 Hz,1H), 7.04 (dd, J=8.2, 2.0 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 6.76 (d,J=1.8 Hz, 1H), 5.71 (ddd, J=15.1, 9.7, 3.5 Hz, 1H), 5.50 (ddd, J=15.2,9.2, 1.1 Hz, 1H), 4.08 (qd, J=7.2, 7.2, 7.2, 1.5 Hz, 1H), 4.04 (d,J=12.3 Hz, 1H), 3.99 (d, J=12.3 Hz, 1H), 3.73 (d, J=14.9 Hz, 1H), 3.56(d, J=14.1 Hz, 1H), 3.53 (dd, J=9.1, 3.3 Hz, 1H), 3.19 (d, J=14.1 Hz,1H), 3.09 (s, 3H), 3.03 (dd, J=15.4, 10.4 Hz, 1H), 2.79 (dt, J=17.0,3.5, 3.5 Hz, 1H), 2.69 (ddd, J=17.0, 10.7, 6.3 Hz, 1H), 2.44-2.36 (m,1H), 2.24-2.12 (m, 2H), 2.09 (ddd, J=15.5, 9.6, 2.3 Hz, 1H), 1.97 (dt,J=13.6, 3.6, 3.6 Hz, 1H), 1.91-1.80 (m, 4H), 1.80-1.66 (m, 3H), 1.38(td, J=12.3, 12.3, 3.5 Hz, 1H), 1.33 (d, J=7.2 Hz, 3H), 0.95 (d, J=6.8Hz, 3H); [α]_(D) (24° C., c=0.0103 g/mL, DCM)=−86.07°; m.p. 222.6-226.0°C.; FT-IR (KBr): 3230 (b), 2931 (b), 1688 (s), 1598 (s), 1570 (s), 1505(s), 1435 (s), 1384 (s), 1335 (s), 1307 (s), 1259 (s), 1155 (s), 1113(s), 877 (s), 736 (s) cm⁻¹; Anal. Calcd. for C₃₃H₄₁ClN₂O₅S: C, 64.64; H,6.74; N, 4.57; Cl, 5.78; S, 5.23. Found: C, 64.71; H, 6.81; N, 4.65; Cl,5.81; S, 5.11; HRMS (ESI) m/z 613.2493 [M+H]⁺ (C₃₃H₄₁ClN₂O₅S requires613.2503).

The mother liquor was concentrated under reduced pressure and furtherpurification of the residue by flash column chromatography (200 g SiO₂,10% and 10% to 45% and 45% EtOA/Hex w/0.3% AcOH, gradient elution)provided additional pure product (3.1 g, 5.1 mmol, 2.6%) as an off-whitesolid.

Example 5(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-CHLORO-7′-METHOXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a solution of(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 3; 34 mg; 0.057 mmol) in THF cooled to 0° C.was added sodium hydride (60% dispersion in mineral oil; 22.70 mg, 0.567mmol). The reaction mixture was stirred at 0° C. for 20 min, and thenMeI (0.018 mL, 0.284 mmol) was added. The reaction mixture was stirredat ambient temperature for 1 h, then quenched with aqueous NH₄Cl, anddiluted with EtOAc. The organic layer was dried over MgSO₄ andconcentrated. Purification of the crude material via columnchromatography eluting with 10-40% EtOAc (containing 0.3% AcOH)/heptanesprovided(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (34 mg, 0.054 mmol, 95% yield). ¹H NMR (400 MHz, CD₂Cl₂)δ 8.29 (s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.2, 8.5 Hz, 1H),7.09 (d, J=2.3 Hz, 1H), 7.01 (dd, J=1.6, 7.8 Hz, 1H), 6.92 (d, J=8.2 Hz,1H), 6.88 (s, 1H), 5.90-5.80 (m, 1H), 5.54 (t, J=10.2 Hz, 1H), 4.14-4.04(m, 3H), 3.87-3.79 (m, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.32 (d, J=14.5 Hz,1H), 3.23 (s, 3H), 3.28-3.19 (m, 1H), 2.82-2.73 (m, 2H), 2.62 (t, J=10.6Hz, 1H), 2.55-2.44 (m, 1H), 2.29-2.21 (m, 1H), 2.10-1.97 (m, 4H),1.97-1.80 (m, 4H), 1.75 (dd, J=8.9, 18.7 Hz, 1H), 1.48 (d, J=7.4 Hz,3H), 1.43 (br. s., 1H), 1.08 (d, J=6.5 Hz, 3H). MS (ESI, +ve ion) m/z613.3 (M+H)⁺.

Example 6(1S,3′R,6′R,7′S,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2, 7.5 mg, 0.013 mmol) and platinum (IV) oxide(2.84 mg, 0.013 mmol) in EtOAc (1.536 mL) was stirred under anatmosphere of H₂ (balloon) at ambient temperature for 45 min. Thereaction mixture was then filtered through a syringe filter. The crudematerial was purified by chromatography through a Redi-Sep® pre-packedSiO₂ gel column (4 g), eluting with 15% to 50% EtOAc (containing 0.3%AcOH)/heptanes, to provide the title product. ¹H NMR (400 MHz, CD₂Cl₂) δ8.24 (br. s., 1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H),7.09 (d, J=2.2 Hz, 1H), 7.06 (d, J=1.8 Hz, 1H), 6.99 (dd, J=2.0, 8.0 Hz,1H), 6.93 (d, J=8.2 Hz, 1H), 4.10 (s, 2H), 4.05 (ddd, J=1.2, 7.2, 14.3Hz, 1H), 3.82 (d, J=15.3 Hz, 1H), 3.74-3.69 (br. S., 1H), 3.68 (d,J=14.3 Hz, 1H), 3.23 (d, J=14.3 Hz, 1H), 3.06 (dd, J=7.3, 15.4 Hz, 1H),2.84-2.68 (m, 2H), 2.38 (d, J=3.5 Hz, 2H), 2.08-1.96 (m, 3H), 1.96-1.88(m, 1H), 1.88-1.75 (m, 2H), 1.74-1.56 (m, 4H), 1.47 (d, J=12.1 Hz, 2H),1.40 (d, J=7.2 Hz, 3H), 1.32-1.26 (m, 2H), 1.23-1.15 (m, 2H), 1.00 (d,J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z 601.2 (M+H)⁺.

Example 7(1S,3′R,6′R,7′S,11′S,12′R)-6-CHLORO-7′-METHOXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from a mixture of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one-13′,13′-dioxide (Example 4) following the procedure described in Example 6.¹HNMR (500 MHz, CD₂Cl₂) δ 8.14 (s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.17(dd, J=2.2, 8.6 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (d, J=1.7 Hz, 1H),6.95 (dd, J=2.0, 8.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.10 (s, 2H), 4.07(ddd, J=1.2, 7.1, 14.2 Hz, 1H), 3.81 (dd, J=2.0, 15.2 Hz, 1H), 3.68 (d,J=14.2 Hz, 1H), 3.25 (s, 3H), 3.22 (dd, J=9.0, 14.4 Hz, 1H), 3.03 (dd,J=8.6, 15.4 Hz, 1H), 2.83-2.69 (m, 2H), 2.60-2.51 (m, 1H), 2.41-2.32 (m,1H), 2.07-2.01 (m, 1H), 1.99-1.88 (m, 2H), 1.88-1.77 (m, 1H), 1.76-1.68(m, 1H), 1.68-1.58 (m, 2H), 1.53-1.46 (m, 2H), 1.45-1.42 (m, 1H), 1.40(d, J=7.1 Hz, 3H), 1.29 (br. s., 1H), 1.25-1.21 (m, 2H), 1.20-1.10 (m,2H), 0.99 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z 615.1 (M+H)⁺.

Example 8(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

Step 1:(S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

To a 100 mL flask was added(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 500 mg, 0.980 mmol), pent-4-ene-1-sulfonamide(Intermediate EE19; 878 mg, 5.88 mmol), and DCE (14 mL). The solutionwas sparged with argon for 15 min at which time Hoveyda-Grubbs II (61.4mg, 0.098 mmol) was added as a 0.2 mL solution in DCE at rt. The mixturewas stirred at rt and sparged with argon (the vial was vented) for 2 h.The reaction mixture was then bubbled with air for 5 min and filtered toseparate the insoluble sulfonamide homodimer. The crude product waspurified on a Combiflash® (24 g gold SiO₂ column), eluting with 50%-90%EtOAc in heptanes+0.2% AcOH) to give(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (439 mg, 0.745 mmol, 76% yield) as a white solid.

Step 2:(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a 1 L flask containing(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (from Step 1, 439 mg, 0.745 mmol), which was previously dried byazeotroping twice with 10 mL of toluene, was addedN,N-dimethylpyridin-4-amine (155 mg, 1.267 mmol) and 400 mL of DCM. Thereaction mixture was cooled to 0° C. at which timeN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (286 mg,1.490 mmol) was slowly added. The reaction was then stirred at rt for 18h. The mixture was quenched with 200 mL of 1N HCl and extracted with 600mL of EtOAc. The organic layer was dried over anhydrous Na₂SO₄,filtered, and concentrated by rotary evaporation. The crude product waspurified on a Combiflash® (24 g gold SiO₂ column), eluting with 30%-70%EtOAc in heptanes, to give the title compound as a white solid. ¹H NMR(500 MHz, CD₃OD) δ 7.75 (d, J=8.3 Hz, 1H), 7.20 (dd, J=2.9, 7.6 Hz, 1H),7.12 (d, J=3.7 Hz, 1H), 7.00 (dd, J=1.7, 8.8 Hz, 1H), 6.94 (d, J=8.3 Hz,1H), 6.88 (d, J=2.2 Hz, 1H), 5.95-5.86 (m, 1H), 5.70 (dd, J=8.8, 15.9Hz, 1H), 4.25-4.19 (m, 1H), 4.22 (dd, J=4.4, 8.6 Hz, 1H), 4.14-4.06 (m,3H), 4.14-4.05 (m, 3H), 3.84 (d, J=15.2 Hz, 1H), 3.68 (d, J=15.2 Hz,1H), 3.09 (dd, J=8.3, 15.9 Hz, 1H), 2.87-2.74 (m, 2H), 2.45-2.30 (m,3H), 2.14-1.88 (m, 5H), 1.86-1.69 (m, 4H). m/z (ESI, +ve ion) 571.2(M+H)⁺.

Example 9(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a 100 mL flask was added(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 8, 138 mg, 0.242 mmol), THF (10 mL), and sodiumhydride (29.0 mg, 1.208 mmol). The reaction was stirred at rt for 15 minat which time MeI (0.092 mL, 1.480 mmol) was added. The reaction wasstirred at rt for 2 h at which time additional sodium hydride (58.0 mg,2.42 mmol) and MeI (0.092 mL, 1.480 mmol) were added and the reactionwas stirred at rt for an additional 16 h. The reaction was quenched with100 mL of satd NH₄Cl and extracted with 400 mL of EtOAc. The organiclayer was dried over Na₂SO₄, filtered, and the solvent was removed byrotary evaporation. The crude product was purified on a Combiflash® (12g gold SiO₂ column), eluting with 10% to 50% EtOAc in heptanes, to give(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-methoxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (120 mg, 0.205 mmol, 85% yield) as an off white solid.¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.19(dd, J=2.2, 8.5 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.97-6.87 (m, 2H), 6.84(d, J=1.6 Hz, 1H), 5.88 (ddd, J=5.2, 8.1, 15.1 Hz, 1H), 5.53 (dd, J=8.7,15.4 Hz, 1H), 4.30 (ddd, J=4.8, 9.8, 15.0 Hz, 1H), 4.15-3.98 (m, 2H),3.84-3.69 (m, 2H), 3.67 (dd, J=3.8, 8.7 Hz, 1H), 3.36-3.21 (m, 2H), 3.25(s, 3H), 3.01 (dd, J=10.3, 15.2 Hz, 1H), 2.87-2.64 (m, 2H), 2.52-2.29(m, 3H), 2.25-1.91 (m, 5H), 1.88-1.75 (m, 3H), 1.71-1.60 (m, 2H), 1.41(t, J=12.4 Hz, 1H). m/z (ESI, +ve ion) 585.0 (M+H)⁺.

Example 10 (1S,3′R, 6′R,7′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′HSPIRO[NAPHTHALENE-1,22′[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

Step 1:(1′S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2R)-2-(1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

DMAP (0.830 g, 6.80 mmol) was added to a solution of(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 1.82 g, 3.78 mmol) and but-3-ene-1-sulfonamide(EE15; 1.873 g, 13.86 mmol) in DCM (140 mL) which was cooled to 0° C.EDC (1.303 g, 6.80 mmol) was added portion by portion and it was stirredat ambient temperature for 16 h. The reaction mixture was diluted withEtOAc (400 mL), washed with 1N HCl solution (2×5 mL), brine (3 mL),dried over anhydrous Na₂SO₄, and concentrated. The residue was loaded toa 80 g ISCO gold column and eluted with 0% to 15% EtOAc (containing 0.3%AcOH)/Hex (containing 0.3% AcOH) to provide the title compound (2.09 g)as a white solid. m/z (ESI, +ve ion) 599.0 (M+H)⁺.

Step 2:(1S,3′R,6′R,7′S,9′E)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A 1 L RBF was charged with(1′S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-(1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(from Step 1, 1.02 g, 1.70 mmol) in toluene (587 mL). The mixture wasstirred at ambient temperature for 10 min to dissolve the solid startingmaterial and then subjected to three cycles of evacuation/back-fillingwith N₂. To the homogeneous solution was added a solution ofHoveyda-Grubbs II (0.213 g, 0.340 mmol) in toluene (20 mL). After themixture was stirred at 106° C. under N₂ for 75 min, air was blown for 10min to deactivate the catalyst, and then concentrated. The residue wasloaded to a 330 g ISCO gold column and eluted with 0% to 25% EtOAc(containing 0.3% AcOH)/Hex (containing 0.3% AcOH). The second peak wasthe title compound (0.27 g) as a white solid. ¹H NMR (400 MHz, CD₂Cl₂) δ9.96 (br. s., 1H), 7.78-7.65 (m, 1H), 7.37 (dd, J=1.96, 8.22 Hz, 1H),7.16 (dd, J=2.35, 8.61 Hz, 1H), 7.10 (d, J=2.15 Hz, 1H), 7.04 (br. s.,1H), 6.98 (m, 1H), 5.66-5.47 (m, 2H), 4.23-4.09 (m, 2H), 3.98 (ddd,J=5.18, 10.56, 15.55 Hz, 1H), 3.86 (dd, J=3.81, 9.49 Hz, 1H), 3.64-3.49(m, 2H), 3.38 (td, J=4.74, 15.36 Hz, 2H), 2.92 (br. s., 1H), 2.81 (br.s., 1H), 2.79-2.73 (m, 2H), 2.73-2.63 (m, 1H), 2.52 (d, J=12.72 Hz, 1H),2.40-2.25 (m, 2H), 2.18 (d, J=8.22 Hz, 1H), 2.01-1.52 (m, 8H). m/z (ESI,+ve ion) 571.0 (M+H)⁺.

Step 3:(1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′HSPIRO[NAPHTHALENE-1,22′[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,9′E)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 2, 0.112 g, 0.196 mmol) and platinum (IV)oxide (0.045 g, 0.196 mmol) in EtOAc (33 mL) was stirred under H₂ atambient temperature for 3 h. The mixture was filtered through syringefilter to remove solid catalyst and the solution was concentrated toprovide title compound (112 mg) as a white solid. ¹H NMR (400 MHz,CD₂Cl₂) δ 8.93 (m, 1H), 7.71 (m, 1H), 7.15 (m, 3H), 7.09 (d, J=2.35 Hz,1H), 6.95 (m, 1H), 4.10 (m, 2H), 3.78-3.62 (m, 4H), 3.46-3.34 (m, 1H),3.26 (d, J=14.28 Hz, 1H), 3.16 (dd, J=9.00, 15.26 Hz, 1H), 2.82-2.71 (m,2H), 2.45-2.33 (m, 1H), 2.26-2.16 (m, 1H), 2.08-1.16 (m, 17H). m/z (ESI,+ve ion) 573.2 (M+H)⁺.

Example 11(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND EXAMPLE 12.(1S,3′R,6′R,7′S,8′E,12′S)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 2 using a mixture of (R)-hex-5-ene-sulfonamide (IntermediateEE20) and of (S)-hex-5-ene-sulfonamide (Intermediate EE202), and thedesired product,(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (the 1st epimer out of preparative reverse-phase HPLC,Example 11) and(1S,3′R,6′R,7′S,8′E,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (the 2nd epimer out of preparative reverse-phase HPLC,Example 12) were isolated. Cocrystal structure of Example 11 confirmsthat the methyl group at the 12-position has an R stereochemistry.(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide: ¹H NMR (400 MHz, CD₃OD) δ 7.74 (d, J=8.0 Hz, 1H), 7.19(dd, J=3.5, 11.5 Hz, 1H), 7.12 (d, J=1.8 Hz, 1H), 7.01 (d, J=9.2 Hz,1H), 7.01 (d, J=7.6 Hz, 1H), 6.94 (d, J=8.0 Hz, 1H), 6.88 (s, 1H),5.89-5.81 (m, 1H), 5.73 (dd, J=7.4, 14.5 Hz, 1H), 4.22 (dd, J=3.5, 7.6Hz, 1H), 4.18-4.12 (m, 1H), 4.09 (d, J=2.0 Hz, 2H), 3.85 (d, J=15.1 Hz,1H), 3.85 (d, J=15.3 Hz, 1H), 3.68 (d, J=14.1 Hz, 1H), 3.08 (dd, J=10.2,15.1 Hz, 1H), 2.87-2.73 (m, 2H), 2.48-2.18 (m, 4H), 2.11 (d, J=13.7 Hz,1H), 2.05-1.65 (m, 8H), 1.52 (d, J=6.8 Hz, 3H), 1.47-1.41 (m, 1H). m/z(ESI, +ve ion) 585.2 (M+H)⁺;

(1S,3′R,6′R,7′S,8′E,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide: ¹H NMR (400 MHz, CD3OD) δ 7.73 (d, J=9.2 Hz, 1H), 7.19(dd, J=2.5, 8.6 Hz, 1H), 7.13 (d, J=2.3 Hz, 1H), 7.12-7.10 (m, 1H), 7.05(dd, J=1.8, 8.0 Hz, 1H), 6.94 (d, J=8.6 Hz, 1H), 5.93-5.83 (m, 1H), 5.65(dd, J=5.5, 15.5 Hz, 1H), 4.12 (d, J=6.8 Hz, 2H), 4.06 (dd, J=4.1, 10.2Hz, 1H), 3.91 (dd, J=6.3, 12.5 Hz, 1H), 3.67-3.55 (m, 2H), 3.53-3.46 (m,1H), 3.29-3.08 (m, 1H), 2.88-2.70 (m, 2H), 2.64-2.52 (m, 1H), 2.49-2.31(m, 2H), 1.98-1.91 (m, 3H), 1.99-1.89 (m, 4H), 1.86-1.73 (m, 4H), 1.49(d, J=7.4 Hz, 3H). m/z (ESI, +ve ion) 585.2 (M+H)⁺.

Example 13(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 4 using(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 11), and the desired product, (1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide was isolated as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.75 (d, J=8.4 Hz, 1H), 7.19 (dd, J=1.8, 8.8 Hz, 1H), 7.12 (d, J=2.0 Hz,1H), 7.00 (dd, J=2.2, 7.8 Hz, 1H), 6.95 (d, J=8.4 Hz, 1H), 6.86 (d,J=1.6 Hz, 1H), 5.92-5.84 (m, 1H), 5.58 (dd, J=9.0, 15.1 Hz, 1H),4.85-4.85 (m, 1H), 4.20 (ddd, J=3.0, 6.7, 9.8 Hz, 1H), 4.08 (d, J=2.2Hz, 2H), 3.86 (d, J=15.3 Hz, 1H), 3.73 (dd, J=2.9, 8.6 Hz, 1H), 3.67 (d,J=14.1 Hz, 1H), 3.26-3.23 (m, 3H), 3.08 (dd, J=10.3, 15.2 Hz, 1H),2.88-2.72 (m, 2H), 2.54-2.25 (m, 4H), 2.12 (d, J=13.1 Hz, 1H), 1.99-1.71(m, 7H), 1.53 (d, J=6.8 Hz, 3H), 1.50-1.40 (m, 1H). m/z (ESI, +ve ion)599.2 (M+H)⁺.

Example 14(1S,3′R,6′R,7′S,12′R)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

STEP 1:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-N—((R)-PENT-4-EN-2-YLSULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 166 mg, 0.344 mmol) and(R)-pent-4-ene-2-sulfonamide (intermediate EE17; 87 mg, 0.585 mmol)following the procedure described for Example 2, Step 1. Purification ofthe crude material provided(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—((R)-pent-4-en-2-ylsulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(134 mg, 0.219 mmol, 63.5% yield).

STEP 2.(1S,3′R,6′R,7′S,9′E,12′R)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′Z,12′R)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A 500 mL RBF was charged with(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—((R)-pent-4-en-2-ylsulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(134 mg, 0.219 mmol) in toluene (146.00 mL). The mixture was stirred atambient temperature for 10 min to dissolve the solid starting materialand then subjected to three cycles of evacuation/back-filling with N₂.To the homogeneous solution was added a solution of Hoveyda-Grubbs II(27.4 mg, 0.044 mmol) in toluene (8 mL) at ambient temperature. Themixture was stirred at 106° C. under N₂ for 80 min. Air was blownthrough the solution for 10 min to deactivate the catalyst, and then themixture was concentrated. The crude dark oil was absorbed onto a plug ofSiO₂ gel and purified by chromatography through a 24 g ISCO column,eluting with 10% to 20% to 40% EtOAc (containing 0.3% AcOH) in Hex over90 min. to provide a mixture of the title compounds.

STEP 3:(1S,3′R,6′R,7′S,12′R)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound (94 mg, 0.160 mmol, 79% yield) was synthesized from amixture of(1S,3′R,6′R,7′S,9′E,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′Z,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 2, 119 mg, 0.203 mmol) following theprocedure described for Example 6. ¹H NMR (400 MHz, CD₂Cl₂) δ 9.03 (br.s., 1H), 7.71 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.3, 8.4 Hz, 1H), 7.13 (dd,J=2.2, 8.2 Hz, 1H), 7.10 (br. s., 1H), 7.09 (d, J=2.3 Hz, 1H), 6.93 (d,J=8.2 Hz, 1H), 4.09 (s, 2H), 3.86 (td, J=5.3, 6.8 Hz, 1H), 3.74 (d,J=14.1 Hz, 1H), 3.70 (br. s., 1H), 3.65 (d, J=14.9 Hz, 1H), 3.25 (d,J=14.1 Hz, 1H), 3.13 (dd, J=8.2, 15.5 Hz, 1H), 2.85-2.68 (m, 2H), 2.44(quin, J=8.8 Hz, 1H), 2.25 (ddd, J=5.5, 9.6, 17.8 Hz, 1H), 2.04-1.94 (m,2H), 1.89 (dt, J=5.0, 9.5 Hz, 2H), 1.85-1.77 (m, 2H), 1.76-1.68 (m, 2H),1.68-1.60 (m, 4H), 1.60-1.50 (m, 3H), 1.48 (d, J=7.0 Hz, 3H), 1.46-1.35(m, 2H). MS (ESI, +ve ion) m/z 587.1 (M+H)⁺.

Example 15(1S,3R,6R,7′S,12′S)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

STEP 1:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-N—((S)-PENT-4-EN-2-YLSULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 15 mg, 0.031 mmol) and(S)-pent-4-ene-2-sulfonamide (Intermediate EE172; 5.6 mg, 0.037 mmol)following the procedure described for Example 2, Step 1. Purification ofthe crude material provided(S)-6′-chloro-5-(((1R,2R)-2-((5)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—((S)-pent-4-en-2-ylsulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(19 mg, 0.031 mmol).

STEP 2:(1S,3′R,6′R,7′S,9′Z,12′S)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′E,12′S)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—((S)-pent-4-en-2-ylsulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(from Step 1, 42.5 mg, 0.067 mmol) following the procedure described forExample 14, Step 2. Purification by chromatography through a 24 g ISCOcolumn, eluting with 10% to 20% to 40% EtOAc (containing 0.3% AcOH) inHex over 90 min. followed by a second purification through a 12 g ISCOcolumn, eluting with 0% to 30% EtOAc (containing 0.3% AcOH) in Hexprovided(1S,3′R,6′R,7′S,9′Z,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide as the first eluting isomer (13.4 mg, 0.023 mmol 34.3%yield) and(1S,3′R,6′R,7′S,9′E,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide was obtained as the second eluting isomer (13.2 mg,0.023 mmol 34.3% yield).

STEP 3:(1S,3′R,6′R,7′S,12′S)-6-CHLORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,241TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound (7.5 mg, 0.013 mmol, 71% yield) was synthesized froma mixture of(1S,3′R,6′R,7′S,9′E,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′Z,12′S)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 2, 10.8 mg, 0.018 mmol) following theprocedure described for Example 6. ¹H NMR (400 MHz, CD₂Cl₂) δ 9.72 (br.s., 1H), 7.71 (d, J=8.6 Hz, 1H), 7.30 (dd, J=2.0, 8.4 Hz, 1H), 7.28 (s,1H), 7.16 (dd, J=2.4, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.94 (d,J=8.4 Hz, 1H), 4.10-4.05 (m, 2H), 3.85-3.76 (m, 1H), 3.70 (d, J=15.1 Hz,1H), 3.60 (br. s., 1H), 3.60 (d, J=13.9 Hz, 1H), 3.26 (d, J=14.3 Hz,1H), 3.23-3.14 (m, 1H), 2.83-2.69 (m, 2H), 2.33 (quin, J=8.6 Hz, 1H),2.12 (quin, J=8.2 Hz, 1H), 2.04-1.94 (m, 2H), 1.94-1.85 (m, 1H),1.84-1.71 (m, 5H), 1.71-1.64 (m, 2H), 1.64-1.52 (m, 3H), 1.49 (d, J=7.2Hz, 3H), 1.52-1.43 (m, 2H), 1.38-1.28 (m, 2H). MS (ESI, +ve ion) m/z587.2 (M+H)⁺.

Example 16(1S,3′R,6′R,7′S,12′R)-6-CHLORO-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 13; 5 mg, 8.34 μmol) and platinum (iv) oxide(0.379 mg, 1.67 μmol, Omega) in EtOAc (2.8 mL) were stirred under H₂(balloon) at rt for 3 hr, then filtered through Celite® to remove solidcatalyst, concentrated, and purified by preparative reverse-phase HPLC(Gemini™ Prep C₁₈ 5 μm column; gradient elution of 40% to 95% MeCN inH₂O, where both solvents contain 0.1% TFA, 30 min method) to give(1S,3′R,6′R,7′S,12′R)-6-chloro-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide (4.4 mg, 7.32 μmol). ¹H NMR (400 MHz, CD₃OD) δ 7.73 (d,J=8.4 Hz, 1H), 7.16 (d, J=8.7 Hz, 1H), 7.11-7.03 (m, 2H), 6.93 (d, J=9.1Hz, 2H), 4.14-4.03 (m, 3H), 3.83 (d, J=14.7 Hz, 1H), 3.69 (d, J=14.3 Hz,1H), 3.33-3.29 (m, 3H overlap with solvent), 3.23 (d, J=14.5 Hz, 1H),3.06 (dd, J=9.1, 15.4 Hz, 1H), 2.85-2.71 (m, 2H), 2.62 (d, J=8.2 Hz,1H), 2.36 (t, J=8.5 Hz, 1H), 2.10-1.84 (m, 5H), 1.84-1.56 (m, 6H),1.55-1.40 (m, 6H), 1.38-1.24 (m, 3H). m/z (ESI, +ve ion) 601.2 (M+H)⁺.

Example 17(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE Example 18(1S,3′R,6′R,7′S,8′Z,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND Example 19(1S,3′R,6′R,7′S,8′E,12′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 2 using(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA11A) and a racemic mixture of(R)-hept-6-ene-3-sulfonamide (Intermediate EE21) and(S)-hept-6-ene-3-sulfonamide (Intermediate EE212), and the desiredproducts,(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 17) as the first eluting major isomer out ofpreparative reverse-phase HPLC,(1S,3′R,6′R,7′S,8′Z,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 18) as the second eluting minor isomer out ofpreparative reverse-phase HPLC, and(1S,3′R,6′R,7′S,8′E,12′S)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 19) as the third eluting major isomer out ofpreparative reverse-phase HPLC were isolated.(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 17): ¹H NMR (400 MHz, CD₃OD) δ 7.75 (d, J=8.4Hz, 1H), 7.19 (dd, J=2.0, 8.8 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.00 (dd,J=1.8, 8.0 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.87 (d, J=1.6 Hz, 1H),5.90-5.82 (m, 1H), 5.73 (dd, J=7.8, 15.1 Hz, 1H), 4.21 (dd, J=3.7, 7.8Hz, 1H), 4.09 (dd, J=12.1, 14.7 Hz, 2H), 4.02 (dd, J=6.5, 13.5 Hz, 1H),3.85 (d, J=15.1 Hz, 1H), 3.68 (d, J=14.1 Hz, 1H), 3.29 (d, J=14.3 Hz,1H), 3.08 (dd, J=10.0, 15.3 Hz, 1H), 2.88-2.73 (m, 2H), 2.46-2.22 (m,4H), 2.16-2.05 (m, 2H), 2.02-1.79 (m, 8H), 1.73 (dd, J=9.0, 17.6 Hz,1H), 1.46 (t, J=12.6 Hz, 1H), 1.20 (t, J=7.5 Hz, 3H). m/z (ESI, +ve ion)599.2 (M+H)⁺;(1S,3′R,6′R,7′S,8′Z,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 18). ¹H NMR (500 MHz, CD₃OD) δ 7.75 (d, J=8.6Hz, 1H), 7.19 (dd, J=2.3, 8.4 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.03 (dd,J=2.0, 8.1 Hz, 1H), 6.97-6.92 (m, 2H), 5.62-5.55 (m, 2H), 4.49 (dd,J=3.5, 7.9 Hz, 1H), 4.09 (dd, J=12.5, 21.8 Hz, 2H), 3.88 (d, J=15.7 Hz,1H), 3.71 (d, J=14.4 Hz, 1H), 3.62 (br. s., 1H), 2.87-2.74 (m, 2H),2.49-2.38 (m, 3H), 2.26-2.10 (m, 3H), 2.06-1.89 (m, 8H), 1.84-1.73 (m,3H), 1.55-1.40 (m, 1H), 1.16 (t, J=7.5 Hz, 3H). m/z (ESI, +ve ion) 599.2(M+H)⁺; and(1S,3′R,6′R,7′S,8′E,12′S)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 19): ¹H NMR (400 MHz, CD₃OD) δ 7.74 (d, J=8.6Hz, 1H), 7.19 (dd, J=2.3, 8.4 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.08-7.02(m, 2H), 6.95 (d, J=9.0 Hz, 1H), 5.92 (ddd, J=5.9, 14.7, 21.5 Hz, 1H),5.66 (dd, J=6.1, 15.3 Hz, 1H), 4.15-4.05 (m, 3H), 3.74-3.62 (m, 3H),3.47 (d, J=14.3 Hz, 1H), 3.51-3.43 (m, 1H), 2.88-2.74 (m, 2H), 2.58-2.33(m, 3H), 2.24-2.03 (m, 4H), 1.97-1.73 (m, 8H), 1.63-1.45 (m, 1H), 1.17(t, J=7.5 Hz, 3H). m/z (ESI, +ve ion) 599.2 (M+H)⁺.

Example 20(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 4 using(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 17), and the desired product,(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-methoxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide was isolated as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.75 (d, J=8.6 Hz, 1H), 7.18 (dd, J=2.2, 8.6 Hz, 1H), 7.12 (d, J=2.0 Hz,1H), 7.00 (dd, J=1.8, 8.2 Hz, 1H), 6.94 (d, J=8.0 Hz, 1H), 6.86 (d,J=1.6 Hz, 1H), 5.94-5.85 (m, 1H), 5.58 (dd, J=8.9, 15.2 Hz, 1H),4.13-4.02 (m, 3H), 3.85 (d, J=14.9 Hz, 1H), 3.74 (dd, J=3.9, 9.0 Hz,1H), 3.68 (d, J=14.3 Hz, 1H), 3.26 (s, 3H), 3.22-3.04 (m, 1H), 2.88-2.73(m, 2H), 2.54-2.39 (m, 2H), 2.33 (t, J=7.4 Hz, 2H), 2.12 (qd, J=7.3,14.4 Hz, 2H), 2.02-1.69 (m, 10H), 1.45 (t, J=12.0 Hz, 1H), 1.21 (t,J=7.5 Hz, 3H). m/z (ESI, +ve ion) 613.2 (M+H)⁺.

Example 21(1S,3′R,6′R,7′S,12′R)-6-CHLORO-12′-ETHYL-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 6 using(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-methoxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 20), and the desired products,(1S,3′R,6′R,7′S,12′R)-6-chloro-12′-ethyl-7′-methoxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide was isolated. ¹H NMR (500 MHz, CD₃OD) δ 7.76 (d, J=8.6Hz, 1H), 7.19 (dd, J=2.3, 8.4 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.06 (dd,J=2.0, 8.3 Hz, 1H), 7.00 (d, J=1.7 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 4.11(ddd, J=2.9, 12.0, 14.2 Hz, 2H), 3.88-3.81 (m, 2H), 3.69 (d, J=14.2 Hz,1H), 3.30 (s, 3H), 3.12 (dd, J=8.1, 14.9 Hz, 1H), 2.86-2.74 (m, 2H),2.69-2.62 (m, 1H), 2.35 (t, J=7.7 Hz, 1H), 2.15-2.05 (m, 2H), 2.01-1.85(m, 5H), 1.82-1.63 (m, 4H), 1.47 (br. s., 5H), 1.42-1.24 (m, 4H), 1.18(t, J=7.6 Hz, 3H). m/z (EST, +ve ion) 615.2 (M+H)⁺.

Example 22(1S,3′R,6′R,7′S,12′R)-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,8′Z,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 18; 5.2 mg, 8.68 μmol) and palladium 10 wt. %(dry basis) on activated carbon, wet (4.6 mg, 4.34 μmol) in 1:1 ratio ofEtOAc:EtOH (3.0 mL) was stirred under H₂ at rt overnight, then filteredthrough Celite® to remove solid catalyst. The organic layer wasconcentrated and purified by preparative reverse-phase HPLC (Gemini™Prep C₁₈ 5 μm column; gradient elution of 40% to 95% MeCN in H₂O, whereboth solvents contain 0.1% TFA, 30 min method) to give(1S,3′R,6′R,7′S,12′R)-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide (1.9 mg, 3.35 μmol). ¹H NMR (400 MHz, CD₃OD) δ 7.77 (d,J=7.0 Hz, 1H), 7.21-7.02 (m, 4H), 6.97 (d, J=8.2 Hz, 1H), 6.93 (d, J=2.2Hz, 1H), 4.13 (dd, J=12.1, 22.7 Hz, 2H), 3.92-3.80 (m, 2H), 3.76-3.70(m, 2H), 3.13 (dd, J=8.8, 19.2 Hz, 1H), 2.87-2.75 (m, 2H), 2.44-2.29 (m,2H), 2.15-2.04 (m, 2H), 1.99-1.37 (m, 17H), 1.18 (t, J=7.6 Hz, 3H). m/z(ESI, +ve ion) 567.2 (M+H)⁺.

Example 23(1S,3′R,6′R,7′S,12′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

STEP 1:(S)-6′-CHLORO-N—((R)-HEX-5-EN-3-YLSULFONYL)-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(S)-6′-CHLORO-N—((S)-HEX-5-EN-3-YLSULFONYL)-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 224 mg, 0.465 mmol) and a racemic mixture of(R)-hex-5-ene-3-sulfonamide (Intermediate EE18) and(S)-hex-5-ene-3-sulfonamide (Intermediate EE182; 167 mg, 1.023 mmol)following the procedure described for Example 2, Step 1. Purification ofthe crude material provided a mixture of(S)-6′-chloro-N—((R)-hex-5-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamideand(S)-6′-chloro-N—((S)-hex-5-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(235 mg, 0.375 mmol, 81% yield).

STEP 2.(1S,3′R,6′R,7′S,9′Z,12′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′E,12′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from a mixture of(S)-6′-chloro-N—((R)-hex-5-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamideand(S)-6′-chloro-N—((R)-hex-5-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(from Step 1, 235 mg, 0.375 mmol) following the procedure described forExample 14, Step 2. The crude material was subjected to a firstpurification by chromatography through a 24 g ISCO column, eluting with10% to 20% to 40% EtOAc (containing 0.3% AcOH) in Hex over 60 min toprovide a mixture of the title compounds.

STEP 3:(1S,3′R,6′R,7′S,12′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound (6.3 mg, 0.010 mmol, 52.3% yield) was synthesizedfrom a mixture of(1S,3′R,6′R,7′S,9′Z,12′S)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′E,12′S)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 2, 12 mg, 0.020 mmol) following the proceduredescribed for Example 6. ¹H NMR (400 MHz, CD₂Cl₂) δ 10.11 (br. s., 1H),7.70 (d, J=8.6 Hz, 1H), 7.36 (dd, J=2.1, 8.3 Hz, 1H), 7.28 (d, J=1.8 Hz,1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.93 (d,J=8.2 Hz, 1H), 4.06 (d, J=11.5 Hz, 1H), 3.99 (d, J=12.1 Hz, 1H), 3.76(d, J=15.5 Hz, 1H), 3.65-3.61 (m, 1H), 3.59 (d, J=14.1 Hz, 1H),3.57-3.50 (m, 1H), 3.16 (d, J=14.3 Hz, 1H), 3.09 (dd, J=8.5, 15.2 Hz,1H), 2.83-2.67 (m, 2H), 2.25 (quin, J=9.0 Hz, 1H), 2.20-2.08 (m, 3H),2.03-1.88 (m, 3H), 1.89-1.74 (m, 7H), 1.72-1.57 (m, 3H), 1.55-1.39 (m,2H), 1.36-1.19 (m, 2H), 1.10 (t, J=7.4 Hz, 3H). MS (ESI, +ve ion) m/z601.2 (M+H)⁺.

Example 24(1S,3′R,6′R,7′S,8′E,11S,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1:(3R,4S)—N,N-BIS(4-METHOXYBENZYL)-4-METHYLHEPT-6-ENE-3-SULFONAMIDE AND(3S,4S)—N,N-BIS(4-METHOXYBENZYL)-4-METHYLHEPT-6-ENE-3-SULFONAMIDE

The title compounds were synthesized fromN,N-bis(4-methoxybenzyl)propane-1-sulfonamide (Intermediate EE14; 1512mg, 4.16 mmol) and (R)-pent-4-en-2-yl 4-methylbenzenesulfonate (preparedaccording to the procedure by Sigman, M. S. et al.; J. Am. Chem. Soc.,2012, 134(28), 11408-11411; 1999 mg, 8.32 mmol) following the proceduredescribed for Example 26, step 1.(3R,4S)—N,N-bis(4-methoxybenzyl)-4-methylhept-6-ene-3-sulfonamide and(3S,4S)—N,N-bis(4-methoxybenzyl)-4-methylhept-6-ene-3-sulfonamide wereobtained as an inseparable mixture (335 mg, 0.776 mmol, 18.7% yield).

STEP 2: (3R,4S)-4-METHYLHEPT-6-ENE-3-SULFONAMIDE AND(3S,4S)-4-METHYLHEPT-6-ENE-3-SULFONAMIDE

The title compounds were synthesized from(3R,4S)—N,N-bis(4-methoxybenzyl)-4-methylhept-6-ene-3-sulfonamide and(3S,4S)—N,N-bis(4-methoxybenzyl)-4-methylhept-6-ene-3-sulfonamide (335mg, 0.776 mmol, Step 1) following the procedure described for Example26, Step 2. (3R,4S)-4-methylhept-6-ene-3-sulfonamide and(3S,4S)-4-methylhept-6-ene-3-sulfonamide were obtained as an inseparablemixture (67.6 mg, 0.35 mmol, 45.5% yield).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,6R,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLOCT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,6S,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLOCT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

The title compounds were synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 40 mg, 0.078 mmol) and a mixture of(3R,4S)-4-methylhept-6-ene-3-sulfonamide and(3S,4S)-4-methylhept-6-ene-3-sulfonamide (67.6 mg, 0.35 mmol) followingthe procedure described for Example 26, Step 3. The mixture of(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6R,E)-1-hydroxy-5-methyl-6-sulfamoyloct-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6S,E)-1-hydroxy-5-methyl-6-sulfamoyloct-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (46 mg, 0.073 mmol, 92% yield) was carried on to the next step.

STEP 4.(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6R,E)-1-hydroxy-5-methyl-6-sulfamoyloct-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6S,E)-1-hydroxy-5-methyl-6-sulfamoyloct-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (63 mg, 0.100 mmol) following the procedure described for Example26, Step 4. The crude material was purified by chromatography through a12 g ISCO gold column, eluting with 10-40-50% EtOAc (containing 0.3%AcOH) in Hex over 24 min, to provide(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-ethyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the second eluting major isomer. This material wasrepurified by chromatography through a 12 g ISCO gold column, elutingwith 0-10% acetone in DCM to provide the title compound (20 mg, 0.033mmol, 32.7% yield). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.33 (br. s., 1H), 7.71(d, J=8.4 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H),6.96-6.88 (m, 3H), 5.86 (ddd, J=3.9, 9.0, 15.1 Hz, 1H), 5.71 (dd, J=8.2,15.1 Hz, 1H), 4.22 (dd, J=3.9, 8.2 Hz, 1H), 4.09-4.08 (m, 2H), 3.98(ddd, J=1.2, 3.7, 8.8 Hz, 1H), 3.82 (d, J=14.7 Hz, 1H), 3.69 (d, J=14.3Hz, 1H), 3.25 (d, J=14.3 Hz, 1H), 3.04 (dd, J=9.5, 15.4 Hz, 1H),2.85-2.69 (m, 2H), 2.41 (ddd, J=3.7, 9.8, 18.4 Hz, 1H), 2.35-2.24 (m,1H), 2.21-2.11 (m, 1H), 2.10-2.03 (m, 2H), 1.99-1.90 (m, 3H), 1.90-1.74(m, 5H), 1.67 (quin, J=9.5 Hz, 2H), 1.45-1.34 (m, 1H), 1.27 (t, J=7.4Hz, 3H), 1.02 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z 613.0 (M+H)⁺.

Example 25(1S,3′R,6′R,7′S,8′E,11S,12′R)-6-CHLORO-12′-ETHYL-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-ethyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 24; 10 mg, 0.016 mmol) following the proceduredescribed for Example 4. Purification of the crude material via columnchromatography eluting with 10-40% EtOAc (containing 0.3% AcOH) inheptanes provided(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-ethyl-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (7.3 mg, 0.012 mmol, 71.4% yield). ¹H NMR (500 MHz,CD₂Cl₂) δ 8.13 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.2, 8.6 Hz,1H), 7.09 (d, J=2.0 Hz, 1H), 6.91 (s, 2H), 6.87 (s, 1H), 5.84 (ddd,J=3.4, 9.6, 15.1 Hz, 1H), 5.51 (dd, J=9.0, 15.2 Hz, 1H), 4.11-4.06 (m,2H), 4.04-4.00 (m, 1H), 3.82 (d, J=15.4 Hz, 1H), 3.69 (d, J=14.2 Hz,1H), 3.64 (dd, J=3.3, 9.2 Hz, 1H), 3.25 (d, J=14.2 Hz, 1H), 3.18 (s,3H), 3.03 (dd, J=10.1, 15.3 Hz, 1H), 2.84-2.69 (m, 2H), 2.44 (ddd,J=3.2, 9.8, 18.6 Hz, 1H), 2.33 (quin, J=8.8 Hz, 1H), 2.28-2.21 (m, 1H),2.15-2.09 (m, 1H), 2.09-2.02 (m, 2H), 2.01-1.90 (m, 3H), 1.90-1.73 (m,4H), 1.72-1.61 (m, 1H), 1.39 (t, J=12.6 Hz, 1H), 1.28 (t, J=7.3 Hz, 3H),1.02 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z 627.1 (M+H)⁺.

Example 26(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (2R,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYLHEX-5-ENE-2-SULFONAMIDEAND (2S,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

N,N-bis(4-methoxybenzyl)ethanesulfonamide (Intermediate EE13; 1030 mg,2.95 mmol) was azeotroped in toluene under vacuum for 2 h. Under argon,THF was added and the solution was cooled to −78° C. N-butyllithiumsolution (2.5 M in Hex, 1.533 mL, 3.83 mmol) was then added and themixture was stirred at −78° C. for 60 min. (S)-pent-4-en-2-yl4-methylbenzenesulfonate (prepared according to the procedure by Sigman,M. S. et al., J. Am. Chem. Soc., 2012, 134(28), 11408-11411; 1417 mg,5.90 mmol) was added as a solution in 3 mL. THF was then added. After 5min the mixture was allowed to warm to ambient temperature and stirredovernight under argon. The mixture was quenched with satd NH₄Cl andextracted with EtOAc, dried over MgSO₄, and concentrated. The crudematerial was injected into a SiO₂ gel cartridge and purified bychromatography through a 40 g ISCO column, eluting with 5% to 10% to 20%to 40% EtOAc in Hex, to provide a 2.3:1 mixture of the title compounds(420 mg, 1.00 mmol, 34.1% yield).

STEP 2: (2R,3R)-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2S,3R)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

To a solution of(2R,3R)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide and(2S,3R)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide (2.3:1mixture of diastereomers; 420 mg, 1.00 mmol) and anisole (1.093 mL,10.06 mmol) in DCM (5.029 mL) at ambient temperature was slowly addedtrifluoroacetic acid (2.99 mL, 40.2 mmol). After stirring overnight, themixture was concentrated. The residue was diluted with EtOAc, washedwith satd NaHCO₃, back extracted with EtOAc, dried over MgSO₄, andconcentrated. The crude material was purified via chromatography on a 24g ISCO gold column eluting with a gradient of 0-50% EtOAc in Hex) toprovide a 2.3:1 mixture of the title compounds (153 mg, 0.863 mmol, 86%yield).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5R,6R,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5R,6S,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

A vial was charged with(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 75 mg, 0.147 mmol) and a 2.3:1 mixture of(2R,3R)-3-methylhex-5-ene-2-sulfonamide and(2S,3R)-3-methylhex-5-ene-2-sulfonamide (153 mg, 0.863 mmol) in 1,2-DCE(2.101 mL). The solution was sparged with argon, then Hoveyda-Grubbs II(9.21 mg, 0.015 mmol) was added as a solution in 1 mL 1,2-DCE at ambienttemperature. The resulting mixture was stirred (sparging with argon andventing the vial) at ambient temperature. After 2 h the reaction mixturewas sparged with air for 5 min and filtered to separate the insolublesulfonamide homodimer. The filtrate was directly injected into a 12 gISCO gold column, and purified eluting with 0-20-50-100% EtOAc in Hexover 16 min to give a mixture of the title compounds (74 mg, 0.120 mmol,82% yield).

STEP 4.(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

N,N-dimethylpyridin-4-amine (24.90 mg, 0.204 mmol) was added to asolution of(S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,6R,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,6S,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (74 mg, 0.120 mmol) (previously azeotroped with 2.0 mL PhMe for 3h) in DCM (59.900 mL) at 0° C.N-(3-dimethylaminopropyl)-‘N’-ethylcarbodiimide hydrochloride (46.0 mg,0.240 mmol) was then slowly added portion-wise and the resulting mixturewas stirred while allowing to warm to ambient temperature for 15 h. Themixture was washed with 1N HCl and brine, the aqueous was back extractedwith EtOAc, and the combined organics were dried over anhydrousmagnesium sulfate, then concentrated. The crude material was purified bychromatography through a 12 g ISCO gold column, eluting with 10-40-50%EtOAc (containing 0.3% AcOH) in Hex over 24 min, to provide(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the first eluting major isomer (19.5 mg, 0.033 mmol,27.1% yield, 90% purity). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.31 (br. s., 1H),7.65 (d, J=8.4 Hz, 1H), 7.62 (br. s., 1H), 7.14 (dd, J=2.4, 8.5 Hz, 1H),7.10 (d, J=2.3 Hz, 1H), 6.93 (dd, J=2.0, 8.2 Hz, 1H), 6.90 (d, J=8.0 Hz,1H), 5.66 (dd, J=3.7, 15.8 Hz, 1H), 5.58-5.45 (m, 1H), 4.22 (s, 2H),4.15-4.08 (m, 2H), 3.87 (br. s., 1H), 3.74 (d, J=13.9 Hz, 1H), 3.33 (d,J=14.1 Hz, 1H), 3.11 (d, J=13.9 Hz, 1H), 2.79-2.69 (m, 2H), 2.57-2.39(m, 2H), 2.06-1.92 (m, 2H), 1.91-1.81 (m, 4H), 1.80-1.73 (m, 4H),1.71-1.55 (m, 2H), 1.41 (d, J=7.4 Hz, 3H), 1.04 (d, J=6.7 Hz, 3H). MS(ESI, +ve ion) m/z 599.1 (M+H)⁺.

Example 27(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized as described for Example 26, Step 4.(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide was isolated as the second eluting minor isomer (11.5mg, 0.019 mmol, 16.0% yield, 95% purity). ¹H NMR (400 MHz, CD₂Cl₂) δ9.08-8.57 (m, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.3, 8.6 Hz, 1H),7.09 (d, J=2.3 Hz, 1H), 7.06 (d, J=8.6 Hz, 1H), 6.93 (d, J=8.0 Hz, 1H),6.83 (s, 1H), 6.03 (ddd, J=5.3, 8.2, 15.7 Hz, 1H), 5.76 (dd, J=7.8, 15.7Hz, 1H), 4.20 (dd, J=3.2, 7.9 Hz, 1H), 4.14-4.03 (m, 3H), 3.78-3.63 (m,2H), 3.29 (d, J=14.3 Hz, 1H), 3.12 (dd, J=9.9, 15.4 Hz, 1H), 2.85-2.68(m, 2H), 2.62 (br. s., 1H), 2.55-2.42 (m, 1H), 2.36 (dq, J=3.2, 9.2 Hz,1H), 2.26-2.16 (m, 1H), 2.14-2.07 (m, 1H), 2.04-1.93 (m, 3H), 1.90 (dd,J=4.1, 9.2 Hz, 1H), 1.87-1.74 (m, 3H), 1.73-1.63 (m, 1H), 1.46 (d, J=7.2Hz, 3H), 1.46-1.39 (m, 1H), 1.07 (d, J=7.0 Hz, 3H). MS (ESI, +ve ion)m/z 599.0 (M+H)⁺.

Example 28(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (2R,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYLHEX-5-ENE-2-SULFONAMIDEAND (2S,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

The title compounds were synthesized fromN,N-bis(4-methoxybenzyl)ethanesulfonamide (Intermediate EE13; 1148 mg,3.29 mmol) and (R)-pent-4-en-2-yl 4-methylbenzenesulfonate (preparedaccording to the procedure by Sigman, M. S. et al.; J. Am. Chem. Soc.,2012, 134(28), 11408-11411; 1579 mg, 6.57 mmol) following the proceduredescribed for Example 26, Step 1.(2R,3S)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide and(2S,3S)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide wereobtained as a 2.4:1 mixture (539 mg, 1.29 mmol, 39.3% yield).

STEP 2: (2R,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2S,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

The title compounds were synthesized from(2R,3S)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide and(2S,3S)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide (539mg; 1.29 mmol) following the procedure described for Example 26, Step 2.(2R,3S)-3-methylhex-5-ene-2-sulfonamide and(2S,3S)-3-methylhex-5-ene-2-sulfonamide were obtained as a 2.3:1 mixture(203 mg, 1.15 mmol, 89% yield).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,6R,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,6S,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

The title compounds were synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 75 mg, 0.147 mmol) and a 2.3:1 mixture of(2R,3S)-3-methylhex-5-ene-2-sulfonamide and(2S,3S)-3-methylhex-5-ene-2-sulfonamide (153 mg, 0.863 mmol) followingthe procedure described for Example 26, Step 3. The mixture of(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6R,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6S,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (73 mg, 0.118 mmol, 80% yield) was carried on to the next step.

STEP 4.(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6R,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,6S,E)-1-hydroxy-5-methyl-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (73 mg, 0.118 mmol) following the procedure described for Example26, Step 4. The crude material was purified by chromatography through a12 g ISCO gold column, eluting with 10-40-50% EtOAc (containing 0.3%AcOH) in Hex over 24 min, to provide(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the first eluting minor isomer. This material wasrepurified via preparative reverse-phase HPLC eluting with 50-70% MeCN(containing 0.1% TFA) in H₂O (containing 0.1% TFA) to provide the titlecompound (5.8 mg, 0.0097 mmol, 8.2% yield, 90% purity). ¹H NMR (400 MHz,CD₂Cl₂) δ 8.21 (s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.18 (dd, J=2.3, 8.4 Hz,1H), 7.14 (dd, J=2.1, 8.1 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.95 (d,J=8.2 Hz, 1H), 6.69 (br. s., 1H), 6.10-5.99 (m, 1H), 5.67 (dd, J=6.4,15.4 Hz, 1H), 4.20-4.14 (m, 1H), 4.11 (d, J=12.1 Hz, 1H), 4.06 (d,J=11.9 Hz, 1H), 3.84-3.74 (m, 1H), 3.76 (d, J=15.5 Hz, 1H), 3.65 (d,J=14.7 Hz, 1H), 3.44 (d, J=14.7 Hz, 1H), 3.33-3.20 (m, 1H), 2.86-2.70(m, 2H), 2.60-2.48 (m, 2H), 2.31-2.20 (m, 2H), 2.08-1.98 (m, 2H),1.97-1.80 (m, 4H), 1.79-1.68 (m, 1H), 1.67-1.49 (m, 2H), 1.46 (d, J=7.2Hz, 3H), 1.42 (br. s., 1H), 1.08 (d, J=7.0 Hz, 3H). MS (ESI, +ve ion)m/z 599.1 (M+H)⁺.

Example 29(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,21)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDEAND (R)—N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDE

N,N-bis(4-methoxybenzyl)methanesulfonamide (Intermediate EE12; 1.05 g,3.13 mmol) was azeotroped in PhMe under vacuum for 12 h. Under argon,THF (21 mL) was added and the solution was cooled to −78° C.Butyllithium solution (2.5 M in Hex; 1.63 mL, 4.07 mmol) was then addedand the mixture was stirred at −78° C. for 30 min. Pent-4-en-2-yl4-methylbenzenesulfonate (prepared according to the procedure by Sigman,M. S. et al.; J. Am. Chem. Soc., 2012, 134(28), 11408-11411; 1.3 g, 5.41mmol) was added as a solution in 1.5 mL THF. After complete addition themixture was allowed to warm to ambient temperature and stir overnight.LC/MS analysis showed 50% conversion to the desired product; prolongedstirring for a further 24 h did not improve the conversion. The mixturewas then quenched with satd NH₄Cl, and extracted with EtOAc, dried overMgSO₄ and concentrated. The crude material was purified bychromatography through a 24 g ISCO column, eluting with 10% to 20% to60% EtOAc in Hex, to provide a racemic mixture of(S)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(R)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (408 mg,1.01 mmol, 32% yield).

STEP 2: (S)-2-METHYLPENT-4-ENE-1-SULFONAMIDE AND(R)-2-METHYLPENT-4-ENE-1-SULFONAMIDE

The title compounds were synthesized from(S)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(R)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (506 mg,1.25 mmol) following the procedure described for Example 26, Step 2.(S)-2-methylpent-4-ene-1-sulfonamide and(R)-2-methylpent-4-ene-1-sulfonamide were obtained as a racemic mixture(152 mg, 0.93 mmol, 74% yield).

STEP 3: (1′S)-TERT BUTYL6′-CHLORO-5-(((1R,2R)-2-((1S,5S,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATEAND (1′S)-TERT BUTYL6′-CHLORO-5-(((1R,2R)-2-((1S,5R,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A vial was charged with ((S)-tert-butyl6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(Intermediate AA12A, Step 1B, first eluting isomer; 120 mg, 0.212 mmol)and a racemic mixture of (S)-2-methylpent-4-ene-1-sulfonamide and(R)-2-methylpent-4-ene-1-sulfonamide (156 mg, 0.954 mmol) in 1,2-DCE(3.028 mL). The solution was sparged with argon and Hoveyda-Grubbs II(13.28 mg, 0.021 mmol) was added as a solution in 1.5 mL 1,2-DCE atambient temperature. The mixture was stirred (sparging with argon andventing the vial) at ambient temperature for 1.5 h (70% conversion byLC/MS analysis). The reaction mixture was then sparged with air for 5min, concentrated, and directly injected into a 24 g ISCO gold column,and purified eluting with 0-20-50-100% EtOAc/Hex over 16 min to give amixture of (1′S)-tert butyl6′-chloro-5-(((1R,2R)-2-((1S,5S,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylateand (1′S)-tert butyl6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(63 mg, 0.096 mmol, 45.1% yield).

STEP 4:(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5R,E)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

To a solid mixture of (1′S)-tert butyl6′-chloro-5-(((1R,2R)-2-((1S,5S,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylateand (1′S)-tert butyl6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate(63 mg, 0.096 mmol) and LiOH monohydrate (0.013 mL, 0.478 mmol) wasadded a 1:1 mixture of dioxane/MeOH (1.911 mL). The reaction was heatedto 70° C. Virtually no reaction was observed after 1.5 h; H₂O (˜0.4 mL)was added and the mixture was stirred for 40 h. The mixture was thenquenched with 1 N HCl (1.0 mL), diluted with brine, extracted withEtOAc, dried over MgSO₄, and concentrated. The crude material obtainedwas taken on to the next step without further purification.

STEP 5.(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (57 mg, 0.095 mmol) following the procedure described for Example26, Step 4. The crude material was purified by chromatography through a12 g ISCO gold column, eluting with 10-40-50% EtOAc (containing 0.3%AcOH) in Hex over 24 min, to provide(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the first eluting minor isomer (11 mg, 0.019 mmol,19.9% yield, 90% purity). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.41 (s, 1H), 7.66(d, J=8.4 Hz, 1H), 7.50 (br. s., 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.10(d, J=2.3 Hz, 1H), 6.95 (dd, J=2.0, 8.2 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H),5.69 (dd, J=4.3, 15.8 Hz, 1H), 5.63-5.54 (m, 1H), 4.20 (s, 2H), 4.04 (d,J=15.3 Hz, 1H), 3.94 (dd, J=2.2, 5.2 Hz, 1H), 3.89-3.81 (m, 1H),3.74-3.63 (m, 1H), 3.39 (d, J=15.3 Hz, 1H), 3.26-3.17 (m, 1H), 3.09-2.96(m, 1H), 2.81-2.71 (m, 2H), 2.57-2.41 (m, 2H), 2.16 (dd, J=6.5, 11.7 Hz,1H), 1.92-1.76 (m, 6H), 1.75-1.63 (m, 3H), 1.62-1.41 (m, 2H), 1.19 (d,J=6.1 Hz, 3H). MS (ESI, +ve ion) m/z 585.1 (M+H)⁺.

Example 30(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized as described for Example 29, Step 5.(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide was isolated as the second eluting major isomer (11.6mg, 0.020 mmol, 21.0% yield). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.44 (br. s.,1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.3, 8.6 Hz, 1H), 7.09 (d,J=2.3 Hz, 1H), 6.95-6.90 (m, 2H), 6.89 (s, 1H), 5.82 (ddd, J=5.1, 7.6,15.1 Hz, 1H), 5.70 (dd, J=8.2, 15.3 Hz, 1H), 4.24 (dd, J=3.9, 12.3 Hz,1H), 4.20 (dd, J=4.7, 8.8 Hz, 1H), 4.10-4.05 (m, 2H), 3.82 (d, J=14.9Hz, 1H), 3.69 (d, J=14.3 Hz, 1H), 3.25 (d, J=14.3 Hz, 1H), 3.05 (dd,J=9.6, 15.1 Hz, 1H), 2.98 (dd, J=8.0, 15.3 Hz, 1H), 2.84-2.67 (m, 2H),2.41 (ddd, J=4.3, 9.8, 18.0 Hz, 1H), 2.36-2.28 (m, 1H), 2.24 (ddd,J=2.2, 7.9, 15.2 Hz, 1H), 2.08-1.99 (m, 2H), 1.98-1.87 (m, 3H),1.87-1.74 (m, 4H), 1.68 (dd, J=9.4, 18.8 Hz, 1H), 1.46-1.35 (m, 1H),1.15 (d, J=6.5 Hz, 3H). MS (ESI, +ve ion) m/z 585.1 (M+H)⁺.

Example 31(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 29; 8.0 mg, 0.014 mmol) following the proceduredescribed for Example 4. Purification of the crude material provided(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (8.1 mg, 0.014 mmol, 99% yield, 94% purity). ¹H NMR (400MHz, CD₂Cl₂) δ 8.22 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.3,8.6 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.97-6.88 (m, 3H), 5.84 (td, J=6.3,15.6 Hz, 1H), 5.48 (dd, J=7.3, 15.4 Hz, 1H), 4.15-4.03 (m, 2H), 3.64(dd, J=6.5, 15.3 Hz, 1H), 3.61-3.56 (m, 2H), 3.55-3.46 (m, 2H), 3.38 (d,J=14.1 Hz, 1H), 3.29 (s, 3H), 3.23 (d, J=14.1 Hz, 1H), 2.84-2.68 (m,2H), 2.48-2.31 (m, 2H), 2.27-2.15 (m, 3H), 2.02-1.93 (m, 1H), 1.93-1.82(m, 3H), 1.77-1.63 (m, 3H), 1.56-1.44 (m, 1H), 1.16 (d, J=6.5 Hz, 3H).MS (ESI, +ve ion) m/z 599.0 (M+H)⁺.

Example 32(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 30; 8.0 mg, 0.014 mmol) following the proceduredescribed for Example 4. Purification of the crude material provided(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (8.1 mg, 0.014 mmol, 99% yield). ¹H NMR (400 MHz,CD₂Cl₂) δ 8.18 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.3, 8.6 Hz,1H), 7.09 (d, J=2.3 Hz, 1H), 6.93-6.87 (m, 2H), 6.82 (s, 1H), 5.82 (ddd,J=5.7, 7.6, 14.9 Hz, 1H), 5.52 (dd, J=9.2, 15.3 Hz, 1H), 4.32 (dd,J=4.9, 15.3 Hz, 1H), 4.07 (s, 2H), 3.81 (d, J=14.9 Hz, 1H), 3.70 (d,J=14.3 Hz, 1H), 3.64 (dd, J=3.5, 9.2 Hz, 1H), 3.23 (d, J=14.3 Hz, 1H),3.19 (s, 3H), 3.02 (dd, J=6.1, 15.3 Hz, 1H), 2.99 (dd, J=3.2, 15.2 Hz,1H), 2.85-2.67 (m, 2H), 2.44 (ddd, J=3.3, 9.6, 18.6 Hz, 1H), 2.36-2.23(m, 2H), 2.15-2.02 (m, 1H), 2.00-1.89 (m, 2H), 1.88-1.82 (m, 1H),1.82-1.74 (m, 2H), 1.71-1.62 (m, 1H), 1.59-1.48 (m, 2H), 1.44-1.34 (m,1H), 1.14 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z 599.0 (M+H)⁺.

Example 33(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-11′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (S)-2-ETHYL-N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE AND(R)-2-ETHYL-N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE

The title compound was synthesized fromN,N-bis(4-methoxybenzyl)methanesulfonamide (Intermediate EE12; 1.10 g,3.28 mmol) and hex-5-en-3-yl 4-methylbenzenesulfonate (preparedaccording to the procedure by Sigman, M. S. et al.; J. Am. Chem. Soc.,2012, 134(28), 11408-11411; 1.50 g, 5.90 mmol) according to theprocedure described for Intermediate 26, Step 1.(S)-2-ethyl-N,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide and(R)-2-ethyl-N,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide wereobtained as a racemic mixture (435 mg, 1.04 mmol, 31.8% yield).

STEP 2: (S)-2-ETHYLPENT-4-ENE-1-SULFONAMIDE AND(R)-2-ETHYLPENT-4-ENE-1-SULFONAMIDE

The title compound was synthesized from a racemic mixture of(S)-2-ethyl-N,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide and(R)-2-ethyl-N,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide (435 mg,1.04 mmol) according to the procedure described for Example 26, Step 2.(S)-2-ethylpent-4-ene-1-sulfonamide and(R)-2-ethylpent-4-ene-1-sulfonamide were obtained as a racemic mixture(149 mg, 0.84 mmol, 81% yield).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5S,E)-1-HYDROXY-5-(SULFAMOYLMETHYL)HEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5R,E)-1-HYDROXY-5-(SULFAMOYLMETHYL)HEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

The title compounds were synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 80 mg, 0.157 mmol) and a mixture of(S)-2-ethylpent-4-ene-1-sulfonamide and(R)-2-ethylpent-4-ene-1-sulfonamide (149 mg, 0.84 mmol) following theprocedure described for Example 26, Step 3. Purification of the crudematerial eluting with a gradient of 0-20-50-100% EtOAc in heptanesfollowed by a gradient of 20-50% EtOAc (containing 0.3% AcOH) inheptanes provided an inseparable mixture of(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,E)-1-hydroxy-5-(sulfamoylmethyl)hept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-(sulfamoylmethyl)hept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (75 mg, 0.122 mmol, 77% yield).

STEP 4.1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-11′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((1S,5S,E)-1-hydroxy-5-(sulfamoylmethyl)hept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid and(S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-(sulfamoylmethyl)hept-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (75 mg, 0.122 mmol) following the procedure described for Example26, Step 4. The crude material was purified by chromatography through a12 g ISCO gold column, eluting with 10-30-50% EtOAc (containing 0.3%AcOH) in Hex over 24 min, to provide(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-11′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the first eluting isomer (20.4 mg, 0.034 mmol, 28.0%yield). ¹H NMR (400 MHz, CD₂Cl₂) δ 8.45 (br. s., 1H), 7.67 (d, J=8.6 Hz,1H), 7.44 (br. s., 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.10 (d, J=2.3 Hz,1H), 6.96 (dd, J=1.8, 8.0 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 5.71 (dd,J=4.7, 15.7 Hz, 1H), 5.66-5.55 (m, 1H), 4.24-4.13 (m, 2H), 3.96 (br. s.,1H), 3.92 (d, J=15.7 Hz, 1H), 3.79 (br. s., 1H), 3.64 (d, J=13.3 Hz,1H), 3.42 (d, J=14.5 Hz, 1H), 3.30-3.11 (m, 2H), 2.79-2.71 (m, 2H),2.56-2.41 (m, 2H), 2.29 (dd, J=5.5, 13.9 Hz, 1H), 1.91-1.75 (m, 7H),1.75-1.63 (m, 4H), 1.45 (dt, J=7.6, 14.3 Hz, 2H), 0.92 (t, J=7.3 Hz,3H). MS (ESI, +ve ion) m/z 599.0 (M+H)⁺.

Example 34(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-11′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized as described for Example 33, Step 4.(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-11′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as the second eluting isomer. This material wasrepurified eluting with 60% EtOAc in heptanes to provide the pure titlecompound (15.7 mg, 0.026 mmol, 21.6% yield). ¹H NMR (500 MHz, CD₂Cl₂) δ8.59 (br. s., 1H), 7.69 (d, J=8.6 Hz, 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H),7.08 (d, J=2.2 Hz, 1H), 6.93 (dd, J=2.0, 8.1 Hz, 1H), 6.90 (d, J=8.1 Hz,1H), 6.85 (d, J=1.5 Hz, 1H), 5.81 (td, J=6.6, 15.2 Hz, 1H), 5.68 (dd,J=8.3, 15.2 Hz, 1H), 4.19 (dd, J=3.9, 8.1 Hz, 1H), 4.12 (dd, J=5.9, 15.4Hz, 1H), 4.06 (s, 2H), 3.78 (d, J=14.9 Hz, 1H), 3.68 (d, J=14.4 Hz, 1H),3.23 (d, J=14.2 Hz, 1H), 3.13 (dd, J=6.7, 15.5 Hz, 1H), 3.02 (dd, J=9.7,15.3 Hz, 1H), 2.82-2.68 (m, 2H), 2.39 (ddd, J=4.2, 9.8, 18.1 Hz, 1H),2.36-2.25 (m, 2H), 2.06-1.96 (m, 3H), 1.96-1.88 (m, 2H), 1.87-1.70 (m,4H), 1.69-1.56 (m, 3H), 1.42-1.35 (m, 1H), 0.90 (t, J=7.5 Hz, 3H). MS(ESI, +ve ion) m/z 599.2 (M+H)⁺.

Example 35(1S,3′R,6′R,7′S,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 26; 17 mg, 0.028 mmol) and platinum (IV) oxide(6.44 mg, 0.028 mmol) in EtOAc (3.5 mL) were stirred under H₂ (balloon)at ambient temperature for 50 min. The reaction mixture was thenfiltered through a syringe filter. The crude material was purified bychromatography through a Redi-Sep® pre-packed SiO₂ gel column (4 g),eluting with 20% to 50% EtOAc (containing 0.3% AcOH) in heptanes, toprovide(1S,3′R,6′R,7′S,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide (12.1 mg, 0.020 mmol, 70.9% yield). ¹H NMR (500 MHz,CD₂Cl₂) δ 8.55 (br. s., 1H), 7.67 (d, J=8.6 Hz, 1H), 7.48 (br. s., 1H),7.14 (dd, J=2.4, 8.6 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.03 (dd, J=1.7,8.1 Hz, 1H), 6.92 (d, J=8.3 Hz, 1H), 4.22-4.13 (m, 2H), 4.05-3.96 (m,1H), 3.66 (br. s., 1H), 3.61 (d, J=13.7 Hz, 1H), 3.51-3.45 (m, 1H), 3.43(d, J=14.4 Hz, 1H), 3.28 (d, J=12.2 Hz, 1H), 2.81-2.69 (m, 2H),2.62-2.53 (m, 1H), 2.48-2.41 (m, 1H), 2.16-2.08 (m, 2H), 1.91 (q, J=9.0Hz, 1H), 1.87-1.78 (m, 3H), 1.78-1.72 (m, 1H), 1.68 (q, J=8.6 Hz, 2H),1.59 (dd, J=6.1, 10.3 Hz, 2H), 1.50-1.43 (m, 1H), 1.41 (d, J=7.1 Hz,3H), 1.37-1.25 (m, 4H), 1.00 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion) m/z601.0 (M+H)⁺.

Example 36(1S,3′R,6′R,7′S,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 27; 9.4 mg, 0.016 mmol) following the proceduredescribed for Example 35. Purification of the crude material provided(1S,3′R,6′R,7′S,11′R,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,11′R,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide (5.2 mg, 0.0087 mmol, 55.1% yield). ¹H NMR (500 MHz,CD₂Cl₂) δ 9.70 (br. s., 1H), 7.70 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.2,8.3 Hz, 1H), 7.16 (d, J=8.3 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.97 (d,J=8.1 Hz, 1H), 4.18 (d, J=11.7 Hz, 1H), 4.12 (d, J=12.0 Hz, 1H),3.69-3.57 (m, 3H), 3.49 (d, J=14.7 Hz, 1H), 3.38 (d, J=14.2 Hz, 1H),3.33 (br. s., 1H), 2.90 (d, J=4.6 Hz, 2H), 2.82-2.70 (m, 2H), 2.46-2.36(m, 1H), 2.31-2.20 (m, 1H), 2.11-2.01 (m, 1H), 1.99-1.91 (m, 3H),1.90-1.78 (m, 3H), 1.77-1.70 (m, 2H), 1.70-1.62 (m, 4H), 1.61-1.55 (m,1H), 1.45 (m, 1H), 1.42 (d, J=7.3 Hz, 3H), 0.97 (d, J=6.8 Hz, 3H). MS(ESI, +ve ion) m/z 601.1 (M+H)⁺.

Example 37(1S,3′R,6′R,7′S,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 28; 3.9 mg, 0.0065 mmol) following theprocedure described for Example 35. Purification of the crude materialprovided(1S,3′R,6′R,7′S,11′S,12′S)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[16,18,24]trien]-15′-one13′,13′-dioxide (2.8 mg, 0.0047 mmol, 71.6% yield, 90% purity). ¹H NMR(500 MHz, CD₂Cl₂) δ 10.44 (s, 1H), 7.73 (d, J=8.3 Hz, 1H), 7.43 (dd,J=2.2, 8.3 Hz, 1H), 7.32 (d, J=2.2 Hz, 1H), 7.17 (dd, J=2.4, 8.6 Hz,1H), 7.09 (d, J=2.4 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 4.10-4.05 (m, 2H),3.87 (d, J=15.4 Hz, 1H), 3.66 (d, J=13.9 Hz, 1H), 3.61 (q, J=8.8 Hz,1H), 3.55 (ddd, J=1.2, 7.1, 14.4 Hz, 1H), 3.16 (d, J=14.2 Hz, 1H), 3.09(dd, J=8.7, 15.3 Hz, 1H), 2.84-2.69 (m, 2H), 2.46-2.37 (m, 1H), 2.34 (d,J=8.6 Hz, 1H), 2.24 (quin, J=8.8 Hz, 1H), 2.17-2.08 (m, 2H), 2.06 (d,J=8.8 Hz, 1H), 2.04-1.96 (m, 1H), 1.96-1.87 (m, 1H), 1.86-1.71 (m, 5H),1.71-1.61 (m, 2H), 1.51-1.46 (m, 1H), 1.45-1.41 (m, 1H), 1.40 (d, J=7.3Hz, 3H), 1.35-1.28 (m, 1H), 1.03 (d, J=6.8 Hz, 3H). MS (ESI, +ve ion)m/z 601.1 (M+H)⁺.

Example 38(1S,3′R,6′R,7′S,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (S)-BENZYL(2-METHYLBUT-3-EN-1-YL)SULFANE AND(R)-BENZYL(2-METHYLBUT-3-EN-1-YL)SULFANE

A mixture of 2-methylbut-3-en-1-ol (1.198 mL, 11.61 mmol),phenylmethanethiol (2.044 mL, 17.42 mmol) and2-(tributylphosphoranylidene) MeCN (4.67 mL, 17.42 mmol) were heated at100° C. for 2 h. The reaction mixture was cooled to rt, diluted withEtOAc, washed with satd NH₄Cl aqueous solution and brine, dried overNa₂SO₄, and concentrated. The crude product was absorbed into 30 g ofSiO₂ gel and dried and then purified by chromatography on SiO₂ geleluting with Hex to provide the title product as a colorless oil (1.62g, 72.4%). ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.27 (m, 5H), 5.84 (ddd,J=17.17, 10.32, 6.75 Hz, 1H), 5.16-5.03 (m, 2H), 3.79 (s, 2H), 2.58-2.39(m, 3H), 1.19-1.14 (m, 3H).

STEP 2: (S)-2-METHYLBUT-3-ENE-1-SULFONAMIDE AND(R)-2-METHYLBUT-3-ENE-1-SULFONAMIDE

To a mixture of (S)-benzyl(2-methylbut-3-en-1-yl)sulfane,(R)-benzyl(2-methylbut-3-en-1-yl)sulfane (0.650 g, 3.38 mmol) andiodosobenzene (2.454 g, 11.15 mmol) in 133 mL of ether was slowly addedconcentrated HCl (18.31 mL, 220 mmol) with vigorous stirring. Theresulting mixture was stirred for 30 min. The reaction mixture wassettled and layers separated. The organic layer was concentrated underreduced pressure. The residue was dried under high vacuum for 1 h. Thesolution of residue in 8 mL of DCM was added into a mixture of ammonia,7.0 M solution in methanol (2.414 mL, 16.90 mmol), N,N-DIPEA (2.94 mL,16.90 mmol) and 4-(dimethylamino)pyridine (8.26 mg, 0.068 mmol) in 10 mLof DCM. The reaction mixture was concentrated after stirring at rt for16 h. The crude product was purified by chromatography on SiO₂ geleluting with 0% to 60% EtOAc in hexane to provide the title compound(0.076 g, 15.1%). ¹H NMR (400 MHz, CDCl₃) δ 5.82 (ddd, J=17.36, 10.03,7.63 Hz, 1H), 5.21-5.05 (m, 4H), 3.25-3.07 (m, 2H), 2.92-2.78 (m, 1H),1.20 (d, J=6.85 Hz, 3H).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-N—(((S)-2-METHYLBUT-3-EN-1-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-N—(((R)-2-METHYLBUT-3-EN-1-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

A mixture of(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 0.010 g, 0.021 mmol),(S)-2-methylbut-3-ene-1-sulfonamide and(R)-2-methylbut-3-ene-1-sulfonamide (0.019 g, 0.124 mmol),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.012 g,0.062 mmol) and 4-(dimethylamino)pyridine (7.60 mg, 0.062 mmol) in DCM(0.5 mL) was stirred at rt for 16 h. The mixture was directly loadedonto a column (5 g SiO₂ gel) for purification by chromatography, elutingwith 0% to 50% EtOAc (containing 0.2% AcOH) in hexane to provide thetitle compound (0.011 g. 86%). m/z (ESI, +ve ion) 613.2 (M+H)⁺.

STEP 4:(1S,3′R,6′R,7′S,9′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE (116762-34-3) AND(1S,3′R,6′R,7′S,9′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′Z,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′Z,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A solution of(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—(((S)-2-methylbut-3-en-1-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamideand(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N—(((R)-2-methylbut-3-en-1-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(21 mg, 0.034 mmol) in toluene (80 mL) was subjected to three cycles ofevacuation/back-filling with N₂. To the homogeneous solution was added asolution of Hoveyda-Grubbs II (4.29 mg, 6.85 μmol) in 1 mL of toluene atrt. The reaction mixture was stirred at 106° C. under N₂ for 2 h. Airwas blown into mixture. The reaction was cooled to rt and concentrated.The residue was purified by preparative reverse-phase HPLC (Gemini™ PrepC18 5 μm column; gradient elution of 40% to 90% MeCN in H₂O, where bothsolvents contained 0.1% TFA, 30 min method) to provide a mixture of thetitle compounds.

STEP 5:(1S,3′R,6′R,7′S,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(1S,3′R,6′R,7′S,9′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (116762-34-3) and(1S,3′R,6′R,7′S,9′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′Z,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′Z,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 4, 1.6 mg, 2.73 μmol) and platinum (iv) oxide(0.621 mg, 2.73 μmol) in EtOAc (2.0 mL) was stirred under H₂ (balloon)at rt for 2 h. The solid catalyst was filtered off using a syringefilter, and filtrate was concentrated to give the crude product. Thecrude product was purified by preparative reverse-phase HPLC (Gemini™Prep C18 5 μm column; gradient elution of 40% to 90% MeCN in H₂O, whereboth solvents contained 0.1% TFA, 30 min method) to provide the titlecompound as the second eluting isomer as a white solid. ¹H NMR (500 MHz,CDCl₃) δ 9.02 (br. s., 1H), 7.73-7.69 (m, 1H), 7.22-7.16 (m, 3H), 7.09(d, J=2.20 Hz, 1H), 6.96 (d, J=8.07 Hz, 1H), 4.16-4.09 (m, 2H),3.88-3.63 (m, 6H), 3.28-3.22 (m, 1H), 3.17 (dd, J=15.16, 5.87 Hz, 1H),3.13-3.07 (m, 1H), 2.80-2.74 (m, 2H), 2.36-2.29 (m, 2H), 2.21-2.18 (m,1H), 2.03-1.98 (m, 2H), 1.94-1.77 (m, 2H), 1.75-1.27 (m, 9H), 1.13 (d,J=6.85 Hz, 3H). m/z (ESI, +ve ion) 587.2 (M+H)⁺.

Example 39(1S,3′R,6′R,7′S,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound was isolated as the second eluting isomer out ofpreparative reverse-phase HPLC in Example 38. ¹H NMR (400 MHz, CDCl₃) δ9.38 (br. s., 1H), 7.69 (d, J=8.61 Hz, 1H), 7.29 (m, 1H), 7.25-7.15 (m,2H), 7.10 (d, J=2.35 Hz, 1H), 6.98 (d, J=8.22 Hz, 1H), 4.16 (s, 2H),3.89-3.83 (m, 1H), 3.67 (d, J=7.83 Hz, 1H), 3.61-3.44 (m, 4H), 3.41 (d,J=12.52 Hz, 2H), 2.81-2.68 (m, 3H), 2.23-2.06 (m, 3H), 2.02-1.72 (m,5H), 1.64-1.51 (m, 5H), 1.49-1.38 (m, 2H), 1.25-1.13 (m, 1H), 1.06 (d,J=6.85 Hz, 3H). m/z (ESI, +ve ion) 587.1 (M+H)⁺.

Example 40(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND Example 41(1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: 2-METHYLHEX-5-ENE-2-SULFONAMIDE

The title compound was prepared in an analogous manner to that describedin Intermediate EE20 using 5 eq. butyllithium solution, 2.5 M in hexanes(Aldrich) and 5 eq. of MeI (Aldrich), and the desired product1-(trifluoromethoxy)hept-6-ene-3-sulfonamide was isolated as a lightbrown oil.

STEP 2:(1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 2, Steps 1 and 2, using Intermediate AA11A and2-methylhex-5-ene-2-sulfonamide from Step 1, and the desired products,(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 40) as the first eluting major isomer out ofpreparative reverse-phase HPLC and(1S,3′R,6′R,7′S,8′Z)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 41) as the second eluting major isomer out ofpreparative reverse-phase HPLC was isolated.(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 40): ¹H NMR (500 MHz, CD₃OD) δ 7.75 (d, J=8.6Hz, 1H), 7.20 (dd, J=2.2, 8.6 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.07 (br.s., 1H), 6.94 (d, J=7.8 Hz, 2H), 5.82 (br. s., 1H), 5.65 (dd, J=7.5,15.5 Hz, 1H), 4.17 (br. s., 1H), 4.10 (dd, J=12.0, 46.0 Hz, 2H), 3.78(d, J=14.4 Hz, 1H), 3.67 (d, J=13.4 Hz, 1H), 3.11-3.00 (m, 1H),2.87-2.75 (m, 2H), 2.54 (br. s., 1H), 2.41-2.07 (m, 5H), 2.01-1.88 (m,3H), 1.80 (dd, J=8.1, 14.2 Hz, 3H), 1.70 (dd, J=9.0, 18.3 Hz, 1H),1.54-1.42 (m, 2H), 1.45 (d, J=8.1 Hz, 6H). m/z (ESI, +ve ion) 599.2(M+H)⁺;(1S,3′R,6′R,7′S,8′Z)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 41): ¹H NMR (400 MHz, CD₃OD) δ 7.76 (d, J=8.6Hz, 1H), 7.29 (d, J=7.8 Hz, 1H), 7.20 (dd, J=2.2, 8.4 Hz, 1H), 7.17 (br.s., 1H), 7.13 (d, J=2.2 Hz, 1H), 6.96 (d, J=7.5 Hz, 1H), 5.68-5.60 (m,1H), 5.53 (dd, J=8.4, 11.2 Hz, 1H), 4.59 (dd, J=1.8, 8.6 Hz, 1H), 4.11(s, 2H), 4.07 (d, J=13.7 Hz, 1H), 3.74 (d, J=15.3 Hz, 1H), 3.45 (d,J=14.5 Hz, 1H), 2.90-2.75 (m, 2H), 2.72-2.53 (m, 1H), 2.50-2.40 (m, 1H),2.40-2.23 (m, 2H), 2.14 (d, J=13.1 Hz, 1H), 2.08-1.96 (m, 4H), 1.96-1.78(m, 5H), 1.53 (d, J=12.7 Hz, 6H) 1.52-1.46 (m, 1H). m/z (ESI, +ve ion)599.2 (M+H)⁺.

Example 42(1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-12′,12′-ETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

STEP 1. N,N-BIS(4-METHOXYBENZYL)2-METHYLPENT-4-ENE-2-SULFONAMIDE

N,N-bis(4-methoxybenzyl)but-3-ene-1-sulfonamide (Intermediate EE16; 500mg, 1.332 mmol) was azeotroped in PhMe under vacuum for 1 h. Underargon, THF was added and the solution was cooled to −78° C. Butyllithiumsolution (Sigma Aldrich, 2.5 M in hexanes; 1.065 mL, 2.66 mmol) was thenadded and the mixture was stirred at −78° C. for 60 min. MeI (SigmaAldrich; 0.166 mL, 2.66 mmol) was added and the mixture was stirred at−78° C. for an additional 30 min, (LC/MS analysis showed completeconversion to a 1:1 mixture of mono and di-methylated products). Themixture was quenched with satd NH₄Cl, allowed to reach ambienttemperature, extracted with EtOAc, dried over MgSO₄, and concentrated.The crude material was purified through a 24 g ISCO gold column elutingwith a gradient of 5-10% EtOAc in hexanes to provideN,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-2-sulfonamide (173 mg, 0.429mmol, 32.2% yield).

STEP 2. 2-METHYLPENT-4-ENE-2-SULFONAMIDE

To a solution ofN,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-2-sulfonamide (173 mg, 0.429mmol) in DCM, thioanisole (0.503 mL, 4.29 mmol) was added followed bythe dropwise addition of trifluoroacetic acid (1.2 mL, 16.15 mmol).After stirring for 6 h (TLC in 30% EtOAc/hexanes showed complete loss ofstarting material) the mixture was diluted with EtOAc, washed with satdNaHCO₃, back extracted with EtOAc, dried over MgSO₄ and concentrated.The crude material was purified via chromatography through a 12 g ISCOgold column eluting with a gradient of 10-50% EtOAc hexanes to provide2-methylpent-4-ene-2-sulfonamide (45 mg, 0.276 mmol, 64.3% yield).

STEP 3:(S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-N-((2-METHYLPENT-4-EN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA13A; 41 mg, 0.085 mmol) and2-methylpent-4-ene-2-sulfonamide (45 mg, 0.276 mmol) following theprocedure described for Example 2, Step 1. Purification of the crudematerial provided(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N-((2-methylpent-4-en-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(45.8 mg, 0.073 mmol, 86% yield).

STEP 4:(1S,3′R,6′R,7′S,9′Z)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE AND(1S,3′R,6′R,7′S,9′E)-6-CHLORO-7′-HYDROXY-12′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was synthesized from(S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N-((2-methylpent-4-en-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide(45.8 mg, 0.073 mmol) following the procedure described for Example 14,Step 2. The crude material was purified by chromatography through a 12 gISCO column, eluting with 10% to 20% EtOAc (containing 0.3% AcOH) inhexanes over 90 min to provide a mixture of the title compounds.

STEP 5:(1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-12′,12′-ETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[16,18,24]TRIEN]-15′-ONE13′,13′-DIOXIDE

The title compound (6.4 mg, 0.011 mmol, 71% yield) was synthesized froma mixture of(1S,3′R,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide and(1S,3′R,6′R,7′S,9′E)-6-chloro-7′-hydroxy-12′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[9,16,18,24]tetraen]-15′-one13′,13′-dioxide (from Step 4, 9 mg, 0.015 mmol) following the proceduredescribed for Example 14, Step 3. ¹H NMR (400 MHz, CD₂Cl₂) δ 10.50 (br.s., 1H), 7.70 (d, J=8.6 Hz, 1H), 7.47 (dd, J=1.2, 8.4 Hz, 1H), 7.35 (s,1H), 7.14 (dd, J=2.0, 8.2 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 6.91 (d,J=8.4 Hz, 1H), 4.02 (d, J=12.1 Hz, 1H), 3.96 (d, J=11.9 Hz, 1H), 3.73(d, J=15.5 Hz, 1H), 3.64-3.54 (m, 1H), 3.13 (d, J=14.3 Hz, 1H), 3.05(dd, J=9.1, 15.6 Hz, 1H), 2.94 (d, J=8.6 Hz, 1H), 2.82-2.71 (m, 2H),2.33 (quin, J=8.6 Hz, 1H), 2.20-2.06 (m, 2H), 2.05-1.96 (m, 2H),1.95-1.87 (m, 3H), 1.86-1.74 (m, 4H), 1.73-1.59 (m, 4H), 1.49 (s, 3H),1.47 (s, 3H), 1.44-1.34 (m, 3H). MS (ESI, +ve ion) m/z 601.2 (M+H)⁺.

Example 43(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(1-METHYLETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE-13′,13′-DIOXIDE

To a solution of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2; 20.4 mg, 0.034 mmol) in THF (0.681 mL)cooled to 0° C. was added sodium hydride (60% dispersion in mineral oil;13.62 mg, 0.340 mmol). The reaction mixture was stirred at 0° C. for 15min and then 2-iodopropane (3.40 μl, 0.034 mmol) was added. The reactionmixture was stirred at ambient temperature for 4 days, adding morereagents to drive the reaction. The mixture was then quenched with aqNH₄Cl and diluted with EtOAc. The organic layer was dried over MgSO₄ andconcentrated. The crude material was purified by chromatography througha Redi-Sep® pre-packed SiO₂ gel column (4 g), eluting with 10-40% EtOAc(containing 0.3% AcOH)/heptanes to provide the title compound (0.6 mg).¹H NMR (500 MHz, CD₂Cl₂) δ 8.03 (br. s., 1H), 7.71 (d, J=8.3 Hz, 1H),7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.91-6.89 (m, 2H),6.88 (s, 1H), 5.72 (ddd, J=3.4, 9.3, 15.2 Hz, 1H), 5.53 (dd, J=8.8, 15.4Hz, 1H), 4.29-4.22 (m, 1H), 4.08 (s, 2H), 3.85-3.80 (m, 2H), 3.69 (d,J=14.2 Hz, 1H), 3.59 (td, J=6.1, 12.2 Hz, 1H), 3.28-3.22 (m, 2H), 3.02(dd, J=9.7, 15.3 Hz, 1H), 2.83-2.70 (m, 2H), 2.39-2.24 (m, 2H),2.20-2.02 (m, 3H), 2.01-1.89 (m, 3H), 1.83 (dd, J=5.6, 12.7 Hz, 1H),1.81-1.75 (m, 1H), 1.70-1.59 (m, 1H), 1.44 (d, J=7.3 Hz, 3H), 1.43-1.35(m, 1H), 1.09 (d, J=5.9 Hz, 3H), 1.04 (d, J=6.1 Hz, 3H), 1.02 (d, J=6.8Hz, 3H). MS (ESI, +ve ion) m/z 641.0 (M+H)⁺.

Example 44(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (2S)-METHYLPENT-4-ENAL AND (2R)-METHYLPENT-4-ENAL

To a solution of oxalyl chloride (6.65 mL, 74.9 mmol) in DCM (30 mL) at−60° C. was added a solution of DMSO anhydrous (10.62 mL, 150 mmol) inDCM (20 mL) under N₂ and stirred for 2 min. A solution of2-methylpent-4-en-1-ol (5.00 g, 49.9 mmol) in DCM (20 mL) was added, andthe resulting mixture was stirred for 15 min at −60° C. Et₃N (34.7 mL,250 mmol) was then added and the reaction mixture was stirred at ambienttemperature for 20 min. The mixture was quenched with DCM and H₂O. Theorganic layer was washed with brine, dried (MgSO₄), and filtered. Thefiltrate was concentrated to afford the title compound (4.90 g, 100%)without further purification.

STEP 2: (1S,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTEN-1-OL AND(1R,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTEN-1-OL AND(1S,2S)-1-CYCLOPROPYL-2-METHYL-4-PENTEN-1-OL AND(1R,2S)-1-CYCLOPROPYL-2-METHYL-4-PENTEN-1-OL

To a solution of (2S)-methylpent-4-enal and (2R)-methylpent-4-enal (9.80g, 100 mmol) in THF (30 mL) was added cyclopropylmagnesium bromide, 1.0M in 2-MeTHF (300 mL, 150 mmol) at −78° C. The reaction mixture wasstirred at ambient temperature for 3 h. The mixture was quenched withsat. aqueous NH₄Cl, and extracted with ether. The organic layer waswashed with brine, dried (Na₂SO₄), and concentrated. The resultingresidue was chromatographed (SiO₂ gel, 0 to 40%, EtOAc/hexane) to affordthe title compound (4.20 g, 30.0%).

STEP 3: (1R,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTENE-1-SULFONAMIDE AND(1R,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTENE-1-SULFONAMIDE AND(1R,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTENE-1-SULFONAMIDE AND(1R,2R)-1-CYCLOPROPYL-2-METHYL-4-PENTENE-1-SULFONAMIDE

The title compound was prepared from a mixture of(1S,2R)-1-cyclopropyl-2-methyl-4-penten-1-ol,(1R,2R)-1-cyclopropyl-2-methyl-4-penten-1-ol,(1S,2S)-1-cyclopropyl-2-methyl-4-penten-1-ol, and(1R,2S)-1-cyclopropyl-2-methyl-4-penten-1-ol (from Step 2) as a startingalcohol, following a similar procedure described in E22, Steps 3 through6.

Step 4:(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A) and a mixture of(1R,2R)-1-cyclopropyl-2-methyl-4-pentene-1-sulfonamide,(1R,2R)-1-cyclopropyl-2-methyl-4-pentene-1-sulfonamide,(1R,2R)-1-cyclopropyl-2-methyl-4-pentene-1-sulfonamide, and(1R,2R)-1-cyclopropyl-2-methyl-4-pentene-1-sulfonamide (from Step 3),following a similar procedure described in Example 2, Steps 1 and 2.This crude oil was purified by preparative reverse-phase HPLC (Gemini™Prep C₁₈ 5 μm column; gradient elution of 50% to 90% MeCN in H₂O, whereboth solvents contain 0.1% TFA, 30 min method) to afford the titlecompound as the first eluting isomer (12 mg, 6.7%). ¹H NMR (400 MHz,CD₂Cl₂) δ 8.15 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.3, 8.6 Hz,1H), 7.09 (d, J=2.2 Hz, 1H), 6.93-6.88 (m, 3H), 5.91-5.63 (m, 2H), 4.22(dd, J=3.9, 7.6 Hz, 1H), 3.81 (d, J=15.1 Hz, 1H), 3.68 (d, J=14.3 Hz,1H), 3.40 (d, J=11.0 Hz, 1H), 3.25 (d, J=14.3 Hz, 1H), 3.04 (dd, J=9.8,15.3 Hz, 1H), 2.82-2.67 (m, 2H), 2.49-2.23 (m, 3H), 2.14-1.84 (m, 11H),1.73-1.62 (m, 1H), 1.45-1.34 (m, 1H), 1.20 (d, J=6.8 Hz, 3H), 1.17-1.07(m, 1H), 0.93-0.76 (m, 3H), 0.50-0.37 (m, 1H). m/z (ESI, +ve ion) 625.2(M+H)⁺.

Example 45(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound (5 mg, 2.8%) was obtained as the second elutingisomer from preparative reverse-phase HPLC separation in Example 49. ¹HNMR (400 MHz, CD₂Cl₂) δ 9.04 (br. s., 1H), 7.83-7.61 (m, 1H), 7.17 (d,J=8.4 Hz, 1H), 7.09 (m, 1H), 6.97-6.88 (m, 1H), 6.84 (m, 1H), 6.15 (br.s., 1H), 5.92-5.69 (m, 1H), 4.26-4.04 (m, 2H), 3.68 (d, J=14.1 Hz, 1H),3.36-2.94 (m, 3H), 2.77 (m, 2H), 2.38 (d, J=7.6 Hz, 2H), 2.24-1.87 (m,6H), 1.69 (dd, J=9.8, 19.4 Hz, 2H), 1.53-1.41 (m, 1H), 1.30-1.06 (m,10H), 0.83 (d, J=3.1 Hz, 2H), 0.44 (br. s., 1H) m/z (ESI, +ve ion) 625.2(M+H)⁺.

Example 46(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound (9 mg, 5.0%) was obtained as the third eluting isomerfrom preparative reverse-phase HPLC separation in Example 49. ¹H NMR(400 MHz, CD₂Cl₂) δ 8.21 (br. s., 1H), 7.66 (d, J=8.6 Hz, 1H), 7.44 (br.s., 1H), 7.14 (dd, J=2.3, 8.6 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.94-6.86(m, 2H), 5.62 (br. s., 2H), 4.20 (s, 2H), 3.92 (d, J=7.4 Hz, 1H), 3.85(d, J=13.9 Hz, 1H), 3.66 (d, J=14.1 Hz, 1H), 3.39 (d, J=14.3 Hz, 1H),3.33 (d, J=11.0 Hz, 1H), 3.17 (d, J=13.7 Hz, 1H), 2.74 (t, J=5.3 Hz,2H), 2.57 (d, J=7.6 Hz, 1H), 2.40 (td, J=8.7, 17.1 Hz, 1H), 2.29-2.16(m, 1H), 2.03-1.62 (m, 10H), 1.60-1.45 (m, 1H), 1.22 (d, J=6.7 Hz, 3H),1.17-1.04 (m, 1H), 0.91-0.78 (m, 3H), 0.52-0.41 (m, 1H). m/z (ESI, +veion) 625.2 (M+H)⁺.

Example 47(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound (3 mg, 1.9%) was obtained as the slowest elutingisomer from preparative reverse-phase HPLC separation in Example 49. ¹HNMR (400 MHz, CD₂Cl₂) δ 8.14 (br. s., 1H), 7.71 (d, J=8.6 Hz, 1H),7.22-7.06 (m, 3H), 6.98-6.91 (m, 1H), 6.62 (br. s., 1H), 6.05 (d, J=7.2Hz, 1H), 5.69 (dd, J=5.8, 15.2 Hz, 1H), 4.19 (br. s., 1H), 4.15-3.99 (m,2H), 3.79 (d, J=14.5 Hz, 1H), 3.65 (d, J=14.5 Hz, 1H), 3.43 (d, J=14.5Hz, 1H), 3.33-3.22 (m, 1H), 2.99 (d, J=11.0 Hz, 1H), 2.86-2.66 (m, 3H),2.51 (br. s., 2H), 2.32-2.18 (m, 2H), 2.09-1.87 (m, 5H), 1.75 (d, J=10.4Hz, 2H), 1.52-1.38 (m, 2H), 1.19 (d, J=7.0 Hz, 3H), 1.11 (br. s., 1H),0.93-0.73 (m, 3H), 0.54-0.40 (m, 1H). m/z (ESI, +ve ion) 625.2 (M+H)⁺.

Example 48(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOPROPYL-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOPROPYL-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound (9.5 mg, 62%) was prepared from(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-chloro-12′-cyclopropyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-cyclopropyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-12′-cyclopropyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-12′-cyclopropyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 49) using a similar procedure described inExample 46. ¹H NMR (400 MHz, CD₂Cl₂) δ 8.15-7.94 (m, 1H), 7.71 (d,J=8.41 Hz, 1H), 7.17 (dd, J=2.35, 8.41 Hz, 1H), 7.09 (d, J=2.15 Hz, 1H),6.91 (d, J=0.98 Hz, 2H), 6.86 (s, 1H), 5.81-5.70 (m, J=3.13, 9.39 Hz,1H), 5.51 (ddd, J=1.17, 8.41, 14.67 Hz, 1H), 4.08 (s, 2H), 3.80 (d,J=15.06 Hz, 1H), 3.69 (d, J=14.28 Hz, 1H), 3.62 (dd, J=3.33, 9.00 Hz,1H), 3.45 (d, J=10.17 Hz, 1H), 3.25 (d, J=14.28 Hz, 1H), 3.17 (s, 3H),3.03 (dd, J=10.17, 15.26 Hz, 1H), 2.80-2.72 (m, 2H), 2.59-2.39 (m, 2H),2.38-2.25 (m, 1H), 2.17-1.73 (m, 8H), 1.72-1.59 (m, 1H), 1.21 (d, J=6.85Hz, 3H), 1.17-1.08 (m, 1H), 0.92-0.78 (m, 4H), 0.47-0.37 (m, 1H). m/z(ESI, +ve ion) 639.2 (M+H)⁺.

Example 49(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (3R,4R)-2,4-DIMETHYLHEPT-6-EN-3-OL AND(3R,4S)-2,4-DIMETHYLHEPT-6-EN-3-OL AND(3S,4R)-2,4-DIMETHYLHEPT-6-EN-3-OL AND(3S,4S)-2,4-DIMETHYLHEPT-6-EN-3-OL

To a solution of 2-methylpent-4-enal (2.40 g, 24.4 mmol) in THF (10 mL)was added isopropylmagnesium chloride, 2.0 M in THF (24.4 mL, 48.9 mmol)at 0° C. The reaction mixture was allowed to warm to ambienttemperature. After being stirred at ambient temperature for 12 h, thereaction mixture was quenched (sat. NH₄Cl), extracted (2×Et₂O), andwashed (brine). The combined organic layers were dried (Na₂SO₄) andconcentrated under reduced pressure. The residue was injected into a 40g ISCO gold column and purified by Combi-Flash®, eluting with 0% to 20%EtOAc/hexanes to give the title compounds (550 mg, 3.85 mmol).

STEP 2:(3S,4R)—N,N-BIS(4-METHOXYBENZYL)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDEAND(3S,4S)—N,N-BIS(4-METHOXYBENZYL)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDEAND(3R,4R)—N,N-BIS(4-METHOXYBENZYL)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDEAND(3R,4S)—N,N-BIS(4-METHOXYBENZYL)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDE

The title compound was prepared from a mixture of(3R,4R)-2,4-dimethylhept-6-en-3-ol, (3R,4S)-2,4-dimethylhept-6-en-3-ol,(3S,4R)-2,4-dimethylhept-6-en-3-ol, and(3S,4S)-2,4-dimethylhept-6-en-3-ol (from Step 1), following a similarprocedure described in Intermediate EE22, Steps 3 through 6.

STEP 3: (3S,4R)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDE AND(3S,4S)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDE AND(3R,4R)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDE AND(3R,4S)-2,4-DIMETHYLHEPT-6-ENE-3-SULFONAMIDE

The title compounds were synthesized from a mixture of(3S,4R)-N,N-bis(4-methoxybenzyl)-2,4-dimethylhept-6-ene-3-sulfonamide,(3S,4S)-N,N-bis(4-methoxybenzyl)-2,4-dimethylhept-6-ene-3-sulfonamide,(3R,4R)-N,N-bis(4-methoxybenzyl)-2,4-dimethylhept-6-ene-3-sulfonamide,and(3R,4S)-N,N-bis(4-methoxybenzyl)-2,4-dimethylhept-6-ene-3-sulfonamide(from Step 2), following a similar procedure described for Example 26,Step 2.

STEP 4:(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE (ISOMER1)

The title compounds was prepared from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A) and a mixture of(3S,4R)-2,4-dimethylhept-6-ene-3-sulfonamide,(3S,4S)-2,4-dimethylhept-6-ene-3-sulfonamide,(3R,4R)-2,4-dimethylhept-6-ene-3-sulfonamide, and(3R,4S)-2,4-dimethylhept-6-ene-3-sulfonamide, following a similarprocedure described in Example 2, Steps 1 and 2. The residue wasinjected into a 40 g ISCO gold column and purified by Combi-Flash®,eluting with 10% to 100% EtOAc (containing 0.5% AcOH)/hexanes to give acrude product as the faster eluting isomer. This crude product waspurified by preparative reverse-phase HPLC (Gemini™ Prep C₁₈ 5 μmcolumn; gradient elution of 50% to 90% MeCN in H₂O, where both solventscontain 0.1% TFA, 30 min method) to provide one of the title compoundsas a white foam. ¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.30 (s, 1H), 7.79-7.70(m, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.14 (m, 1H), 7.10 (m, 1H), 6.95-6.87(m, 2H), 5.67 (dd, J=4.1, 15.8 Hz, 1H), 5.44-5.34 (m, 1H), 4.29-4.13 (m,3H), 4.04 (m, 1H), 3.89-3.77 (m, 2H), 3.29 (d, J=14.3 Hz, 1H), 3.05 (dd,J=3.5, 16.0 Hz, 1H), 2.78-2.69 (m, 2H), 2.62-2.53 (m, 1H), 2.48 (m, 1H),2.31-2.19 (m, 1H), 2.05-1.70 (m, 9H), 1.61 (m, 1H), 1.37 (d, J=7.0 Hz,3H), 1.35-1.26 (m, 4H), 1.17 (d, J=6.7 Hz, 3H); m/z (ESI, +ve ion) 627(M+H)⁺.

Example 50(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the second (slower) elutingisomer using Combi-Flash® separation as described in Example 54. ¹H NMR(400 MHz, CD₂Cl₂) δ ppm 8.13 (s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd,J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.91 (m, 3H), 5.79-5.67 (m,2H), 4.22-4.13 (m, 2H), 4.09 (s, 2H), 3.90-3.78 (m, 1H), 3.69 (d, J=14.3Hz, 1H), 3.24 (d, J=14.3 Hz, 1H), 3.03 (dd, J=9.3, 15.4 Hz, 1H),2.83-2.70 (m, 2H), 2.46-2.37 (m, 1H), 2.35-2.23 (m, 2H), 2.19-1.91 (m,6H), 1.88-1.75 (m, 3H), 1.70-1.61 (m, 1H), 1.44-1.30 (m, 7H), 1.14 (d,J=6.7 Hz, 3H); m/z (ESI, +ve ion) 627 (M+H)⁺.

Example 51(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,21)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the third (slower) elutingisomer using Combi-Flash® separation as described in Example 54. ¹H NMR(400 MHz, CD₂Cl₂) δ ppm 8.11 (s, 1H), 7.77-7.69 (m, 1H), 7.16 (d, J=8.4Hz, 1H), 7.13-7.06 (m, 1H), 7.00-6.88 (m, 3H), 5.85-5.60 (m, 2H),4.24-4.06 (m, 4H), 3.95-3.80 (m, 1H), 3.69 (d, J=14.1 Hz, 1H), 3.51-3.34(m, 2H), 2.83-2.70 (m, 2H), 2.46-2.24 (m, 3H), 2.18-1.90 (m, 6H),1.87-1.70 (m, 4H), 1.35 (dd, J=7.0, 14.3 Hz, 7H), 1.22-1.07 (m, 3H); m/z(ESI, +ve ion) 627 (M+H)⁺.

Example 52(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the fourth (slower) elutingisomer using Combi-Flash® separation as described in Example 54. ¹H NMR(400 MHz, CD₂Cl₂) δ ppm 8.11 (br. s., 1H), 7.71 (t, J=6.9 Hz, 1H),7.25-6.87 (m, 5H), 5.88-5.43 (m, 2H), 4.20-4.02 (m, 3H), 3.84 (m, 1H),3.74-3.55 (m, 2H), 3.55-3.40 (m, 1H), 3.40-3.12 (m, 1H), 2.82-2.62 (m,3H), 2.53 (d, J=5.3 Hz, 2H), 2.32 (m, 3H), 2.08-1.62 (m, 8H), 1.37-1.12(m, 10H); m/z (ESI, +ve ion) 627 (M+H)⁺.

Example 53(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-METHOXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-METHOXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-METHOXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-METHOXY-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a solution of the product (from Example 54; 9 mg, 0.014 mmol) in THF(1 mL) was added sodium hydride, 60% dispersion in mineral oil (1.43 mg,0.036 mmol), followed by MeI (3.1 mg, 0.022 mmol). The solution wasstirred at room temperature overnight. The reaction was then quenchedwith sat. NH₄Cl and brine, extracted (2×Et₂O), and washed (1×brine). Thecombined organic layers were dried (Na₂SO₄) and concentrated under thereduced pressure. The residue was injected into a 4 g ISCO gold columnand purified by Combi-Flash®, is eluting with 0% to 100% EtOAc(containing 0.5% AcOH)/hexanes to give one of the title compounds (7 mg,10.9 μmol) as colorless oil. ¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.15 (br.s., 1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d,J=2.2 Hz, 1H), 6.90 (m, 2H), 6.84 (m, 1H), 5.73 (ddd, J=3.9, 8.7, 15.2Hz, 1H), 5.52 (dd, J=8.8, 15.5 Hz, 1H), 4.23 (m, 1H), 4.12-4.04 (m, 2H),3.82 (d, J=15.1 Hz, 1H), 3.72-3.62 (m, 2H), 3.25-3.17 (m, 4H), 3.02 (dd,J=10.0, 15.5 Hz, 1H), 2.83-2.69 (m, 2H), 2.47-2.38 (m, 1H), 2.35-2.23(m, 3H), 2.21-2.02 (m, 3H), 1.97-1.72 (m, 5H), 1.68-1.60 (m, 1H),1.40-1.30 (m, 7H), 1.13 (d, J=6.7 Hz, 3H); m/z (ESI, +ve ion) 641(M+H)⁺.

Example 54(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-12′-(1-METHYLETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a solution of the product from Example 54 (10 mg, 0.016 mmol) in THF(1 mL) was added sodium hydride, 60% dispersion in mineral oil (1.6 mg,0.040 mmol), followed by 2-bromoethyl methyl ether (2.2 mg, 0.016 mmol).The solution was stirred at room temperature for ˜48 h. The reaction wasthen quenched with sat. NH₄Cl and brine, extracted (2×Et₂O), and washed(1×brine). The combined organic layers were dried (Na₂SO₄) andconcentrated under the reduced pressure. This crude product was purifiedby preparative reverse-phase HPLC (Gemini™ Prep C₁₈ 5 μm column;gradient elution of 50% to 90% MeCN in H₂O, where both solvents contain0.1% TFA, 30 min method) to provide one of the title compounds (4 mg,5.8 μmol) as a white amorphous solid. ¹H NMR (400 MHz, CD₂Cl₂) δ ppm8.09 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.16 (dd, J=2.2, 8.5 Hz, 1H), 7.09(d, J=2.2 Hz, 1H), 6.94-6.87 (m, 2H), 6.84 (s, 1H), 5.71 (ddd, J=4.0,8.5, 15.3 Hz, 1H), 5.60-5.48 (m, 1H), 4.21 (m, 1H), 4.08 (s, 2H),3.86-3.74 (m, 2H), 3.68 (d, J=13.9 Hz, 1H), 3.53-3.36 (m, 4H), 3.32 (s,3H), 3.23 (d, J=14.3 Hz, 1H), 3.01 (dd, J=10.1, 15.2 Hz, 1H), 2.83-2.69(m, 2H), 2.48-2.39 (m, 1H), 2.34-2.12 (m, 4H), 2.12-2.01 (m, 2H),1.99-1.75 (m, 5H), 1.72-1.63 (m, 1H), 1.45-1.30 (m, 7H), 1.13 (d, J=6.8Hz, 3H); m/z (ESI, +ve ion) 685 (M+H)⁺.

Example 55(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (R)-2-METHYLPENT-4-ENAL AND (S)-2-METHYLPENT-4-ENAL

To a solution of oxalyl chloride (6.65 mL, 74.9 mmol) in DCM (30 mL) at−60° C. was added a solution of DMSO anhydrous (10.6 mL, 150 mmol) inDCM (20 mL) under Nz. After being stirred for 2 min, a solution of2-methylpent-4-en-1-ol (5.00 g, 49.9 mmol) in DCM (20 mL) was added, andthe resulting mixture was stirred for 15 min at −60° C. Et₃N (34.7 mL,250 mmol) was then added. After being stirred at ambient temperature for20 min, the to mixture was quenched with DCM and H₂O, extracted(2×Et₂O), and washed (1×brine). The combined organic layers were dried(Na₂SO₄) and concentrated under the reduced pressure to afford the titlecompound. The title compound was taken to the next step without furtherpurification.

STEP 2: (1R,2R)-1-CYCLOBUTYL-2-METHYLPENT-4-EN-1-OL AND(1R,2S)-1-CYCLOBUTYL-2-METHYLPENT-4-EN-1-OL AND(1S,2R)-1-CYCLOBUTYL-2-METHYLPENT-4-EN-1-OL AND(1S,2S)-1-CYCLOBUTYL-2-METHYLPENT-4-EN-1-OL

To a solution of (R)-2-methylpent-4-enal and (S)-2-methylpent-4-enal (5g, 50.9 mmol) (Example 183, Step 1) in THF (30 mL) was addedcyclobutylmagnesium bromide (17.8 g, 112 mmol) at −78° C. The reactionwas allowed to warm to room temperature. After being stirred at roomtemperature for 3 h, the reaction was quenched (sat. NH₄Cl), extracted(2∴Et₂O), and washed (1×brine). The combined organic layers were dried(Na₂SO₄) and concentrated under the reduced pressure. The residue wasinjected into a 40 g ISCO gold column and purified by Combi-Flash®,eluting with 0% to 30% EtOAc/hexanes to give the title compound (4.2 g,27.2 mmol).

STEP 3:(1S,2R)-1-CYCLOBUTYL-N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDEAND(1R,2R)-1-CYCLOBUTYL-N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDEAND(1S,2S)-1-CYCLOBUTYL-N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDEAND(1R,2S)-1-CYCLOBUTYL-N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDE

The title compound was prepared from a mixture of(1R,2R)-1-cyclobutyl-2-methylpent-4-en-1-ol,(1R,2S)-1-cyclobutyl-2-methylpent-4-en-1-ol,(1S,2R)-1-cyclobutyl-2-methylpent-4-en-1-ol, and(1S,2S)-1-cyclobutyl-2-methylpent-4-en-1-ol (from Step 2), following asimilar procedure described in Intermediate EE22, Steps 3 through 6.

STEP 4: (1S,2R)-1-CYCLOBUTYL-2-METHYLPENT-4-ENE-1-SULFONAMIDE AND(1R,2R)-1-CYCLOBUTYL-2-METHYLPENT-4-ENE-1-SULFONAMIDE AND(1S,2S)-1-CYCLOBUTYL-2-METHYLPENT-4-ENE-1-SULFONAMIDE AND(1R,2S)-1-CYCLOBUTYL-2-METHYLPENT-4-ENE-1-SULFONAMIDE

The title compounds were synthesized from a mixture of(1S,2R)-1-cyclobutyl-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide,(1R,2R)-1-cyclobutyl-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide,(1S,2S)-1-cyclobutyl-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide,and(1R,2S)-1-cyclobutyl-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide(from Step 2), following a similar procedure described in Example 26,Step 2.

STEP 5:(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,244)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compounds was prepared from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12) and a mixture of(1S,2R)-1-cyclobutyl-2-methylpent-4-ene-1-sulfonamide,(1R,2R)-1-cyclobutyl-2-methylpent-4-ene-1-sulfonamide,(1S,2S)-1-cyclobutyl-2-methylpent-4-ene-1-sulfonamide, and(1R,2S)-1-cyclobutyl-2-methylpent-4-ene-1-sulfonamide (from Step 3),following a similar procedure described in Example 2, Steps 1 and 2. Theresidue was injected into a 40 g ISCO gold column and purified byCombi-Flash®, eluting with 10% to 100% EtOAc (containing 0.5%AcOH)/hexanes to give a crude product as the faster eluting isomer. Thiscrude product was purified by preparative reverse-phase HPLC (Gemini™Prep C₁₈ 5 μm column; gradient elution of 50% to 90% MeCN in H₂O, whereboth solvents contain 0.1% TFA, 30 min method) to provide one of thetitle compounds as a white foam. ¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.26(br. s., 1H), 7.71 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.3, 8.4 Hz, 1H), 7.09(d, J=2.3 Hz, 1H), 6.95-6.89 (m, 3H), 5.91 (ddd, J=3.8, 8.9, 15.0 Hz,1H), 5.70 (dd, J=8.1, 15.2 Hz, 1H), 4.25 (dd, J=3.8, 8.1 Hz, 1H),4.12-4.05 (m, 3H), 3.84 (m, 1H), 3.68 (d, J=14.3 Hz, 1H), 3.25 (d,J=14.3 Hz, 1H), 3.09-3.02 (m, 1H), 3.00-2.89 (m, 1H), 2.82-2.70 (m, 2H),2.47-2.38 (m, 1H), 2.36-2.12 (m, 5H), 2.06-1.94 (m, 6H), 1.88-1.77 (m,4H), 1.73-1.62 (m, 1H), 1.49-1.32 (m, 2H), 1.08 (d, J=6.8 Hz, 3H); m/z(ESI, +ve ion) 639 (M+H)⁺.

Example 56(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the second (slower) elutingisomer using Combi-Flash® separation as described in Example 55. ¹H NMR(400 MHz, CD₂Cl₂) δ ppm 8.10 (br. s., 1H), 7.73-7.67 (m, 1H), 7.17 (m,1H), 7.11-7.05 (m, 2H), 6.97-6.89 (m, 2H), 6.01 (m, 1H), 5.65 (dd,J=6.1, 15.5 Hz, 1H), 4.18 (m, 1H), 4.13-4.01 (m, 2H), 3.75 (m, 2H), 3.60(m, 1H), 3.40 (m, 1H), 3.25 (m, 1H), 2.92 (m, 1H), 2.83-2.72 (m, 2H),2.53 (m, 2H), 2.35-1.56 (m, 16H), 1.44 (m, 1H), 1.15-1.03 (m, 3H); m/z(ESI, +ve ion) 639 (M+H)⁺.

Example 57(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-CYCLOBUTYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the third (slower) elutingisomer using Combi-Flash® separation as described in Example 55. ¹H NMR(400 MHz, CD₂Cl₂) δ ppm 8.22 (br. s., 1H), 7.67 (d, J=8.4 Hz, 1H), 7.58(m, 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.94-6.88(m, 2H), 5.78-5.61 (m, 2H), 4.26-4.18 (m, 2H), 4.07 (d, J=11.0 Hz, 1H),4.02-3.87 (m, 2H), 3.72 (m, 1H), 3.36 (m, 1H), 3.14 (m, 1H), 3.00-1.60(m, 21H), 1.55-1.40 (m, 1H), 1.10 (d, J=6.7 Hz, 3H); m/z (ESI, +ve ion)639 (M+H)⁺.

Example 58(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (2S)—N,N-BIS(4-METHOXYBENZYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDEAND (2R)—N,N-BIS(4-METHOXYBENZYL)-2-METHYL-4-PENTENE-1-SULFONAMIDE

The title compound was prepared from Intermediate EE12 andpent-4-en-2-yl 4-methylbenzenesulfonate following a similar proceduredescribed in Example 26, Step 1.

STEP 2:(2S,3R)-1-CYCLOPROPYL-N,N-BIS(4-METHOXYBENZYL)-3-METHYL-5-HEXENE-2-SULFONAMIDEAND(2R,3S)-1-CYCLOPROPYL-N,N-BIS(4-METHOXYBENZYL)-3-METHYL-5-HEXENE-2-SULFONAMIDEAND(2R,3R)-1-CYCLOPROPYL-N,N-BIS(4-METHOXYBENZYL)-3-METHYL-5-HEXENE-2-SULFONAMIDEAND(2S,3S)-1-CYCLOPROPYL-N,N-BIS(4-METHOXYBENZYL)-3-METHYL-5-HEXENE-2-SULFONAMIDE

To a solution of(2S)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(2R)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (600 mg,1.49 mmol) in THF was added butyllithium solution, 2.5 N in hexanes(0.624 mL, 1.561 mmol) at −78° C. under N₂. After the reaction wasstirred at −78° C. for 15 min, a solution of (bromomethyl)-cyclopropane(0.288 mL, 2.97 mmol) in THF (1 mL) was added. The reaction mixture wasstirred at −78° C. for 1 h and then allowed to warm to ambienttemperature. The mixture was quenched with H₂O and extracted with EtOAc.The organic layer was washed with H₂O and dried (Na₂SO₄). Solvent wasevaporated, and the resulting residue was purified by chromatography(SiO₂ gel, 10 to 50%, EtOAc/Hexanes) to afford the title compounds as acolorless liquid.

STEP 3: (120637-9):(2S,3S)-1-CYCLOPROPYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2S,3R)-1-CYCLOPROPYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND (2R,3S)-1-CYCLOPROPYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND (2R,3R)-1-CYCLOPROPYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE

A mixture of(2S,3R)-1-Cyclopropyl-N,N-bis(4-methoxybenzyl)-3-methyl-5-hexene-2-sulfonamide,(2R,3S)-1-cyclopropyl-N,N-bis(4-methoxybenzyl)-3-methyl-5-hexene-2-sulfonamide,(2R,3R)-1-cyclopropyl-N,N-bis(4-methoxybenzyl)-3-methyl-5-hexene-2-sulfonamide,and(2S,3S)-1-cyclopropyl-N,N-bis(4-methoxybenzyl)-3-methyl-5-hexene-2-sulfonamide(510 mg, 1.11 mmol) was treated with anisole (1.81 g, 16.7 mmol) in TFA(3.81 g, 33.4 mmol). The mixture was stirred, heated at 40° C. for 18 h,and then concentrated. The resulting residue was purified bychromatography (SiO₂ gel, hexane/EtOAc, 9:1 to 1:1) to afford the titlecompounds as a light brown oil.

STEP 4:(3S)-6′-CHLORO-N-(((2R,3S)-1-CYCLOPROPYL-3-METHYL-5-HEXEN-2-YL)SULFONYL)-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-N-(((2R,3R)-1-CYCLOPROPYL-3-METHYL-5-HEXEN-2-YL)SULFONYL)-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-N-4(2S,3S)-1-CYCLOPROPYL-3-METHYL-5-HEXEN-2-YL)SULFONYL)-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-N-(((2S,3R)-1-CYCLOPROPYL-3-METHYL-5-HEXEN-2-YL)SULFONYL)-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

A mixture of (2S, 3S)-1-cyclopropyl-3-methylhex-5-ene-2-sulfonamide,(2S, 3R)-1-cyclopropyl-3-methylhex-5-ene-2-sulfonamide, (2R,3S)-1-cyclopropyl-3-methylhex-5-ene-2-sulfonamide, and (2R,3R)-1-cyclopropyl-3-methylhex-5-ene-2-sulfonamide (160 mg, 0.74 mmol)was added to(S)-6′-chloro-5-(((1R,2S)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A; 250 mg, 0.49 mmol),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (141 mg,0.74 mmol), DMAP (90 mg, 0.74 mmol) and Et₃N (0.20 mL, 1.47 mmol) in DCM(1 mL). The reaction mixture was stirred at ambient temperature for 3days. The mixture was then diluted with DCM and H₂O was added. Theorganic layer was dried (MgSO₄) and concentrated. The resulting residuewas chromatographed (SiO₂ gel, 1:0 to 1:1, hexane/EtOAc+0.5% HOAc) toafford the title compound.

STEP 5: (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A RBF was charged with the above mixture of(3S)-6′-chloro-n-(((2R,3S)-1-cyclopropyl-3-methyl-5-hexen-2-yl)sulfonyl)-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexane-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide,(3S)-6′-chloro-n-(((2R,3R)-1-cyclopropyl-3-methyl-5-hexen-2-yl)sulfonyl)-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide,(3S)-6′-chloro-n-(((2S,3S)-1-cyclopropyl-3-methyl-5-hexen-2-yl)sulfonyl)-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamideand(3S)-6′-chloro-n-(((2S,3R)-1-cyclopropyl-3-methyl-5-hexen-2-yl)sulfonyl)-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide(210 mg, 0.30 mmol) in DCE (100 mL). After bubbling into the flask withargon for 15 min, to the homogeneous solution was added Hoveyda-GrubbsII (65 mg, 0.35 mmol) and the contents of the flask was stirred at 50°C. for 18 h. The reaction mixture was cooled and air was introduced bybubbling into the flask for 2 min. Solvent was evaporated, and the cruderesidue was purified by preparative reverse-phase HPLC (Gemini™ Prep C₁₈5 μm column; gradient elution of 25% to 75% MeCN in H₂O, where bothsolvents contain 0.1% TFA, 30 min method) to afford the title compoundas the first eluting isomer. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.08 (s, 1H),7.70 (d, J=8.3 Hz, 1H), 7.19 (dd, J=2.2, 8.6 Hz, 1H), 7.10 (d, J=2.0 Hz,1H), 6.99 (br s, 1H), 6.97-6.89 (m, 2H), 5.97-5.88 (m, 1H), 5.72 (dd,J=8.1, 15.2 Hz, 1H), 4.30-4.22 (m, 2H), 4.10 (s, 2H), 3.82 (d, J=14.9Hz, 1H), 3.69 (d, J=14.2 Hz, 1H), 3.26 (d, J=14.2 Hz, 1H), 3.06 (br s,1H), 2.85-2.71 (m, 2H), 2.53-2.39 (m, 1H), 2.33 (quin, J=8.7 Hz, 1H),2.27-2.12 (m, 2H), 2.09-1.86 (m, 5H), 1.86-1.77 (m, 3H), 1.75-1.61 (m,1H), 1.50-1.31 (m, 2H), 1.23-1.12 (m, 1H), 1.05 (d, J=6.8 Hz, 3H), 0.63(d, J=7.8 Hz, 2H), 0.35-0.25 (m, 1H), 0.13-0.06 (m, 1H). m/z (ESI, +veion) 639.2 (M+H)⁺.

Example 59 (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was obtained as a single isomer (second eluting peak)from the preparative reverse-phase HPLC separation in Example 58. ¹H NMR(500 MHz, CDCl₃) δ ppm 8.17 (br s, 1H), 7.79 (d, J=8.6 Hz, 1H),7.24-7.15 (m, 2H), 7.10 (s, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.67 (br s,1H), 6.03 (m, 1H), 5.66 (dd, J=6.4, 15.2 Hz, 1H), 4.32-4.02 (m, 3H),3.91-3.82 (m, 1H), 3.80-3.72 (m, 1H), 3.63 (m, 1H), 3.42-3.38 (m, 1H),3.30-3.20 (m, 1H), 2.85-2.73 (m, 2H), 2.55-2.50 (m, 2H), 2.29 (br s,1H), 2.20-2.15 (m, 1H), 2.10-1.60 (m, 9H), 1.55-1.43 (m, 2H), 1.42-1.35(m, 1H), 1.13 (d, J=7.1 Hz, 3H), 0.61 (d, J=8.6 Hz, 2H), 0.30-0.25 (m,1H), 0.15-0.11 (m, 1H). m/z (ESI, +ve ion) 639.2 (M+H)⁺.

Example 60 (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was obtained as a single isomer (third eluting peak)from the preparative reverse-phase HPLC separation in Example 58. ¹H NMR(500 MHz, CDCl₃) δ ppm 8.19 (br s, 1H), 7.72 (br s, 1H), 7.65 (d, J=8.6Hz, 1H), 7.17 (dd, J=2.2, 8.6 Hz, 1H), 7.11 (s, 1H), 6.92 (s, 2H), 5.72(dd, J=3.7, 15.7 Hz, 1H), 5.55 (br s, 1H), 4.27-4.20 (m, 2H), 4.20-4.14(m, 1H), 4.14-4.10 (m, 1H), 4.00-3.88 (m, 1H), 3.79 (d, J=12.7 Hz, 1H),3.30 (d, J=13.9 Hz, 1H), 3.10 (d, J=15.7 Hz, 1H), 2.80-2.70 (m, 2H),2.58-2.39 (m, 2H), 2.35-2.06 (m, 3H), 2.05-1.93 (m, 3H), 1.90-1.62 (m,4H), 1.70-1.64 (m, 1H), 1.51-1.30 (m, 2H), 1.24-1.15 (m, 1H), 1.11 (d,J=5.1 Hz, 3H), 0.71-0.50 (m, 2H), 0.31 (qd, J=4.8, 9.4 Hz, 1H), 0.15(qd, J=4.6, 9.3 Hz, 1H). m/z (ESI, +ve ion) 639.2 (M+H)⁺.

Example 61 (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was obtained as a single isomer (fourth eluting peak)from the preparative reverse-phase HPLC separation in Example 58. ¹H NMR(500 MHz, CDCl₃) δ ppm 7.72 (d, J=11 Hz, 1H), 7.50-7.44 (m, 1H),7.21-7.16 (m, 1H), 7.15-7.05 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 5.75 (m,1H), 5.54 (m, 1H), 4.42 (br s, 1H), 4.16-4.01 (m, 2H), 3.90 (d, J=15.2Hz, 1H), 3.80-3.60 (m, 2H), 3.25-3.04 (m, 2H), 2.87-2.70 (m, 2H),2.27-2.10 (m, 3H), 2.09-1.52 (m, 9H), 1.53-1.39 (m, 3H), 1.21-1.14 (m,1H), 1.08 (d, J=6.8 Hz, 3H), 0.71-0.50 (m, 2H), 0.31-0.20 (m, 1H),0.16-0.10 (m, 1H). m/z (ESI, +ve ion) 639.2 (M+H)⁺.

Example 62(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a 15-mL RBF was added sodium hydride, 60% dispersion in mineral oil(8.3 mg, 0.203 mmol) and(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (13 mg, 0.020 mmol) in THF (1 mL) at 0° C. The reactionmixture was stirred at 0° C. for 30 min and MeI (6.32 μl, 0.102 mmol)was added. The mixture was stirred and allowed to warm from 0° C. toambient temperature for 18 h, quenched with aqueous 1.0 N HCl, andextracted with EtOAc. The organic layer was dried (MgSO₄) andconcentrated. The residue was chromatographed (SiO₂ gel, 10-40%,EtOAc+10% methanol/hexane) to afford the title compound as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.08 (s, 1H), 7.70 (d, J=8.4 Hz,1H), 7.19 (dd, J=2.2, 8.5 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.96-6.90 (m,3H), 5.90-5.70 (m, 1H), 5.53 (dd, J=9.8, 14.5 Hz, 1H), 4.32 (dd, J=4.7,7.0 Hz, 1H), 4.10 (s, 2H), 3.83 (d, J=15.1 Hz, 1H), 3.74-3.66 (m, 2H),3.28-3.20 (m, 4H), 3.02 (dd, J=10.2, 15.3 Hz, 1H), 2.84-2.71 (m, 2H),2.51-2.43 (m, 1H), 2.39-2.18 (m, 3H), 2.14-1.92 (m, 4H), 1.90-1.75 (m,3H), 1.65-1.50 (m, 2H), 1.47-1.35 (m, 2H), 1.25-1.18 (m, 1H), 1.05 (d,J=6.8 Hz, 3H), 0.67-0.58 (m, 2H), 0.34-0.26 (m, 1H), 0.12-0.04 (m, 1H).m/z (ESI, +ve ion) 653.2 (M+H)⁺.

Example 63(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (2R,3R)-1-CYCLOBUTYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2S,3S)-1-CYCLOBUTYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2R,3S)-1-CYCLOBUTYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE AND(2S,3R)-1-CYCLOBUTYL-3-METHYLHEX-5-ENE-2-SULFONAMIDE

The title compound was prepared from(R)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(S)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(bromomethyl)cyclobutane by a procedure analogous to that described inExample 58, Steps 2 through 3.

STEP 2:(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12) and a mixture of(2R,3R)-1-cyclobutyl-3-methylhex-5-ene-2-sulfonamide,(2S,3S)-1-cyclobutyl-3-methylhex-5-ene-2-sulfonamide,(2R,3S)-1-cyclobutyl-3-methylhex-5-ene-2-sulfonamide, and(2S,3R)-1-cyclobutyl-3-methylhex-5-ene-2-sulfonamide (from Step 1) by aprocedure analogous to that described in Example 58, Steps 4 through 5.The residue was purified by preparative reverse-phase HPLC (Gemini™ PrepC₁₈ 5 μm column; gradient elution of 50% to 95% MeCN in H₂O, where bothsolvents contain 0.1% TFA, 30 min method) to provide one of the titlecompounds as the faster eluting isomer as a white foam. ¹H NMR (400 MHz,CD₂Cl₂) δ ppm 8.09 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.2, 8.5Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95-6.88 (m, 3H), 5.82-5.68 (m, 2H),4.19 (dd, J=4.1, 7.6 Hz, 1H), 4.08 (s, 2H), 3.93 (dd, J=2.5, 8.8 Hz,1H), 3.82 (m, 1H), 3.68 (d, J=14.3 Hz, 1H), 3.25 (d, J=14.3 Hz, 1H),3.05 (dd, J=9.4, 15.3 Hz, 1H), 2.83-2.68 (m, 3H), 2.41 (m, 1H), 2.31 (m,1H), 2.23-2.10 (m, 4H), 2.08-2.00 (m, 2H), 1.98-1.52 (m, 12H), 1.48-1.33(m, 1H), 1.01 (d, J=6.8 Hz, 3H); m/z (ESI, +ve ion) 653 (M+H)⁺.

Example 64(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOBUTYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as the second (slower) elutingisomer using preparative reverse-phase HPLC as described in Example 63.¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.05 (s, J=7.4, 7.4 Hz, 1H), 7.70 (d,J=8.4 Hz, 1H), 7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.14-7.08 (m, 2H),6.97-6.90 (m, 1H), 6.65 (m, 1H), 6.00 (m, 1H), 5.65 (dd, J=6.1, 15.1 Hz,1H), 4.19-4.02 (m, 3H), 3.76 (m, 1H), 3.61 (m, 1H), 3.52 (m, 1H), 3.43(d, J=14.5 Hz, 1H), 3.24 (m, 1H), 2.83-2.73 (m, 2H), 2.73-2.62 (m, 1H),2.55-2.46 (m, 1H), 2.35-2.10 (m, 5H), 2.08-1.96 (m, 3H), 1.95-1.81 (m,6H), 1.79-1.65 (m, 5H), 1.47 (d, J=15.3 Hz, 1H), 1.16-1.07 (m, 3H); m/z(ESI, +ve ion) 653 (M+H)⁺.

Example 65(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (4R,5R)-2,5-DIMETHYLOCT-7-ENE-4-SULFONAMIDE AND(4S,5S)-2,5-DIMETHYLOCT-7-ENE-4-SULFONAMIDE AND(4R,5S)-2,5-DIMETHYLOCT-7-ENE-4-SULFONAMIDE AND(4S,5R)-2,5-DIMETHYLOCT-7-ENE-4-SULFONAMIDE

The title compound was prepared from(R)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and(S)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (Example58, Step 1) and isobutyl bromide by a procedure analogous to thatdescribed in Example 58, Steps 2 through 3.

STEP 2:(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared from(S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12) and a mixture of(4R,5R)-2,5-dimethyloct-7-ene-4-sulfonamide,(4S,5S)-2,5-dimethyloct-7-ene-4-sulfonamide,(4R,5S)-2,5-dimethyloct-7-ene-4-sulfonamide, and(4S,5R)-2,5-dimethyloct-7-ene-4-sulfonamide (from Step 1) by a procedureanalogous to that described in Example 58, Steps 4 through 5. Theresidue was purified by preparative reverse-phase HPLC (Gemini™ Prep C₁₈5 μm column; gradient elution of 50% to 95% MeCN in H₂O, where bothsolvents contain 0.1% TFA, 30 min method) to provide one of the titlecompounds as the faster eluting isomer as a white foam. ¹H NMR (400 MHz,CD₂Cl₂) δ ppm 8.09 (s, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.17 (dd, J=2.3, 8.6Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96-6.90 (m, 3H), 5.86-5.78 (m, 1H),5.76-5.68 (m, 1H), 4.22-4.12 (m, 2H), 4.09 (s, 2H), 3.84 (m, 1H), 3.69(d, J=14.3 Hz, 1H), 3.26 (d, J=14.3 Hz, 1H), 3.05 (dd, J=9.4, 15.3 Hz,1H), 2.83-2.70 (m, 2H), 2.46-2.28 (m, 2H), 2.18-1.91 (m, 8H), 1.88-1.76(m, 3H), 1.76-1.66 (m, 1H), 1.46-1.31 (m, 2H), 1.04-0.98 (m, 9H); m/z(ESI, +ve ion) 641 (M+H)+.

Example 66(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as a single isomer (second,slower, eluting peak) using preparative reverse-phase HPLC as describedin Example 65. ¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.11-8.04 (m, 1H), 7.71(d, J=8.4 Hz, 1H), 7.18 (dd, J=2.2, 8.4 Hz, 1H), 7.15-7.09 (m, 2H),6.97-6.90 (m, 1H), 6.65 (m, 1H), 6.04 (m, 1H), 5.65 (dd, J=6.4, 15.4 Hz,1H), 4.17 (m, 1H), 4.07 (q, J=12.2 Hz, 2H), 3.81-3.69 (m, 2H), 3.63 (m,1H), 3.43 (d, J=14.3 Hz, 1H), 3.24 (m, 1H), 2.82-2.71 (m, 2H), 2.56-2.48(m, 1H), 2.29-2.18 (m, 1H), 2.07-1.82 (m, 9H), 1.81-1.65 (m, 2H),1.51-1.38 (m, 3H), 1.09 (d, J=7.0 Hz, 3H), 1.05-0.93 (m, 6H); m/z (ESI,+ve ion) 641 (M+H)⁺.

Example 67(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-METHYLPROPYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

One of the title compounds was obtained as single isomer (third elutingpeak) using preparative reverse-phase HPLC as described in Example 65.¹H NMR (400 MHz, CD₂Cl₂) δ ppm 8.17 (br. s., 1H), 7.74 (d, J=8.6 Hz,1H), 7.66 (d, J=8.8 Hz, 1H), 7.16 (s, 1H), 7.10 (d, J=3.1 Hz, 1H), 6.98(d, J=8.2 Hz, 1H), 6.91 (s, 1H), 5.73-5.66 (m, 2H), 4.43 (br. s., 1H),4.23 (s, 2H), 4.15-4.04 (m, 4H), 3.90 (d, J=15.1 Hz, 1H), 3.70 (d,J=14.3 Hz, 1H), 3.33 (d, J=12.9 Hz, 1H), 3.22 (d, J=14.5 Hz, 1H), 3.11(d, J=15.1 Hz, 2H), 2.75 (d, J=5.7 Hz, 3H), 2.51 (d, J=6.5 Hz, 1H),2.07-1.88 (m, 10H), 1.06-1.00 (m, 9H) m/z (ESI, +ve ion) 641 (M+H)⁺.

Example 68(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

STEP 1: (4R,5S)—N,N-BIS(4-METHOXYBENZYL)-5-METHYL-7-OCTENE-4-SULFONAMIDEAND (4S,5S)—N,N-BIS(4-METHOXYBENZYL)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND(4S,5R)—N,N-BIS(4-METHOXYBENZYL)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND(4R,5R)—N,N-BIS(4-METHOXYBENZYL)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND

The title compounds were prepared from (2S)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and (2R)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (from Example58, Step 1) with 1-bromopropane, following a similar procedure describedin Example 58, Step 2.

STEP 2: (4R,5S)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND(4R,5R)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND(4S,5S)-5-METHYL-7-OCTENE-4-SULFONAMIDE AND(4S,5R)-5-METHYL-7-OCTENE-4-SULFONAMIDE

The title compounds was prepared from a mixture of(4R,5S)-N,N-bis(4-methoxybenzyl)-5-methyl-7-octene-4-sulfonamide,(4S,5S)-N,N-bis(4-methoxybenzyl)-5-methyl-7-octene-4-sulfonamide,(4S,5R)-N,N-bis(4-methoxybenzyl)-5-methyl-7-octene-4-sulfonamide and(4R,5R)-N,N-bis(4-methoxybenzyl)-5-methyl-7-octene-4-sulfonamide by asimilar procedure described in Example 58, Step 3.

STEP 3:(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E,5R,6S)-1-HYDROXY-5-METHYL-6-SULFAMOYL-2-NONEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E,5R,6R)-1-HYDROXY-5-METHYL-6-SULFAMOYL-2-NONEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E,5S,6S)-1-HYDROXY-5-METHYL-6-SULFAMOYL-2-NONEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID AND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E,5S,6R)-1-HYDROXY-5-METHYL-6-SULFAMOYL-2-NONEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLICACID

A mixture of(S)-6′-chloro-5-(((1R,2S)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A, 120 mg, 0.24 mmol), a mixture of(4R,5S)-5-methyl-7-octene-4-sulfonamide,(4R,5R)-5-methyl-7-octene-4-sulfonamide,(4S,5S)-5-methyl-7-octene-4-sulfonamide, and(4S,5R)-5-methyl-7-octene-4-sulfonamide (from Step 2,121 mg; 0.59 mmol)in 1,2 dichloroethane (2 mL) was introduced to argon by bubbling argoninto the reaction flask for 20 min. Hoveyda-Grubbs II was then added.The mixture was stirred at ambient temperature for 2 h, concentrated,and the residue was chromatographed (SiO₂ gel, 9:1 to 0:1, hexane/0.3%AcOH+EtOAc) to afford a grey oil as the title compounds.

STEP 4:(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A mixture of(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E,5R,6S)-1-hydroxy-5-methyl-6-sulfamoyl-2-nonen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxylicacid,(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E,5R,6R)-1-hydroxy-5-methyl-6-sulfamoyl-2-nonen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxylicacid,(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E,5S,6S)-1-hydroxy-5-methyl-6-sulfamoyl-2-nonen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxylicacid, and(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E,5S,6R)-1-hydroxy-5-methyl-6-sulfamoyl-2-nonen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxylicacid (110 mg, 0.170 mmol) was added to1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, HCl (98 mg, 0.51 mmol),and DMAP (41.7 mg, 0.341 mmol) in DCM (80 mL) at 0° C. The reactionmixture was then allowed to warm to ambient temperature and stirred for18 h. Solvent was evaporated, and the crude residue was chromatographed(Sift gel, 9:1 to 0:1, hexane/EtOAc+0.3% AcOH) to afford a grey oil (65mg). Further purification of the oil by preparative reverse-phase HPLC(Gemini™ Prep C18 5 μm column; gradient elution of 25% to 75% MeCN inH₂O, where both solvents contain 0.1% TFA, 30 min method) afforded thefirst eluting isomer as the title compound as a white solid. ¹H NMR (500MHz, CDCl₃) δ ppm 8.07 (s, 1H), 7.70 (d, J=8.3 Hz, 1H), 7.19 (dd, J=2.0,8.6 Hz, 1H), 7.10 (s, 1H), 6.98-6.88 (m, 3H), 5.93-5.85 (m, 1H), 5.72(dd, J=7.9, 15.3 Hz, 1H), 4.26 (dd, J=4.0, 8.2 Hz, 1H), 4.16-4.06 (m,3H), 3.83 (d, J=14.9 Hz, 1H), 3.70 (d, J=14.4 Hz, 1H), 3.24 (d, J=14.2Hz, 1H), 3.03 (dd, J=9.8, 15.2 Hz, 1H), 2.83-2.72 (m, 2H), 2.45 (dd,J=3.7, 8.6 Hz, 1H), 2.32 (t, J=9.0 Hz, 1H), 2.16-1.94 (m, 7H), 1.91-1.74(m, 5H), 1.74-1.62 (m, 2H), 1.40 (t, J=12.8 Hz, 1H), 1.10-0.98 (m, 6H).m/z (ESI, +ve ion) 627.2 (M+H)⁺.

Example 69(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compounds were obtained as the second eluting isomer from thepreparative reverse-phase HPLC separation in Example 68. ¹H NMR (500MHz, CDCl₃) δ ppm 7.71 (d, J=8.3 Hz, 1H), 7.11-7.08 (m, 1H), 7.00-6.87(m, 2H), 6.84 (br s, 1H), 6.14 (br s, 1H), 5.81 (br s, 1H), 4.23 (br s,1H), 4.19-4.04 (m, 3H), 3.69 (d, J=14.4 Hz, 2H), 3.58 (br s, 1H),3.40-3.18 (br, 2H), 3.15-3.00 (br s, 1H), 2.85-2.70 (m, 2H), 2.44 (br s,1H), 2.35 (br s, 2H), 2.18 (br s, 1H), 2.10-1.90 (m, 3H), 1.80-1.63 (m,6H), 1.63-1.54 (m, 1H), 1.48 (br s, 1H), 1.11 (br s, 3H), 1.05-0.99 (m,3H). m/z (ESI, +ve ion) 627.2 (M+H)⁺.

Example 70(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO [14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-PROPYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compounds were obtained as the third eluting isomer from thepreparative reverse-phase HPLC separation in Example 68. ¹H NMR (500MHz, CDCl₃) δ ppm 8.32 (br s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.23-7.16 (m,2H), 7.10 (s, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.66 (br s, 1H), 6.08 (br s,1H), 5.66 (dd, J=6.2, 15.3 Hz, 1H), 4.21 (br s, 1H), 4.15-4.00 (m, 2H),3.83-3.60 (m, 3H), 3.42 (d, J=14.7 Hz, 1H), 3.25 (br s, 1H), 2.85-2.74(m, 2H), 2.60-2.47 (m, 2H), 2.38-2.18 (m, 2H), 2.15-2.00 (m, 3H),2.00-1.58 (m, 9H), 1.46 (br s, 1H), 1.17-1.08 (m, 3H), 1.07-0.96 (m,3H). m/z (ESI, +ve ion) 627.2 (M+H)⁺.

Example 71(1S,3′R,6′R,7′S,8′E,11′S,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO [14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′, 13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

Step 1: (4S,5R)—N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDEAND (4R,5R)—N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND(4S,5S)—N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND(4R,5S)—N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE

The title compounds were prepared from (2S)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and (2R)-N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (from Example58, Step 1) with 1-bromobutane following a similar procedure describedin Example 58, Step 2.

Step 2: (4S,5R)-4-METHYL-1-NONENE-5-SULFONAMIDE AND(4S,5R)-4-METHYL-1-NONENE-5-SULFONAMIDE AND(4S,5R)-4-METHYL-1-NONENE-5-SULFONAMIDE AND(4S,5R)-4-METHYL-1-NONENE-5-SULFONAMIDE

The title compounds were prepared from a mixture of(4S,5R)-N,N-bis(4-methoxybenzyl)-4-methyl-1-nonene-5-sulfonamide,(4R,5R)-N,N-bis(4-methoxybenzyl)-4-methyl-1-nonene-5-sulfonamide,(4S,5S)-N,N-bis(4-methoxybenzyl)-4-methyl-1-nonene-5-sulfonamide,(4R,5S)-N,N-bis(4-methoxybenzyl)-4-methyl-1-nonene-5-sulfonamide by asimilar procedure described in Example 58, Step 3.

Step 3:(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3S)-3-(2-PROPEN-1-YL)-2-HEPTANYL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3S)-3-(2-PROPEN-1-YL)-2-HEPTANYL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3S)-3-(2-PROPEN-1-YL)-2-HEPTANYL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDEAND(3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3S)-3-(2-PROPEN-1-YL)-2-HEPTANYL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were prepared from a mixture of(4S,5R)-4-methyl-1-nonene-5-sulfonamide,(4R,5R)-4-methyl-1-nonene-5-sulfonamide,(4S,5S)-4-methyl-1-nonene-5-sulfonamide and(4R,5R)-4-methyl-1-nonene-5-sulfonamide (Step 2) and(S)-6′-chloro-5-(((1R,2S)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylicacid (Intermediate AA12A) using a similar procedure described in Example58, Step 4.

Step 4:(1S,3′R,6′R,7′S,8′E,11′S,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compounds were prepared from the above mixture(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((2R,3S)-3-(2-propen-1-yl)-2-heptanyl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamideand(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((2R,3S)-3-(2-propen-1-yl)-2-heptanyl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamideand(3S)-6′-chloro-5-(((1R,2R)-2-((1s,2e)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((R,3S)-3-(2-propen-1-yl)-2-heptanyl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamideand(3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((2R,3S)-3-(2-propen-1-yl)-2-heptanyl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamideusing a similar procedure described in Example 58, Step 5. ¹H NMR (500MHz, CDCl₃) δ ppm 8.07 (br s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.19 (d,J=8.3 Hz, 1H), 7.11-7.09 (m, 1H), 6.99-6.87 (m, 3H), 5.93-5.86 (m, 1H),5.72 (dd, J=8.2, 15.3 Hz, 1H), 4.26 (dd, J=3.9, 8.3 Hz, 1H), 4.13-4.07(m, 3H), 3.83 (d, J=15.4 Hz, 1H), 3.70 (d, J=14.4 Hz, 1H), 3.24 (d,J=14.2 Hz, 1H), 3.03 (dd, J=9.5, 15.2 Hz, 1H), 2.83-2.72 (m, 2H),2.51-2.39 (m, 1H), 2.32 (t, J=9.4 Hz, 1H), 2.20-1.64 (m, 6H), 1.63-1.63(m, 7H), 1.63-1.53 (m, 1H), 1.50-1.33 (m, 3H), 1.06 (d, J=6.8 Hz, 3H),0.97 (t, J=7.3 Hz, 3H). m/z (ESI, +ve ion) 641.2 (M+H)⁺.

Example 72(1S,3′R,6′R,7′S,8′Z,11′R,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′R,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′S,12′R)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′Z,11′S,12′S)-12′-BUTYL-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compounds were obtained as single isomer (second eluting peak)from the preparative reverse-phase HPLC separation in Example 71. ¹H NMR(500 MHz, CDCl₃) δ=9.92 (br s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.47 (d,J=8.1 Hz, 1H), 7.20-7.12 (m, 1H), 7.12-7.06 (m, 2H), 6.98 (d, J=8.3 Hz,1H), 5.75 (br s, 1H), 5.53 (td, J=2.4, 2.4, 11.8 Hz, 1H), 4.41 (br s,1H), 4.13-4.01 (m, 2H), 3.88 (d, J=15.4 Hz, 1H), 3.64 (d, J=14.4 Hz,1H), 3.57 (br s, 1H), 3.19-2.99 (m, 2H), 2.83-2.71 (m, 2H), 2.29-2.15(m, 2H), 2.13-2.02 (m, 2H), 2.02-1.87 (m, 4H), 1.77-1.63 (m, 7H),1.62-1.50 (m, 1H), 1.49-1.31 (m, 3H), 1.12-1.03 (m, 3H), 1.02-0.88 (m,3H). m/z (ESI, +ve ion) 641.2 (M+H)⁺.

Example 73(1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-BUTOXY-6-CHLORO-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

To a solution of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2; 60 mg, 0.1 mmol) in THF (2 mL) was added 60%sodium hydride in mineral oil (20 mg, 0.5 mmol) at 0° C. The mixture wasstirred at 0° C. for 30 min. 1-Iodobutane (92 mg, 54 uL, 0.5 mmol) wasadded and the mixture thus obtained was stirred at 0° C. for 4 h andHPLC-MS analysis indicated completion of the reaction. The reaction wasquenched with sat. NH₄Cl and extracted with EtOAc. The combined organiclayers were washed with brine and dried over MgSO₄. The solvent wasevaporated under reduced pressure and the residue was purified by flashchromatography on SiO₂ gel (24 g, HP SiO₂, Teledyne ISCO) eluting with15% to 65% EtOAc in hexane to provide(1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-butoxy-6-chloro-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide as a white solid (15 mg, 23% yield). ¹H NMR (500 MHz,CDCl₃) δ ppm 8.13 (s, 1H), 7.70 (d, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.2Hz, 1H), 6.92-6.95 (m, 2H), 6.89 (s, 1H), 5.80 (ddd, J=15.1, 9.6, 3.2Hz, 1H), 5.54 (dd, J=15.1, 9.6 Hz, 1H), 4.31-4.36 (m, 1H), 4.07-4.11 (m,2H), 3.84 (d, J=15.4 Hz, 1H), 3.68-3.74 (m, 2H), 3.39 (dt, J=9.3, 6.7Hz, 1H), 3.22-3.27 (m, 2H), 3.00 (dd, J=15.2, 10.3 Hz, 1H), 2.75-2.83(m, 2H), 2.41-2.47 (m, 1H), 2.30-2.36 (m, 1H), 2.14-2.21 (m, 1H),1.94-2.12 (m, 2H), 1.73-1.88 (m, 4H), 1.58-1.62 (m, 1H), 1.48-1.55 (m,4H), 1.20-1.42 (m, 4H), 1.05 (d, J=10.0 Hz, 3H), 0.92 (t, J=10.0 Hz,3H); MS m/z (ESI, +ve ion) 656.0 (M+H)⁺.

Example 74(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE-13′,13′-DIOXIDE

To a solution of(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2, 100 mg, 0.167 mmol) in DMF (3.34 mL) cooledto 0° C. was added sodium hydride, 60% dispersion in mineral oil (66.8mg, 1.67 mmol). The reaction mixture was stirred at 0° C. for 15 min,and then 2-bromoethyl methyl ether (Alfa Aesar, 0.078 mL, 0.834 mmol)was added. The reaction mixture was stirred at ambient is temperature.After 48 h, the mixture was quenched with aq. NH₄Cl and diluted withwater, then extracted with EtOAc. The organic layer was dried over MgSO₄and concentrated. The crude material was purified by chromatographythrough a Redi-Sep pre-packed silica gel column (12 g), eluting with10-40% EtOAc (containing 0.3% AcOH)/heptanes to provide the titlecompound (61 mg, 0.093 mmol, 55.6% yield). ¹H NMR (500 MHz, CD₂Cl₂) δ8.02 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.2, 8.6 Hz, 1H), 7.09(d, J=2.2 Hz, 1H), 6.91 (s, 2H), 6.86 (s, 1H), 5.79 (ddd, J=3.3, 9.6,15.2 Hz, 1H), 5.54 (dd, J=9.8, 14.4 Hz, 1H), 4.26 (ddd, J=1.0, 7.3, 14.4Hz, 1H), 4.12-4.04 (m, 2H), 3.82 (d, J=15.2 Hz, 1H), 3.75 (dd, J=3.3,9.2 Hz, 1H), 3.69 (d, J=14.7 Hz, 1H), 3.53-3.49 (m, 1H), 3.48-3.41 (m,2H), 3.39-3.34 (m, 1H), 3.32 (s, 3H), 3.25 (d, J=14.2 Hz, 1H), 3.02 (dd,J=10.3, 15.4 Hz, 1H), 2.83-2.70 (m, 2H), 2.49-2.41 (m, 1H), 2.36-2.28(m, 1H), 2.21-2.13 (m, 1H), 2.13-2.07 (m, 1H), 2.05 (d, J=13.7 Hz, 1H),1.99-1.91 (m, 3H), 1.89-1.77 (m, 3H), 1.71-1.59 (m, 1H), 1.44 (d, J=7.3Hz, 3H), 1.39 (t, J=13.1 Hz, 1H), 1.02 (d, J=6.8 Hz, 3H). MS (ESI, +veion) m/z 657.1 (M+H)⁺.

Example 75(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-(2-METHOXYETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 17) and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (400 MHz, CD₃OD) δ 7.75 (d, J=8.6 Hz, 1H), 7.19 (dd, J=2.2, 8.8 Hz,1H), 7.12 (d, J=2.2 Hz, 1H), 7.01 (dd, J=1.6, 8.2 Hz, 1H), 6.94 (d,J=8.2 Hz, 1H), 6.88 (d, J=1.6 Hz, 1H), 5.89 (ddd, J=6.1, 13.1, 21.5 Hz,1H), 5.60 (dd, J=9.0, 15.1 Hz, 1H), 4.09 (dd, J=12.7, 15.3 Hz, 2H),4.05-3.99 (m, 1H), 3.91-3.82 (m, 2H), 3.69 (d, J=14.5 Hz, 1H), 3.62-3.57(m, 1H), 3.53 (dd, J=4.1, 8.0 Hz, 2H), 3.50-3.45 (m, 1H), 3.38 (s, 3H),3.08 (dd, J=10.3, 15.2 Hz, 1H), 2.87-2.73 (m, 2H), 2.55-2.40 (m, 2H),2.40-2.26 (m, 2H), 2.11 (dd, J=7.4, 15.1 Hz, 2H), 1.98-1.65 (m, 10H),1.46 (t, J=10.9 Hz, 1H), 1.20 (t, J=7.4 Hz, 3H). m/z (ESI, +ve ion)657.2 (M+H)⁺.

Example 76(1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 11) and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (400 MHz, CD₃OD) δ 7.72 (d, J=8.6 Hz, 1H), 7.16 (dd, J=8.5, 2.2 Hz,1H), 7.10 (d, J=2.2 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.91 (d, J=8.2 Hz,1H), 6.85 (d, J=1.8 Hz, 1H), 5.80-5.87 (m, 1H), 5.58 (dd, J=15.5, 8.8Hz, 1H), 4.03-4.18 (m, 3H), 3.80-3.86 (m, 2H), 3.41-3.68 (m, 5H), 3.35(s, 3H), 3.06 (dd, J=15.3, 10.4 Hz, 1H), 2.70-2.81 (m, 2H), 2.24-2.53(m, 4H), 2.09 (d, J=13.7 Hz, 1H), 1.68-1.96 (m, 7H), 1.50 (d, J=7.0 Hz,3H), 1.39-1.47 (m, 2H). m/z (ESI, +ve ion) 643.2 (M+H)⁺.

Example 77(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,21)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 30) and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (500 MHz, CDCl₃) δ ppm 8.32 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.17(dd, J=2.2, 8.6 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.05-6.97 (m, 1H), 6.92(d, J=8.1 Hz, 1H), 5.94-5.85 (m, 1H), 5.51 (dd, J=7.0, 15.3 Hz, 1H),4.17-4.04 (m, 2H), 3.75-3.68 (m, 2H), 3.66-3.46 (m, 7H), 3.44-3.34 (m,4H), 2.80-2.72 (m 2H), 2.45-2.40 (m, 2H), 2.22-2.10 (m, 3H), 2.00-1.75(m, 6H), 1.75-1.55 (m, 2H), 1.53-1.48 (m, 1H), 1.18 (d, J=6.4 Hz, 3H).m/z (ESI, +ve ion) 643.2 (M+H)⁺.

Example 78(1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 31) and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (500 MHz, CDCl₃) δ ppm 8.22 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18(dd, J=2.1, 8.4 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.95-6.88 (m, 2H), 6.83(s, 1H), 5.88-5.80 (m, 1H), 5.56 (dd, J=9.0, 15.2 Hz, 1H), 4.36 (dd,J=4.8, 15.3 Hz, 1H), 4.14-4.04 (m, 2H), 3.85-3.78 (m, 2H), 3.71 (d,J=14.2 Hz, 1H), 3.60-3.48 (m, 3H), 3.45-3.34 (m, 4H), 3.23 (d, J=14.4Hz, 1H), 3.09-2.91 (m, 2H), 2.84-2.71 (m, 2H), 2.53-2.44 (m, 1H),2.36-2.23 (m, 2H), 2.13-1.92 (m, 5H), 1.89-1.74 (m, 3H), 1.69-1.54 (m,1H), 1.39 (t, J=12.6 Hz, 1H), 1.16 (d, J=6.6 Hz, 3H). m/z (ESI, +ve ion)643.2 (M+H)⁺.

Example 79(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-(2-METHOXYETHOXY)ETHOXY)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

A mixture of dry(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (15 mg, 0.025 mmol) (Examples 2) and sodium hydride, 60%dispersion in mineral oil (9.9 mg, 0.43 mmol) in DMF was stirred underargon for 10 min. 1-(2-bromoethoxy)-2-methoxyethane (22.6 mg, 0.124mmol) was added at ambient temperature. The reaction mixture was stirredfor 18 h, quenched with saturated aqueous NH₄Cl, and extracted withEtOAc (×3). The combined organic layers were dried (MgSO₄) andconcentrated. The residue was chromatographed (silica gel, 0-50%,EtOAc+0.3% HOAc/hexane) to afford the title compound as a white solid.¹H NMR (400 MHz, CDCl₃) δ ppm 8.09 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18(dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95-6.87 (m, 3H), 5.82(ddd, J=3.2, 9.4, 15.1 Hz, 1H), 5.54 (dd, J=9.1, 15.2 Hz, 1H), 4.35-4.24(m, 1H), 4.16-4.05 (m, 2H), 3.87-3.74 (m, 2H), 3.70-3.54 (m, 8H),3.45-3.44 (m, 1H), 3.40 (s, 3H), 3.23 (d, J=14.3 Hz, 1H), 2.99 (dd,J=10.2, 15.3 Hz, 1H), 2.84-2.71 (m, 2H), 2.53-2.42 (m, 1H), 2.38-2.24(m, 1H), 2.15-1.93 (m, 4H), 1.90-1.72 (m, 3H), 1.72-1.57 (m, 3H), 1.49(d, J=7.2 Hz, 3H), 1.42-1.35 (m, 1H), 1.05 (d, J=6.8 Hz, 3H). m/z (ESI,+ve ion) 701.2 (M+H)⁺.

Example 80(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-(2-(2-METHOXYETHOXY)ETHOXY)ETHOXY)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared from(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2) using a similar procedure described inExample 79 replacing 1-(2-bromoethoxy)-2-methoxyethane with1-bromo-2-[2-(2-methoxyethoxy)ethoxy]ethane. ¹H NMR (400 MHz, CDCl₃) δppm 7.97 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.19 (dd, J=2.2, 8.4 Hz, 1H),7.10 (d, J=2.0 Hz, 1H), 6.95-6.87 (m, 3H), 5.86-5.75 (m, 1H), 5.54 (dd,J=9.0, 15.1 Hz, 1H), 4.35-4.22 (m, 1H), 4.13-4.05 (m, 2H), 3.86-3.76 (m,2H), 3.72-3.63 (m, 7H), 3.63-3.54 (m, 5H), 3.44-3.42 (m, 1H), 3.40 (s,3H), 3.23 (d, J=14.3 Hz, 1H), 2.99 (dd, J=10.1, 15.4 Hz, 1H), 2.84-2.71(m, 2H), 2.48 (d, J=10.6 Hz, 1H), 2.38-2.26 (m, 1H), 2.21-1.90 (m, 4H),1.89-1.72 (m, 3H), 1.70-1.58 (m, 3H), 1.50 (d, J=7.2 Hz, 3H), 1.45-1.32(m, 1H), 1.06 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 745.2 (M+H)⁺.

Example 81(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(3,6,9,12-TETRAOXATRIDEC-1-YLOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24] TETRAEN]-15′-ONE13′,13′-DIOXIDE

The title compound was prepared from(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 2) using a similar procedure described inExample 79, replacing 1-(2-bromoethoxy)-2-methoxyethane with triethyleneglycol 2-bromoethyl methyl ether. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.02 (s,1H), 7.70 (d, J=8.6 Hz, 1H), 7.19 (dd, J=2.2, 8.4 Hz, 1H), 7.09 (d,J=2.2 Hz, 1H), 6.94-6.88 (m, 3H), 5.85-5.77 (m, 1H), 5.54 (dd, J=8.5,15.4 Hz, 1H), 4.31 (q, J=7.4 Hz, 1H), 4.09 (s, 2H), 3.85-3.75 (m, 2H),3.74-3.62 (m, 11H), 3.62-3.50 (m, 5H), 3.45-3.42 (m, 1H), 3.39 (s, 3H),3.23 (d, J=14.3 Hz, 1H), 3.03-2.95 (m, 1H), 2.83-2.72 (m, 2H), 2.52-2.43(m, 1H), 2.32 (t, J=9.5 Hz, 1H), 2.21-1.92 (m, 4H), 1.90-1.74 (m, 3H),1.68-1.56 (m, 3H), 1.50 (d, J=7.2 Hz, 3H), 1.40 (t, J=13.2 Hz, 1H), 1.06(d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 789.2 (M+H)⁺.

Example 82(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11R,12′R)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide or(1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 59), and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (400 MHz, CDCl₃) δ ppm 8.05 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18(dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.96-6.90 (m, 3H),5.91-5.83 (m, 1H), 5.56 (dd, J=9.0, 15.1 Hz, 1H), 4.30 (dd, J=4.5, 7.2Hz, 1H), 4.09 (s, 2H), 3.87-3.79 (m, 2H), 3.74-3.67 (m, 1H), 3.59-3.50(m, 3H), 3.48-3.41 (m, 1H), 3.41-3.35 (s, 3H), 3.23 (d, J=14.5 Hz, 1H),3.00 (dd, J=10.2, 15.3 Hz, 1H), 2.84-2.71 (m, 2H), 2.50 (d, J=10.6 Hz,1H), 2.37-2.16 (m, 3H), 2.13-1.92 (m, 4H), 1.91-1.73 (m, 3H), 1.71-1.52(m, 2H), 1.51-1.34 (m, 2H), 1.23-1.14 (m, 1H), 1.05 (d, J=6.8 Hz, 3H),0.67-0.58 (m, 2H), 0.29 (dd, J=4.4, 9.1 Hz, 1H), 0.08 (dd, J=4.1, 9.0Hz, 1H). m/z (ESI, +ve ion) 697.3 (M+H)⁺.

Example 83(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-12′-ETHYL-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0^(3,6).0^(19,24)]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE-13′, 13′-DIOXIDE

The title compound was prepared in an analogous manner to that describedin Example 74 using(1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-12′-ethyl-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^(3,6).0^(19,24)]pentacosa[8,16,18,24]tetraen]-15′-one13′,13′-dioxide (Example 24), and 1-bromo-2-methoxyethane (Aldrich). ¹HNMR (500 MHz, CD₂Cl₂) δ 8.08 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd,J=2.4, 8.6 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.91 (d, J=0.7 Hz, 2H), 6.87(s, 1H), 5.82 (ddd, J=3.4, 9.4, 15.3 Hz, 1H), 5.54 (dd, J=9.4, 15.8 Hz,1H), 4.11-4.05 (m, 2H), 4.00 (dd, J=2.8, 9.4 Hz, 1H), 3.82 (d, J=14.9Hz, 1H), 3.78 (dd, J=3.2, 9.0 Hz, 1H), 3.69 (d, J=14.4 Hz, 1H), 3.53(ddd, 5.4, 9.3 Hz, 1H), 3.45 (dt, 5.0 Hz, 2H), 3.38 (ddd, 5.9, 9.5 Hz,1H), 3.32 (s, 3H), 3.25 (d, J=14.4 Hz, 1H), 3.02 (dd, J=10.3, 15.4 Hz,1H), 2.84-2.70 (m, 2H), 2.45 (ddd, J=3.7, 10.0, 19.1 Hz, 1H), 2.37-2.29(m, 1H), 2.29-2.19 (m, 1H), 2.13-2.08 (m, 1H), 2.08-2.01 (m, 2H),2.00-1.89 (m, 3H), 1.89-1.77 (m, 4H), 1.66 (quin, J=8.6 Hz, 1H),1.44-1.35 (m, 1H), 1.28 (t, J=7.3 Hz, 3H), 1.02 (d, J=6.8 Hz, 3H). MS(ESI, +ve ion) m/z 671.1 (M+H)⁺; 693.1 (M+Na)⁺.

The foregoing description is merely illustrative of the invention and isnot intended to limit the invention to the disclosed compounds,compositions and methods. Variations and changes, which are obvious toone skilled in the art, are intended to be within the scope and natureof the invention, as defined in the appended claims. From the foregoingdescription, one skilled in the art can easily ascertain the essentialcharacteristics of this invention, and without departing from the spiritand scope thereof, can make various changes and modifications of theinvention to adapt it to various usages and conditions. All patents andother publications recited herein are hereby incorporated by referencein their entireties.

What is claimed is:
 1. A method of treating cancer, the methodcomprising: administering to a patient in need thereof a therapeuticallyeffective amount of a compound or a pharmaceutically acceptable saltthereof, wherein the cancer is a hematologic malignancy selected frommultiple myeloma, non-Hodgkin's lymphoma, or acute myelogenous leukemia,wherein the compound has a structure selected from:


2. The method of claim 1, wherein the cancer is acute myelogenousleukemia.
 3. The method of claim 1, wherein the cancer is multiplemyeloma.
 4. The method of claim 1, wherein the cancer is non-Hodgkin'slymphoma.
 5. The method of claim 1, wherein the compound or thepharmaceutically acceptable salt thereof is:


6. The method of claim 5, wherein the cancer is acute myelogenousleukemia.
 7. The method of claim 5, wherein the cancer is multiplemyeloma.
 8. The method of claim 5, wherein the cancer is non-Hodgkin'slymphoma.